Leitlinienreports
Leitlinienreports
Leitlinienreports
1. Aktualisierung 2011-2014
Impressum | 2
Impressum
Autoren des Leitlinienreports
Ärztliches Zentrum für Qualität in der Medizin (ÄZQ), Gemeinsame Einrichtung von
Bundesärztekammer und Kassenärztlicher Bundesvereinigung (Dr. med. Julia Köpp
Leitlinienbeauftragter der Deutschen Adipositas-Gesellschaft (DAG) (Prof. Dr. med. Alfred
Wirth)
AWMF-Leitlinienberaterin, ständige Kommission zur Pflege und Aktualisierung der DAG-
Leitlinien (Dr. biol. hum. Anja Moss)
Herausgeber
Deutsche Adipositas Gesellschaft e. V. (DAG)
(Präsident: Prof. Dr. M. Wabitsch)
Federführende Fachgesellschaft
Deutsche Adipositas-Gesellschaft e.V. (DAG)
(Präsident: Prof. Dr. M. Wabitsch)
Kontakt
Deutsche Adipositas-Gesellschaft e.V.
Geschäftsstelle
Fraunhoferstr. 5
82152 Martinsried
http://www.adipositas-gesellschaft.de/
Tel. 089 - 710 48 358
Fax. 089 - 710 49 464
E-Mail: [email protected]
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
Impressum | 3
INHALTSVERZEICHNIS
INHALTSVERZEICHNIS ...................................................................................................................................... 3
5. METHODIK............................................................................................................................................. 6
11. TABELLENVERZEICHNIS.........................................................................................................................22
12. ANHÄNGE.............................................................................................................................................22
13. LITERATUR..........................................................................................................................................289
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
1 Informationen zur Leitlinie | 4
2.2. Adressaten
Die folgenden Empfehlungen richten sich an alle Betroffenen und alle Berufsgruppen, die mit
der Prävention und Therapie von Übergewicht und Adipositas befasst sind. Weitere
Adressaten dieser Leitlinie sind übergeordnete Organisationen (z. B. Krankenkassen,
Rentenversicherung, Sozialrichter, Einrichtungen der ärztlichen Selbstverwaltung) und die
interessierte Fachöffentlichkeit.
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
3 Zusammensetzung der Leitliniengruppe | 5
3.2. Fachgesellschaften
Deutsche Adipositas Gesellschaft (DAG), Deutsche Diabetes Gesellschaft (DDG), Deutsche
Gesellschaft für Ernährung (DGE), Deutsche Gesellschaft für Ernährungsmedizin (DGEM),
Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM), Deutsche
Gesellschaft für Sportmedizin und Prävention (DGSP), Deutsche Gesellschaft für
Psychosomatische Medizin und Ärztliche Psychotherapie (DGPM), Deutsche Kollegium für
Psychosomatische Medizin (DKPM), Deutschen Gesellschaft für Essstörungen (DGESS),
Chirurgische Arbeitsgemeinschaft Adipositastherapie und metabolische Chirurgie (CAADIP)
der Deutschen Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV).
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
4 Fragestellung und Gliederung | 6
3.4. Patienten
An der 1. Aktualisierung der Leitlinie waren Vertreter der Patientenorganisation
„Adipositaschirurgie-Selbsthilfe Deutschland (AcSDeV)“ direkt beteiligt. Die Vertreterin des
AcSDeV (siehe Tabelle 1) war an allen Konsensuskonferenzen beteiligt und stimmberechtigt.
5. Methodik
5.1. Evidenzbasierung
5.1.1. Ersterstellung der Leitlinie
Bei der Erstellung der vorliegenden Leitlinie wurde sorgfältig darauf geachtet, die
Anforderungen der evidenzbasierten Medizin zu erfüllen. Als Basis dienten nationale und
internationale Qualitätskriterien für gute Leitlinien, wie sie u.a. von dem Scottish
Intercollegiate Guidelines Network [1] oder vom Ärztlichen Zentrum für Qualität in der
Medizin (ÄZQ) und der Leitlinienkommission der Arbeitsgemeinschaft der wissenschaftlichen
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
5 Methodik | 7
Literaturrecherche
Festlegung der Suchbegriffe mit den Experten der Fachdisziplinen, Allgemeinmedizinern und
Patientenvertretern durch Konsensfindung. Umfassende, systematische, computergestützte
Recherche in den Datenbanken von Medline, Cochrane Library, Embase, ERIC und PsycInfo
der wissenschaftlichen Literatur (englisch und deutsch, klinische Studien, Metaanalysen) für
den Zeitraum 01.2002 bis 12.2004 (Ersterstellung) mit anschließender Selektion der
recherchierten Literatur im Hand-Searching-Verfahren und darüber hinaus eine Recherche
bereits vorhandener Leitlinien, Empfehlungen, Expertenmeinungen und deren Referenzen in
einem Nebensuchverfahren. Der Zugriff auf ältere Fachliteratur war über eine bereits
bestehende Datenbank, die für die letzte Version der Leitlinie eingerichtet worden war,
gewährleistet. Überprüfung der Suchergebnisse auf ihre Relevanz durch Fachkräfte
(Wissenschaftler und Ärzte des Expertengremiums). Einteilung der recherchierten Studien
entsprechend ihrem Studiendesign und ihrer wissenschaftlichen Aussagekraft in
Evidenzklassen I bis IV (siehe Tabelle 2).
Tabelle 2: Bewertung der publizierten Literatur gemäß der wissenschaftlichen
Aussagekraftnach Evidenzklassen und Gewichtung in Empfehlungsgrade (modifiziert nach [1])
Evidenzklassen
Ia Evidenz aufgrund von Metaanalysen randomisierter, kontrollierter Studien
Ib Evidenz aufgrund mindestens einer randomisierten, kontrollierten Studie
IIa Evidenz aufgrund mindestens einer gut angelegten, kontrollierten Studie
ohne Randomisierung
IIb Evidenz aufgrund mindestens einer gut angelegten, nicht-randomisierten
und nicht-kontrollierten klinischen Studie
III Evidenz aufgrund gut angelegter, nicht-experimenteller, deskriptiver
Studien, wie z.B. Vergleichsstudien, Korrelationsstudien und Fall-Kontroll-
Studien
IV Evidenz aufgrund von Berichten der Experten-Ausschüsse oder Experten-
Meinungen und/oder Klinischer Erfahrung anerkannter Autoritäten
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
5 Methodik | 9
durchgeführt. Es wurden außerdem auf den Niveau der aggregierten Evidenz Studien
berücksichtigt, die durch die Experten der Leitliniengruppe zusätzlich identifiziert und als
relevant eingestuft wurden (Milestone papers).
Die systematische Recherche erfolgte in der Literaturdatenbank Medline über
www.pubmed.org (Sprache Deutsch oder Englisch, Erscheinungsjahr ab 2005, unter
Verwendung von Suchfiltern für aggregierte Evidenz und randomisierte kontrollierte Studien).
Vorliegende systematische Übersichtarbeiten/Metaanalysen/HTA-Berichte/RCTs wurden in
den Evidenztabellen gesondert ausgewiesen und den extrahierten Einzelpublikationen
vorangestellt.
Die in der zu aktualisierenden Leitlinie genutzte Suchstrategie wurde etwas modifiziert. Die
vom ÄZQ vorgeschlagene Strategie wurde bezüglich des Vokabulars von den Experten
ergänzt.
Folgende Suchstrategien (im Folgenden mit Trefferzahlen aufgeführt) wurden verwendet:
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
5 Methodik | 10
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
5 Methodik | 11
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
5 Methodik | 12
Die erste Relevanzprüfung erfolgte bereits im Rahmen der Recherchen. Dabei wurden
doppelte Publikationen sowie Publikationen zu anderen Erkrankungen ausgeschlossen. Bei
der Aktualisierungsrecherche zum Thema Prävention wurden zusätzlich Studien an Kindern
und Jugendlichen ausgeschlossen. Bei der Aktualisierungsrecherche zum Thema Therapie
wurden darüber hinaus Publikationen zu den operativen Verfahren sowie Studien an Tieren
und In-vitro-Studien ausgeschlossen.
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
5 Methodik | 13
Das Ergebnis der Literatursuche wurde zentral beim ÄZQ erfasst und in eine Datenbank
eingespeist. Die Ergebnislisten wurden den Experten als Listen mit bibliographischen
Angaben und Abstrakts zur Verfügung gestellt.
Die Auswahl der Studien zu den einzelnen Fragestellungen erfolgte durch Methodikerinnen
(Julia Köpp, Svenja Siegert) des ÄZQ nach vorab definierten Ein- und Ausschlusskriterien
und entsprechend der Methodik der evidenzbasierten Medizin.
Die Zielgruppe wurde auf Erwachsenen beschränkt, nur in Ausnahmefällen und nach
Absprache mit den Experten wurden Publikationen mit Aussagen zu Kindern einbezogen.
Die in den Recherchen identifizierte Literatur wurde durch die Methodikerinnen des ÄZQ
einem Titel-/Abstraktscreening unterzogen. Die ausgewählten Abstrakts wurden im Volltext
bestellt und nach erneuter Sichtung eingeschlossen, wenn die Volltexte als relevant und
methodisch geeignet bewertet wurden. Dabei wurden Publikationen aus folgenden
Ausschlussgründen ausgeschlossen:
A1 die Publikation beinhaltet ein anderes Thema bzw. eine andere Fragestellung oder
die Publikation ist nicht spezifisch für die Fragestellung.
A4 die Publikation beschreibt keine Studie (z.B. Editorial, Comments, Notes) bzw.
Ergebnisse liegen noch nicht vor (z.B. Studienprotokoll)
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
5 Methodik | 14
A8 Doppelpublikationen
Grad Beschreibung
1++ Qualitativ hochwertige Metaanalysen, Systematische Übersichten von
RCTs, oder RCTs mit sehr geringem Risiko systematischer Fehler (Bias)
1+ Gut durchgeführte Metaanalysen, Systematische Übersichten von RCTs,
oder RCTs mit geringem Risiko systematischer Fehler (Bias)
1- Metaanalysen, Systematische Übersichten von RCTs, oder RCTs mit
hohem Risiko systematischer Fehler (Bias)
2++ Qualitativ hochwertige systematische Übersichten von Fall-Kontroll- oder
Kohortenstudien oder
Qualitativ hochwertige Fall-Kontroll- oder Kohortenstudien mit sehr
niedrigem Risiko systematischer Verzerrungen (Confounding, Bias,
„Chance“) und hoher Wahrscheinlichkeit, dass die Beziehung ursächlich ist
2+ Gut durchgeführte Fall-Kontroll Studien oder Kohortenstudien mit niedrigem
Risiko systematischer Verzerrungen (Confounding, Bias, „Chance“) und
moderater Wahrscheinlichkeit, dass die Beziehung ursächlich ist
2- Fall-Kontroll Studien oder Kohortenstudien mit einem hohen Risiko
systematischer Verzerrungen (Confounding, Bias, „Chance“) und
signifikantem Risiko, dass die Beziehung nicht ursächlich ist
3 Nicht-analytische Studien, z.B. Fallberichte, Fallserien
4 Expertenmeinung
Die Evidenztabellen mit den extrahierten Angaben sind in im Kapitel 12.4.2.2 aufgeführt.
Nach Einschätzung der Experten war für das Kapitel 2 “Definition und Klassifikation von
Übergewicht und Adipositas“ keine systematische Literaturrecherche erforderlich, weil für
dieses Kapitel für Erwachsene zum Beginn der Aktualisierung keine wesentlichen neuen
Erkenntnisse bzw. Klassifikationen vorlagen. Daher erfolgte die Aktualisierung dieses
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
5 Methodik | 15
Bei der Ersterstellung der Leitlinie wurden die Entwürfe diskutiert und in einem informellen
Konsens im Expertengremium verabschiedet.
Bei der 1. Aktualisierung erfolgten die Verabschiedung von Empfehlungen und Statements
sowie die Festlegung der Empfehlungsgrade vorwiegend im Rahmen von
Konsensuskonferenzen unter Verwendung formaler Konsensusverfahren. Empfehlungen, die
nicht in den Konsensuskonferenzen abschließend abgestimmt werden konnten, wurden
schriftlich durch die Leitlinienautoren im Delphi-Verfahren konsentiert. Bei den
Konsensuskonferenzen erfolgte jeweils eine Einführung zum Stand der Leitlinienbearbeitung
durch einen Methodiker des ÄZQ und die Teilnehmer wurden in die Technik der
strukturierten Konsensusfindung eingewiesen.
Tabelle 7: Konsensuskonferenzen und behandelte Themen der 1. Aktualisierung
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
5 Methodik | 16
Bei der Ersterstellung der Leitlinie brachten die Experten ihre Entwürfe in
Konsensuskonferenzen ein, wo sie konsentiert wurden.
Bei der 1. Aktualisierung der Leitlinie arbeiteten Arbeitsgruppen mit je drei bis acht
Mitgliedern zunächst parallel themenbezogen in moderierten Telefonkonferenzen
(Moderation: Susanne Weinbrenner, Günter Ollenschläger, Anja Dippmann). In zehn
Telefonkonferenzen wurden die von den Kapitelautoren erarbeiteten Empfehlungen und
Statements vor der jeweiligen Konsensuskonferenz diskutiert, gegebenenfalls modifiziert und
(vor-)abgestimmt. Änderungen und Kommentare galten als angenommen, wenn alle
Teilnehmer zugestimmt haben bzw. keiner der Teilnehmer einen Einwand erhoben hat.
Wurde im Rahmen der Telefonkonferenzen in den Arbeitsgruppen keine Zustimmung aller
Teilnehmer erreicht, konnten in den Konsensuskonferenzen auch Alternativen (Sondervotum
etc.) dargestellt werden. Die (vor-)abgestimmten Empfehlungen dienten als Vorlage für die
Konsensuskonferenzen.
Die Teilnehmer des Konsensustreffens wurden zu Beginn der Konferenz in die Technik der
strukturierten Konsensusfindung nach dem Nominalen Gruppenprozess eingewiesen. Jedem
Teilnehmer wurde eine Tischvorlage zur Verfügung gestellt. Zusätzlich wurden die zu
konsentierenden Aussagen/Empfehlungen elektronisch präsentiert, Kommentare bzw.
Änderungen zur Diskussion integriert und der Abstimmungsprozess dokumentiert. Die
Abstimmung wurde kapitelweise vorgenommen, wobei jede Empfehlung einzeln aufgerufen
wurde.
Folgender Ablauf wurde befolgt (gemäß AWMF-Regelwerk):
· stille Notizen (Generierung von Änderungsvorschlägen)
· Registrierung der Stellungnahmen im Einzel-Umlaufverfahren (noch keine Diskussion)
· Gelegenheit zu Rückfragen und Klärung der Evidenzgrundlage, Vorabstimmung über
Diskussion der einzelnen Kommentare
· Reihendiskussion und Debatte der Diskussionspunkte
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
5 Methodik | 17
5.2.3. Delphi-Abstimmung
Nach der ersten Konsensuskonferenz wurden Empfehlungen aus dem Kapitel zum Thema
Prävention in der Delphi-Abstimmung abgestimmt (Zeitraum April/Mai 2012). Im Rahmen der
Delphi-Abstimmung von Empfehlungen aus dem Kapitel Prävention haben sieben von zwölf
Experten fristgerecht geantwortet, eine Rückmeldung ist verspätet im ÄZQ eingegangen und
konnte daher nicht regelrecht berücksichtigt werden. Die Stimmen von weiteren vier
Experten, die keine Rückmeldung im Rahmen des Delphi-Verfahrens gegeben haben,
wurden als Zustimmung bewertet. Dies wurde den entsprechenden Experten im Vorfeld
mitgeteilt. Eine Stimme wurde als Enthaltung eingestuft. Nach der zweiten
Konsensuskonferenz fand vom 1.-4.11.2013 eine Delphi-Konferenz zu weiteren
gesammelten Änderungsvorschlägen aus den Fachgesellschaften statt. Zehn von elf
Experten haben fristgerecht rückgemeldet. Von den 17 Änderungsentwürfen konnte keiner
einen Konsens erzielen. Da die betreffenden Punkte im Vorfeld ausführlich diskutiert wurden
und im Delphi kein Konsens erreicht werden konnte, wurde sich geeinigt entsprechende
Sonder-Voten bzw. Sonder-Kommentare zu formulieren.
Die Vergabe von Empfehlungsgraden erfolgte durch die Leitlinienautoren im Rahmen eines
formalen Konsensusverfahrens. Dementsprechend wurde ein durch das ÄZQ moderierter
Nominaler Gruppenprozess durchgeführt. Die Empfehlungsgrade drücken den Grad der
Sicherheit aus, dass der erwartete Nutzen der Intervention den möglichen Schaden aufwiegt
(Netto-Nutzen) und die erwarteten positiven Effekte ein für die Patienten relevantes Ausmaß
erreichen. Im Fall von Negativempfehlungen (soll nicht) wird entsprechend die Sicherheit
über einen fehlenden Nutzen bzw. möglichen Schaden ausgedrückt.
Bei der Graduierung der Empfehlungen werden neben den Ergebnissen der zugrunde
liegenden Studien, die klinische Relevanz der in den Studien untersuchten Effektivitätsmaße,
die beobachteten Effektstärken, die Konsistenz der Studienergebnisse; die Anwendbarkeit
der Studienergebnisse auf die Patientenzielgruppe, die Umsetzbarkeit im ärztlichen Alltag,
ethische Verpflichtungen sowie die Patientenpräferenzen berücksichtigt.
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
6 Externe Begutachtung (öffentliche Konsultation) | 18
5.2.5. Statements
5.2.6. Expertenkonsens
5.2.7. Sondervoten
Die öffentliche Konsultation der 1. Aktualisierung wurde durch die Experten koordiniert. Die
aktualisierte Fassung der Leitlinie konnte vom 15.7.2013. bis 31.8.2013 öffentlich von allen
Mitgliedern der beiteiligen Fachgesellschaften kommentiert werden. Es gingen in dieser Zeit
insgesamt Kommentare von 18 Personen oder Organisationen ein. Von den inhaltlichen
Kommentaren bezogen sich 110 Kommentare ausschließlich auf Änderungen an
Hintergrundtexten. Auf Wunsch können die vollständigen Kommentare bei der
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
7 Redaktionelle Unabhängigkeit | 19
Geschäftsstelle der DAG eingesehen werden. Nach der Konsultationsphase wurden die
Kommentare im Expertengremium in drei Telefonkonferenzen besprochen. Dabei wurden
redaktionelle Änderungen vorgenommen oder Empfehlungen zur Neuabstimmung in Delphi-
Verfahren vorgeschlagen. Die Entscheidung des Expertengremiums zum Umgang mit den
eingegangenen Kommentaren wurde den Kommentierenden rückgemeldet.
7. Redaktionelle Unabhängigkeit
Die Ersterstellung der Leitlinie wurde unabhängig von Interessengruppen durch die
beteiligten Fachgesellschaften vorgenommen. Alle Mitglieder der Kommission arbeiteten
ehrenamtlich und erhielten lediglich die Reisekosten ersetzt. Alle Mitglieder haben mögliche
Interessenkonflikte schriftlich gegenüber den Fachgesellschaften dargelegt. Kein Experte
wurde ausgeschlossen.
Für die 1. Aktualisierung der Leitlinie haben alle Beteiligten das aktuelle Formblatt der AWMF
zur Erklärung von Interessenkonflikten ausgefüllt. Die darin offengelegten Beziehungen und
Sachverhalte sind in Kapitel 12.3 dargestellt. Das Thema Interessenkonflikte wurde während
des Aktualisierungsprozesses mehrfach in der Leitliniengruppe besprochen. Ein Ausschluss
von Experten wurde durch das Expertengremium geprüft und nicht vorgenommen. Die
Gefahr von unangemessener Beeinflussung durch Interessenkonflikte wurde dadurch
reduziert, dass die Recherche, Auswahl und Bewertung der Literatur durch Methodikerinnen
des ÄZQ, ohne Beziehungen zu Industrie oder Interessengruppen erfolgte. Die formale
Konsensbildung und die interdisziplinäre Erstellung, sowie die Möglichkeit der öffentlichen
Begutachtung bildeten weitere Elemente, die das Risiko von Verzerrungen (auch aufgrund
von Interessenkonflikten einzelner Personen) reduzieren können.
1. Publikation der Leitliniendokumente auf den Internetseiten der DAG sowie der
beteiligten Fachgesellschaften und Organisationen,
4. Bundesweite Fortbildungsveranstaltungen.
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
9 Gültigkeitsdauer der Leitlinie | 20
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
10 Abkürzungsverzeichnis | 21
10. Abkürzungsverzeichnis
Abkürzung Erläuterung
AcSDeV Adipositaschirurgie-Selbsthilfe Deutschland
AWMF Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen
Fachgesellschaften
ÄZQ Ärztliches Zentrum für Qualität in der Medizin
CAADIP Chirurgische Arbeitsgemeinschaft Adipositastherapie und metabolische
Chirurgie der Deutschen Gesellschaft für Allgemein- und Viszeralchirurgie
CMAJ Canada's Database of Clinical Practice Guidelines
DAG Deutsche Adipositas Gesellschaft
DELBI Deutsches Leitlinien-Bewertungsinstrument
DDG Deutsche Diabetes Gesellschaft
DEGAM Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin
DGAV Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie
DGE Deutsche Gesellschaft für Ernährung
DGEM Deutsche Gesellschaft für Ernährungsmedizin
DGESS Deutschen Gesellschaft für Essstörungen
DGPM Deutsche Gesellschaft für Psychosomatische Medizin und Ärztliche
Psychotherapie
DGSP Deutsche Gesellschaft für Sportmedizin und Prävention
DKPM Deutsche Kollegium für Psychosomatische Medizin
GIN Guideline International Network
HTA Health Technology Assessment
ICSI Institute for Clinical Systems Improvement
LoE Level of Evidence
NGC National Guideline Clearinghouse
NGP nominaler Gruppenprozess
NICE National Institute of Clinical Excellence
RCT Randomized Controlled Trial
SIGN Scottish Intercollegiate Guidelines Network
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
11 Tabellenverzeichnis | 22
11. Tabellenverzeichnis
Tabelle 1: Mitglieder der Leitliniengruppe 5
Tabelle 2: Bewertung der publizierten Literatur gemäß der wissenschaftlichen
Aussagekraftnach Evidenzklassen und Gewichtung in Empfehlungsgrade
(modifiziert nach [1]) 7
Tabelle 3: Suchstrategie in Medline für erste themenübergreifende Recherche 9
Tabelle 4: Suchstrategie in Medline für die Aktualisierungsrecherche zum Thema
Prävention 10
Tabelle 5: Suchstrategie in Medline für die Aktualisierungsrecherche zum Thema Therapie
(ausgenommen chirurgische Therapie) 12
Tabelle 6: Schema der Evidenzgraduierung des Scottish Intercollegiate Guidelines
Network [1] 14
Tabelle 7: Konsensuskonferenzen und behandelte Themen der 1. Aktualisierung 15
Tabelle 8: Definition der Konsensusstärke 16
Tabelle 9: Einstufung von Leitlinienempfehlungen in Empfehlungsgrade 18
12. Anhänge
12.1. Themenkomplexe und beteiligte Autoren
Die Zuordnung der Themenkomplexe zu den beteiligten Experten erfolgte durch den
Leitlinienkoordinator.
Themenkomplexe Zuständigkeit
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 23
Themenkomplexe Zuständigkeit
Therapie von Übergewicht und Adipositas: Therapie Hauner, Ellrott, Wirth, Bischoff
- Ernährungstherapie
Therapie von Übergewicht und Adipositas: Therapie Shang (bis 05.2012), Colombo-
- Chirurgische Therapie Benkmann (ab 06.2012), Wirth,
Wabitsch
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 24
Die Entwicklung von Leitlinien für die medizinische Versorgung verlangt über die fachliche Expertise
hinaus eine Vermeidung kommerzieller Abhängigkeiten oder anderer Interessenkonflikte, die die
Leitlinieninhalte beeinflussen. Es gibt eine Vielzahl von materiellen (z. B. finanzielle oder kommerzielle)
und immateriellen (z. B. politische, akade-mische oder persönliche) Beziehungen, deren
Ausprägungsgrade und Bedeutungen variieren können. Interessenkonflikte sind somit zumeist
unvermeidbar, aber nicht zwangsläufig problematisch in Hinblick auf eine Beeinflussung der
Leitlinieninhalte.
Eine Erklärung zu den Beziehungen und den daraus entstehenden Interessenkonflikten durch die
Autoren der Leitlinien und die Teilnehmer am Konsensusverfahren ist für die Qualitätsbeurteilung von
Leitlinien, aber auch für ihre allgemeine Legitimation und Glaubwürdigkeit in der Wahrnehmung durch
Öffentlichkeit und Politik entscheidend.
Die Inhalte der Erklärungen und die Ergebnisse der Diskussion zum Umgang mit Interessenkonflikten
sollten im Leitlinienreport offen dargelegt werden. In der Langfassung der Leitlinien ist auf das Verfahren
der Sammlung und Bewertung der Erklärungen hinzu-weisen.
Erklärung
Die Erklärung betrifft finanzielle und kommerzielle (materielle) sowie psychologische und soziale
(immaterielle) Aspekte sowie Interessen der Mitglieder selbst und/oder ihrer persönlichen/professionellen
Partner innerhalb der letzten 3 Jahre. Bitte machen Sie konkrete Angaben zu folgenden Punkten:
1. Berater- bzw. Gutachtertätigkeit oder bezahlte Mitarbeit in einem wissenschaftlichen Beirat eines
Unternehmens der Gesundheitswirtschaft (z. B. Arzneimittelindustrie, Medizinproduktindustrie), eines
kommerziell orientierten Auftragsinstituts oder einer Versicherung.
Nein
Ja
2. Honorare für Vortrags- und Schulungstätigkeiten oder bezahlte Autoren- oder Co-Autorenschaften
im Auftrag eines Unternehmens der Gesundheitswirtschaft, eines kommerziell orientierten
Auftragsinstituts oder einer Versicherung.
Nein
Ja
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 25
Nein
Ja
Nein
Ja
5. Besitz von Geschäftsanteilen, Aktien, Fonds mit Beteiligung von Unternehmen der
Gesundheitswirtschaft
Nein
Ja
Nein
Ja
Nein
Ja
Nein
Ja
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 26
Bewertung
Ergeben sich aus allen oben angeführten Punkten nach Ihrer Meinung für Sie oder die ganze
Leitliniengruppe bedeutsame Interessenkonflikte?
Nein
Ja
Falls ja, bitte Angabe eines Vorschlags zur Diskussion in der Leitliniengruppe
Name/Anschrift (Stempel)
______________________ __________________________
Ort, Datum Unterschrift
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
27
12 Anhänge | 27
Punkte Prof. Dr. Prof. Dr. Prof. Dr. Prof. Dr. U. Prof. Dr. Dr. T. PD Dr. C. Prof. Dr. Prof. Dr. Dr. M. Prof. Dr.
A. Wirth H. M. N. Stefan Kanthak S. C. Ellrott Heintze A. Berg D. Kunze Teufel M. Wa-
Hauner Colom- Bischoff bitsch
bo-Benk-
mann
1 Berater- bzw. Mitarbeit Mitglied nein Berater- nein Danone, nein nein ALMA- nein nein nein
Gutachtertätigkeit im Data- im tätigkeit Yakult, SEG
oder bezahlte Monito- Interna- für die Fresenius, GmbH
Mitarbeit in einem ring tional Firmen Covidien Bienen-
wissenschaftlichen Commit- Advisory Boeh- büttel
Beirat eines Unter- tee einer Board der ringer
nehmens der wissen- Weight Ingelheim,
Gesundheits- schaftli- Watchers MediGene
wirtschaft (z. B. chen Int. Corp.,
Arzneimittelindustrie, Studie der New York
Medizinprodukt- Fa.
industrie), eines Riemser
kommerziell orientier-
ten Auftragsinstituts
oder einer
Versicherung
2 Honorare für Honorare In den Covidien Honorare nein Zahl- Glaxo nein ALMA- nein nein nein
Vortrags- und für Vor- letzten 3 Deutsch- für Vor- reiche, Smith- SEG
Schulungstätigkeiten träge/ Jahren land: tragstätig- wechselnd Kline, GmbH
oder bezahlte Artikel Honorare Vortrags- keiten im Kirchheim- Bienen-
Autoren- oder Co- von Cert- für Vor- und Schu- Rahmen Verlag, büttel
Autorenschaften im medica, träge von lungs- der ärzt- Nestle
Auftrag eines MSD, Novartis, tätigkeit lichen Health-
Unternehmens der Lilly, BMS, im Rah- Weiter- care
Gesundheitswirt- Actavis, Sanofi- men von bildung Nutrition,
schaft, eines Medical Aventis, Opera- unterstützt Weight-
kommerziell Training, Novo- tions- durch die Watchers,
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
28
12 Anhänge | 28
Punkte Prof. Dr. Prof. Dr. Prof. Dr. Prof. Dr. U. Prof. Dr. Dr. T. PD Dr. C. Prof. Dr. Prof. Dr. Dr. M. Prof. Dr.
A. Wirth H. M. N. Stefan Kanthak S. C. Ellrott Heintze A. Berg D. Kunze Teufel M. Wa-
Hauner Colom- Bischoff bitsch
bo-Benk-
mann
orientierten Cardio- Nordisk work- Firmen NSA;
Auftragsinstituts oder vasc shops Sanofi- Preven-
einer Versicherung gegen Aventis, tias Institut
Honorar Bristol- für Ar-
Myers beits- und
Squibb, Sozialhy-
Astra- giene
Zeneca Stiftung,
Deynique
Cosmetics
3 Finanzielle nein LKP einer nein Drittmittel nein Almirall, Allgemei- nein ALMA- nein nein nein
Zuwendungen klinischen für die Merck ne SEG
(Drittmittel) für Studie Durch- Ortskran- GmbH
Forschungsvorhaben Phase II führung kenkasse Bienen-
oder direkte für die von (AOK), büttel
Finanzierung von Riemser Studien Weight-
Mitarbeitern der AG der Watchers,
Einrichtung von (Alvalin) Industrie Nestle
Seiten eines Klinische (Roche) Health-
Unternehmens der Studie für und für care
Gesundheitswirt- Certme- Investiga- Nutrition
schaft, eines dica tor-Initi-
kommerziell orien- (Formolin ated-
tierten Auftrags- e L112) Studies
instituts oder einer (Sanofi-
Versicherung Aventis)
4 Eigentümerinteresse nein nein nein nein nein nein nein nein nein nein nein nein
an Arzneimitteln/
Medizinprodukten (z.
B. Patent,
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
29
12 Anhänge | 29
Punkte Prof. Dr. Prof. Dr. Prof. Dr. Prof. Dr. U. Prof. Dr. Dr. T. PD Dr. C. Prof. Dr. Prof. Dr. Dr. M. Prof. Dr.
A. Wirth H. M. N. Stefan Kanthak S. C. Ellrott Heintze A. Berg D. Kunze Teufel M. Wa-
Hauner Colom- Bischoff bitsch
bo-Benk-
mann
Urheberrecht,
Verkaufslizenz)
5 Besitz von nein nein nein nein nein Besitz von nein nein nein nein nein nein
Geschäftsanteilen, Geschäfts
Aktien, Fonds mit anteilen,
Beteiligung von Aktien,
Unternehmen der Fonds mit
Gesundheitswirt- Beteili-
schaft gung von
Unter-
nehmen
der
Gesund-
heitswirt-
schaft; Die
Zusam-
menset-
zung des
Besitzes
wechselte
über den
abgefrag-
ten Zeit-
raum, ist
nicht
doku-
mentiert,
bewegt
sich in
einer
Größen-
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
30
12 Anhänge | 30
Punkte Prof. Dr. Prof. Dr. Prof. Dr. Prof. Dr. U. Prof. Dr. Dr. T. PD Dr. C. Prof. Dr. Prof. Dr. Dr. M. Prof. Dr.
A. Wirth H. M. N. Stefan Kanthak S. C. Ellrott Heintze A. Berg D. Kunze Teufel M. Wa-
Hauner Colom- Bischoff bitsch
bo-Benk-
mann
ordnung
von unter
100.000
Euro und
stellt
meines
Erachtens
keinerlei
Interes-
senkonflikt
dar
6 Persönliche nein nein nein nein nein nein nein nein nein nein nein nein
Beziehungen zu
einem Vertretungs-
berechtigten eines
Unternehmens
Gesundheits-
wirtschaft
7 Mitglied von in Deutsche Präsident Deutsche Deutsche- nein DGEM Deutsche DEGAM Beirat Leitlinien- Deut- Feder-
Zusammenhang mit Diabetes- der Deut- Gesell- Diabetes- DAG Gesell- DAG / koordinato sche führen-
der Leitlinien- Gesellsch schen schaft für Gesell- schaft für Präsidium r der AGA Kolle- der Autor
DGE
entwicklung aft / Adipositas Chirurgie / schaft Ernährung DGSP – Arbeits- gium für der S3-
relevanten Fach- Lipidliga / Gesell- Deutsche EJSEN / Deutsche gemein- Psycho- LL
gesellschaften/ Deutsche schaft / Gesell- Gesell,sch schaft somati- „Adipo-
Berufsverbänden, Hoch- Mitglied schaft für aft für Adipositas sche sitas im
Mandatsträger im druck im Präsi- Allgemein Ernäh- im Kindes- Medizin / Kinder-
Rahmen der Liga/ dium der - und Vis- rungsme- und Deut- und
Leitlinienentwicklung Deutsche Deut- zeral- dizin, Jugend- sche Jugen-
Gesell- schen chirurgie / Deutsche alter der Gesell- dalter“
schaft für Gesell- Arbeits- Adipositas DAG schaft
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
31
12 Anhänge | 31
Punkte Prof. Dr. Prof. Dr. Prof. Dr. Prof. Dr. U. Prof. Dr. Dr. T. PD Dr. C. Prof. Dr. Prof. Dr. Dr. M. Prof. Dr.
A. Wirth H. M. N. Stefan Kanthak S. C. Ellrott Heintze A. Berg D. Kunze Teufel M. Wa-
Hauner Colom- Bischoff bitsch
bo-Benk-
mann
Sport und schaft für gemein- Gesell- für
Präven- Ernäh- schaft schaft, Essstö-
tion rung Adipositas Deutsche rungen
(DGE) / chirurgie Gesell-
Vorsit- und schaft für
zender metabo- Prävention
der LL- lische und
Kommis- Chirurgie / Rehabili-
sion für Deutsche tation,
Kohle- Gesell- Verband
hydrate schaft für für
der DGE Chirurgie Ernährung
der und
Adiposi- Diätetik,
tas / Vor- Deutsche
sitzender Gesell-
der schaft für
Leitlinien- Prävention
kommis- und
sion Rehabili-
Adipositas tation
chirurgie
8 Politische, nein nein nein nein nein nein nein nein nein nein nein nein
akademische (z.B.
Zugehörigkeit zu
bestimmten
„Schulen“),
wissenschaftliche
oder persönliche
Interessen, die
mögliche Konflikte
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
32
12 Anhänge | 32
Punkte Prof. Dr. Prof. Dr. Prof. Dr. Prof. Dr. U. Prof. Dr. Dr. T. PD Dr. C. Prof. Dr. Prof. Dr. Dr. M. Prof. Dr.
A. Wirth H. M. N. Stefan Kanthak S. C. Ellrott Heintze A. Berg D. Kunze Teufel M. Wa-
Hauner Colom- Bischoff bitsch
bo-Benk-
mann
begründen könnten
9 Gegenwärtiger Deutsche Klinikum Universi- Medizini- Rentnerin Universität Institut für Charite, Seit 10/ Kein Universi- Universi-
Arbeitgeber, Renten- rechts der tät sche Hohen- Ernäh- Institut für 2008 Arbeit- tätsklini- tätsklini-
relevante frühere versiche- Isar der Münster Univer- heim rungs- Allge- selbst- geber, kum kum Ulm
Arbeitgeber der rung Techni- von dort sitäts- psycholo- mein- ständig sondern Tübin-
letzten 3 Jahre Braun- schen abgeord- klinik der gie an der medizin freiberuf- gen
schweig- Universi- net an Universität Universi- liche
Hannover tät das Tübingen täts- Tätigkeit
München Univer- und medizin im MVZ
sitäts- Deutsche Göttingen Endokri-
klinikum For- Balzer- nologikum
Münster schungs- born-Klinik München
gesell- Bad
schaft Sooden
Allendorf
10 Ergeben sich aus nein nein nein nein nein nein nein nein nein nein nein nein
allen oben
angeführten Punkten
nach Ihrer Meinung
für Sie oder die
ganze
Leitliniengruppe
bedeutsame
Interessenkonflikte?
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 33
12.4.1. Recherchestrategien
12.4.2.1 Flow-Chart
12 Anhänge | 34
12.4.2.2 Evidenztabellen
Aggregierte Evidenz
a) Leitlinien
Quelle Text Evidenz- bzw. Literaturbelege Methodische
Empfehlungs- Bewertung
grad
SIGN (2010): Health consequences of obesity in adults Vazquez G, et al. Epidemiol Rev 2007;29:115-28 Domäne 3 (DELBI) 19
Management of Asthma 2++ Chu SY, Callaghan WM. Diabetes Care Punkte
Obesity. A national 2007;30(8):2070-6 Bei der Suche nach
Overweight and obese patients are more likely to
clinical guideline Evidenz wurden
develop asthma in a given period; odds ratio (OR) of Carey VJ, et al. Am J Epidemiol 1997;145(7):614-9
[4] systematischen Methoden
incident asthma in obese compared to normal weight Chan JM, et al. Diabetes Care 1994;17(9):961-9
adults was 1.92 (OR 1.38 for overweight patients). angewandt.
Rana JS, et al. Diabetes Care 2007;30(1):53-8
Cancer 2++
Guh DP, et al. BMC Public Health 2009;9:88
There is an association between obesity and increased 2+
Brown CD, et al. Obes Res 2000;8(9):605-19
risk of developing leukaemia and cancer of the breast,
gallbladder, ovaries, pancreas, prostate, colon, Kannel WB, et al. Nutrition 1997;13(2):157-8
oesophagus, endometrium, and renal cells. Anderson JW, Konz EC. Obes Res
Coronary heart disease (CHD) / 2++ 2001;9(Suppl 4):326S-34S
Cardiovascular disease (CVD) 4 Romero-Corral A, et al. Lancet 2006;368(9536):666-
Obesity is a major risk factor for CHD. Severe obesity is 2+ 78
associated with increased cardiovascular mortality. Nightingale AL, et al. Eur J Contracept Reprod Health
Obesity-induced dyslipidaemia andhypertension are Care 2000;5(4):265-74
factors in the increased risk of cardiovascular disease. In Wanahita N, et al. Am Heart J 2008;155(2):310-5
a meta-analysis, BMI>25 kg/m2 was positively
associated with increased risk of venous Larsson SC, Wolk A. Int J Cancer 2008;122(6):1418-
21
thromboembolism in combined oral contraceptive users.
A meta-analysis reported an RR for hypertension in Connolly BS, et al. Nutr Cancer 2002;44(2):127-38
overweight men of 1.28 and obese men 1.84. The RR for Harvie M, et al. Obesity Reviews 2003;4(3):157-73
hypertension in overweight women was 1.65 and in Olsen CM, et al. Eur J Cancer 2007;43(4):690-709
12 Anhänge | 35
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 36
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 37
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 38
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 39
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 40
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 41
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 42
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 43
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 44
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
Men: OR 1.3; 95 % CI 1.0 – 1.5 2008
Women: OR 1.4; 95 % CI 1.1 – 1.7 Simon, et al. Arch Gen
Psychiatry 2006
Zhao, et al. Int J Obes
2009
Bjerkeset, et al. Am J
Epidemiol 2008
Kasen, et al. Int J
Obes 2008
Meta- Luppino Search Primary outcome: Included studies: Anderson SE, et al. 2++ Gute methodische
analysis FS, et al. strategy is depression or Study quality: Psychosom Med. Qualität des SR
(2010) reported overweight/obesity 2007;69(8):740-7 anhand der
- Quality assessment is reported, 15-item checklist
[12] 3 Databases : (BMI) Bjerkeset O, et al. Am Kohortenstudien
adapted from Kuijpers et al. was used
Medline J Epidemiol. (5 von 15 haben sehr
- 5 studies with high quality gute Qualität)
(PubMed), 2008;167(2):193-202
EMBASE, and Descriptive statistics:
Herva A, et al. Int J
PsycINFO - In children, adolescent and adult; total N = 58 745 Obes (Lond).
Studies - 8 studies with obesity/overweight exposure and 2006;30(3):520-7
design: outcome depression Kasen S, et al. Int J
prospective Heterogeneity: Obes (Lond).
cohort studies - Random effects model was used 2008;32(3):558-66
- Q-Statistic was used, I2 was calculated: not Koponen H, et al. J
significant or low heterogeneity Clin Psychiatry.
Publication bias: 2008;69(2):178-82
- Egger test, Duval and Tweedie: no significant Roberts RE, et al. Int J
publication bias Obes Relat Metab
Disord.
Results (obesity/overweight exposure and outcome
2003;27(4):514-21
depression):
Sachs-Ericsson N, et
- Overweight increased the risk of onset of depression al. Am J Geriatr
at follow-up: N = 53 639: unadjusted OR = 1.27
Psychiatry.
(95 % CI, 1.07 - 1.51; p < 0.01); N = 48 739:
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 45
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
adjusted OR = 1.08 (95 % CI, 1.02 - 1.14; p < 0.01) 2007;15(9):815-25
- Obesity at baseline increased the risk of onset van Gool CH, et al.
depression in follow-up: N = 55 387: unadjusted OR Am J Public Health.
= 1.55 (95 % CI, 1.22 - 1.98; p < 0.001), N = 48 739: 2007;97(5):887-94
adjusted OR = 1.57 (95 % CI, 1.23 - 2.01; p < 0.001) Bardone AM, et al. J
Subgroup analysis: Am Acad Child
- Age: Overweight: Not significant: mean age < 20 Adolesc Psychiatry.
years (N = 3 799, OR = 1.05 (95 % CI, 0.86 - 1.29) 1998;37(6):594-601
and mean age > 60 (N = 3 981, OR = 1.77 (95 % CI, Barefoot JC, et al. Int
1.00 - 0.32); Significant: mean age 20 - 60 J Obes Relat Metab
(N = 45 859, OR = 1.48 (95 % CI, 1.19 - 1.83); Disord.
Obesity: Significant: mean age < 20 years 1998;22(7):688-94
(N = 3 799, OR = 1.70 (95 % CI, 1.25 - 2.30) and Hasler G, et al. Mol
mean age > 60 (N = 5 729, OR = 1.98 (95 % CI, Psychiatry.
1.26 - 3.10); not significant: mean age 20 - 69 2005;10(9):842-50
(N = 45 859, OR = 1.34 (95 % CI, 0.83 - 2.19)
Koponen H, et al. J
- Sex: Overweight (N = 48 195): not significant
Clin Psychiatry.
(women: OR = 0.98 (95 % CI, 0.80 - 1.20); men: 2008;69(2):178-82
OR = 1.30 (95 % CI, 0.78 - 2.17); Obesity
(N = 48 195): significant for women (OR = 1.67 Pine DS, et al. Am J
(95 % CI, 1.11 - 2.51), not significant for men Public Health.
(OR = 1.31 (95 % CI, 1.13 - 1.15) 1997;87(8):1303-10
- Follow-up duration: < 10 years: Not significant: Pine DS, et al.
Overweight: N = 4900, OR = 0.89, 95 % CI, 0.71, Pediatrics.
1.12; Obesity: N = 6648; OR = 1.26, 95 % CI, 0.78, 2001;107(5):1049-56
2.03; ≥ 10 years: not significant for overweight: Richardson LP, et al.
N = 48 739, OR = 1.19, 95 % CI, 0.97, 1.45; Arch Pediatr Adolesc
significant for obesity: N = 48 739; OR = 1.72, 95 % Med.
CI, 1.40, 2.13 2003;157(8):739-45
- High versus low quality of studies: Overweight and Roberts RE, et al. Int J
Obesity: not significant in high quality (N = 1 146 Obes Relat Metab
OR = 1.17, 95 % CI, 0.80, 1.70; obesity: N = 1 146 Disord.
OR = 1.24, 95 % CI, 0.49, 3.17); significant in low 2003;27(4):514-21
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 46
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
quality (N = 52 493 OR = 1.32, 95 % CI, 1.06, 1.63; van Gool CH, et al.
obesity: N = 54 241 OR = 1.62, 95 % CI, 1.28, 2.05) Am J Public Health.
- Europeans: Overweight: significant (N = 48 440 2007;97(5):887-94
OR = 1.29, 95 % CI, 1.05, 1.58); Obesity: not Vogelzangs N, et al.
significant (N = 48 440 OR = 1.33, 95 % CI, 0.98, Arch Gen Psychiatry.
1.81), p-value between groups < 0.05 2008;65(12):1386-93
- Clinical depressive disorder: Overweight: not
significant (N = 1 218 OR = 1.13, 95 % CI, 0.74,
1.84); Obesity: significant (N = 2 966 OR = 2.15, 95
% CI, 1.48, 3.12), p-value between groups < 0.05
Meta- Yusuf E, et Search exposure: Included studies: 15 high quality 2++ Eine Meta-Analyse
analysis al. (2010) strategy, weight or BMI Study quality: studies: guter methodischer
[13] inclusion and Andrianakos AA, et al. Qualität.
outcome: - 25 observational studies: 2 cohort, 3 case-control, 20
exclusion J Rheumatol. 2006 Informationen im
hand osteoarthritis cross-sectional design
criteria were Anhang (Datenbanken
- Quality assessment: 19 criteria scoring system Carman WJ. Am J
reported usw.) sind nicht
- 15 studies had high quality, the mean of quality Epidemiol. 1994
Databases verfügbar.
scores was 63 % Cicuttini FM. J
were in Eine positive
- Potential confounder were reported: age, gender, Rheumatol. 1996
Appendix 1 Assoziation ist durch
reported, smoking, hormone therapy, workload Cvijetic S. Croat Med
die meisten
Appendix 1 n. - Rating of evidence level using SR of Cochrane J. 2000
eingeschlossenen
a. Collaboration Back review group Dahaghin S. Ann Studien belegt, welche
Period: up to Descriptive statistics: Rheum Dis. 2007 gute methodische
April 2008 - 8 studies investigated only women, 1 study - only Ding H. Obes Res Clin Qualität haben. In
Studies men Pract. 2008 einigen Studien wurde
design: - Outcome was diagnosed using only radiographic Haara MM. Ann allerdings keine
observational criteria in 18 studies, 3 studies used radiographic Rheum Dis. 2003 Assoziation
studies and clinical criteria, 2 studies used only clinical festgestellt.
Jones G. J Rheumatol
criteria, in 2 studies outcome was reported 2002
Heterogeneity: Kessler S. Clin
- n. a. Rheumatol. 2003
Publication bias: Oliveria SA.
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 47
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
- Funnel plot, symmetry was determined visually: the Epidemiology. 1999
plot was asymmetric Sayer AA. Arthritis
Results: Rheum. 2003
- Pooled RR = 1.9 (forest plot), 14 studies Sowers M. Osteoarthr
- Total 25 studies, 15 showed significant association Cartil. 2000
- 15 studies with high quality: Szoeke CE. Bone.
Cohort studies: 1 showed a positive association 2006
(RR = 3.12, 95 % CI 1.65 - 5.88), 1 showed no Hart DJ. J Rheumatol.
association 1993
Case-control studies: reported positive significant Van Saase JL. Ann
association (OR = 1.30, 95 % CI 1.06 - 1.59 and Rheum Dis. 1989
OR = 8.3 95 % 1.2 - 56.5)
11 cross-sectional studies: 7 reported positive
association
13 of high quality studies that used radiographic criteria
for hand osteoarthritis: 10 of these studies showed
positive association
Systematic Van Search Primary outcome: Included studies: Alexopoulus, et al. 2++ Eine systematische
review Duijven- strategy, BMI, waist Study quality: Occup Environ Med. Übersichtsarbeit von
bode DC, inclusion and circumference 2001 13 longitudinalen
- 13 longitudinal studies
et al. criteria were Burdorf A, et. al. Studien guter Qualität.
(2009) reported - Quality assessment was reported: scoring system Keine Analyse der
Occup Environ Med.
[14] adapted from Ariens and Hayden: 12 studies had Heterogenität und
Databases: 1998
high quality Publications bias.
PubMed, Christensen KB, et al.
Embase, - Level of evidence was assessed according up to the
rating system of Hoogendoorn, et al. Ind Health. 2007
PsycInfo,
Descriptive statistics: Ferrie JE, et al.
SportDiscus
Obesity. 2007
Period: 1987 - - Study population of included studies varied from 255
April 2009 to 21 419 workers Jans MP, et al. J
Occup Environ Med.
Studies - Follow up time varied from 1 to 10 years
2007
design: - All studies used BMI as independent variable, one
longitudinal Laaksonen M, et al.
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 48
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
studies study used both BMI and waist circumference Obesity 2007
- Weight was evaluated by self-reports in half of Labriola M et al.
studies Occup Med (Lond).
- the same recommended cut-off points were used to 2006
define overweight or obesity except for one study Moreau M, et al. Int J
(Tsai et al.) that defined obesity as BMI ≥ 27.2 kg/m2 Obes Relat Metab
for men and 26.9 kg/m2 for women Disord. 2004
- sick leave were mostly collected from company Östbye T, et al. Arch
records Intern Med. 2007
- 8 studies distinguished between duration of sick Parkes KR. J Appl
leave Psychol. 1987
- 2 studies analysed the cause of sickness absence
Tsai SP, et al. J
Heterogeneity: Occup Environ Med.
- n. a. 1997
Publication bias: Tsai SP, et al. J
- n. a. Occup Environ Med.
2005
Results:
Vingard E, et al.
Overweight: Scand J Public Health.
- 8 high quality studies: 2005
- 1 study did not distinguished between duration of
sick leave: statistically significant association
- long-term sick leave: 7 studies investigated the
relationship between overweight and long-term sick
leave: 4 reported an association, 3 no association
- short-term sick leave: 5 studies investigated the
relationship with short-term sick leave: inconsistent
and different results
Obesity:
- 10 studies: 1 low quality, 9 high quality
- 1 low quality study: differences in average absence
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 49
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
duration
- 8 studies investigated the relationship with long-term
sick leave, 5 of them investigated also the
relationship with shorter spells
- long-term sick leave: 7 studies reported an
association, 1 study reported no association
- short-term sick leave: inconsistent and different
results: 3 studies reported an association, 2 studies
reported no association
Meta- Muthuri Databases: outcome: Risk Included studies: Cooper C, et al. 2- Different study design,
analysis SG, et al. Ovid Medline Reduction in Knee 47 studies were included: 14 cohort, 19 cross-sectional, Arthritis Rheum 2000 high heterogeneity,
(2011) (1950), OA and 14 case–control studies (flow chart) Shiozaki H, et al. study quality n.a.
[15] Embase Osteoarthritis Survey.
Study quality:
(1980), and Knee 1999
AMED (1985), - 2 reviewers, criteria recommended by the Meta-
Analysis of Observational Studies in Epidemiology Gelber AC, et al. Am J
PubMed, ISI
were used Med 1999
Web of
Science and Descriptive statistics: Grotle M, et al. BMC
CINAHL Musculoskelet Disord
- 446 219 subjects were included
2008
up to July - Risk reduction using population-attributable risk
2010 percentage (PAR %) (the proportion of knee OA that Jarvholm B, et al. Eur
J Epidemiol 2005
Search would have been avoided if obesity had not been
strategy was present in the population) Lohmander LS, et al.
reported - Countries: USA, Europe, others Ann Rheum Dis 2009
Inclusion - Obesity was obtained from the International Obesity Toivanen AT, et al.
criteria: Task Force Rheumatology
(Oxford) 2010
1) design Heterogeneity:
association Wang Y, et al. Arthritis
- significant, random-effects model
between Res Ther 2009
Publication bias:
overweight or Abbate LM, et al.
obesity and - significant (funnel plot, Eggers test): smaller studies Obesity (Silver Spring)
knee OA, or with larger ORs were more likely to be published; n. 2006
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 50
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
knee pain; s. in only cohort or case–control studies Al-Arfaj AS. Saudi
2) BMI as a Results (for weight): Med J 2002
measure - By BMI categories: Anderson JJ, Am J
- Pooled OR for overweight: 2.02 (95 % CI 1.84 - Epidemiol 1988
3) knee
OA = primary 2.22), Aoda H, et al. Acta
outcome - Pooled OR for obesity: 3.91 (95 % CI 3.32 - 4.56) Med Biol (Niigata)
(defined using 2006
- Overweight and obesity: 2.78 (2.45 - 3.15)
radiographs Bagge E, et al. J
- Risk reduction (PAR %): varied from 8 % in China to
and clinical or Rheumatol 1991
50 % in the US (depending on the prevalence of
physician- overweight and obesity) Bernard TE, et al. J
diagnosed Occup Environ Med
OA) - Risk reduction: greater in severe symptomatic OA
than in asymptomatic radiographic OA 2010
Cicuttini FM, et al. J
Rheumatol 1997
Du H, et al. China.
Rheumatol Int 2005
Fernandez-Lopez JC,
et al. Clin Exp Rheu-
matol 2008
Janssen I, et al. Int J
Obes 2006
Kim I, et al. J Korean
Med Sci 2010
Lachance L, et al.
Osteoarthritis
Cartilage 2001
Muraki S, et al.
Osteoarthritis
Cartilage 2009
Sudo A, et al. J
Orthop Sci 2008
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 51
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
Tangtrakulwanich B, J
Orthop Sci 2006
Tukker A, et al. Public
Health Nutr 2009
Von Muhlen D, J
Womens Health Gend
Based Med 2002
Wang W, et al. Chin J
Clin Rehabil 2006
Zeng QY, et al. Chin
Med J (Engl) 2006
Coggon D, et al.
Arthritis Rheum 2000
Dawson J, et al. J
Epidemiol Community
Health 2003
Holmberg S, et al.
Scand J Rheumatol
2005
Klussmann A, et al.
Arthritis Res Ther
2010
Kohatsu ND, Clin
Orthop Relat Res
1990
Limer KL, et al.
Osteoarthritis
Cartilage 2009
Manninen P, et al.
Scand J Work Environ
Health 2002
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 52
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
Mounach A et al. Clin
Rheumatol 2008
Oliveria SA, et al.
Epidemiology 1999
Sahlstrom A, et al.
Clin Orthop Relat Res
1997
Sandmark H, et al.
Ann Rheum Dis 1999
Soeroso J, et al.
APLAR J Rheumatol
2005
Sutton AJ, et al. Ann
Rheum Dis 2001
Vrezas I, et al. Int
Arch Occup Environ
Health 2010
Systematic Sikorski C, Databases: Outcome: Included studies: Hilbert A, et al. J 2- Moderate Reporting
review et al. Medline, Web stigmatizing 7 observ. studies (flow chart) Epidemiol Community quality
(2011) of Science, attitudes Health. 2007,61:585-
Study quality (Randomization/Dropout rate/intention-to-
[16] PSYNDEXplus 90
treat):
,EMBASE and Barry CL, et al.
Cochrane - three studies recruited their participants through
Milbank Q. 2009,87:7-
Library Random Digit Dialing sampling
47
up to February - Most studies: investigation via telephone interviews,
Oliver JE, et al. J
2011 1 study applied an internet survey procedure
Health Polit Policy
inclusion - PRISMA Quality assestment Law. 2005,30:923-54.
criteria: Descriptive statistics: Seo DC, et al. J Natl
nationally or - 3 studies: US population Med Assoc.
community- - 3 studies: German population 2006,98:1300-8
based
- Sample sizes varied 909 to 2 250 Taylor P, et al.
representative
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 53
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
studies; adult - Mean age: 45.9 years [http://pewresearch.or
general Heterogeneity: g]
population; Hilbert A, et al.
- n. a.
reporting on Psychother
attitudes Publication bias:
Psychosom Med
towards, - n. a. Psychol. 2007,57:242-
stereotypes of, Results: 7
or the
- Only 1 study (non RCT) reported explicit measures Hilbert A, et al.
perception of
of stigmatizing attitudes: average „Weight Obesity (Silver Spring,
overweight
Control/Blame” (WCB) score 3.01 = neutral (scale Md). 2008,16:1529-34
and obese
people range: 1 = strongly disagree to 5 = strongly agree)
- Other studies reported causal attributions: The most
prevailing causal attributions were lack of activity
behavior (82.4 %) and overeating (72.8 %)
Meta- Harrington Databases: Comparison: Included studies: See study references 2- Only 2 databases,
analysis M, et al. PubMed weight loss vs. 26 prospective observational studies heterogeneity n. a.
(2009) (Medline), minimal or no
Study quality (Randomization/Dropout rate/intention-to-
[17] ScienceDirect, weight loss
treat):
checking of
criss - 2 investigators, quality assestment n. a.
references Descriptive statistics:
Articles - sample sizes: 34 to 5 008 subjects;
published - majority of the data from white population of US and
between 1987- UK origin,
2008 - follow up: from 2 to 20 years,
English - usually self reporting of body weight,
language
- different confounders
Search terms
Heterogeneity:
were reported
- n. a.
Inclusion
criteria were Publication bias:
reported: - n. a.
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 54
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
prospective Results (for weight):
studies in - Intentional: overall weight loss n. s. effect: RR 1.01,
English of 95 % CI 0.93, 1.09, p = 0.89; Subgroup analysis: for
adults, with “unhealthy” (with obesity related risk factors)
data of body individuals: RR 0.87, 95 % CI 0.77, 0.99, p = 0.028;
weight, weight for “unhealthy” obese: RR 0.84, 95 % CI 0.73, 0.97,
loss over more p = 0.018; for “healthy” individuals: RR 1.11, 95 % CI
than 1 year, 1.00, 1.22, p = 0.05; for overweight individuals: RR
RR or CI were 1.09, 95 % CI 1.02, 1.17, p = 0.008
reported,
- Unintentional (= ill-defined) weight loss: higher
comparison:
mortality risk (RR 1.22, 95 % CI 1.09, 1.37,
minimal or no
p = 0.001)
weight loss
- Unspecified cause of weight loss: RR 1.39, 95 % CI
1.29, 1.51, p < 0.001
Meta- Fabricato- Databases: Different treatment Included studies: Andersen RE, et al. 1- Only 2 studies with
analysis re AN, et Medline, categories: 31 RCTs JAMA. 1999 ITT, low to high
al. (2011) articles 1) lifestyle Annesi JJ, et al. Am J heterogeneity, the typ
Study quality (Randomization/Dropout rate/intention-to-
[18] published modification vs. Med Sci. 2008 of analysis were not
treat):
between 1950- control; spezified in nearly half
- 2 investigators, Bacon L, et al. Int J
2009 of studies
2) lifestyle Obes. 2002
Search terms - only 2 studies reported results from intent-to-treat
modification vs. Cabioglu MT, et al. Int
were reported, and completers’ analyses,
nondieting; J Neurosci. 2007
Inclusion - handling of missing data was not specified in the
3) lifestyle remaining 15 studies Carels RA, et al. J
criteria were modification vs.
Descriptive statistics: Women's Health. 2004
reported dietary counseling;
(human - N = 7 937 Dennis KE, et al.
4) lifestyle Obes Res. 1999
subjects, Heterogeneity:
modification vs.
English), Evangelista LS, et al.
exercise-alone; - different (I2: from 0 to high)
assessment of Am J Cardiol. 2006
weight and 5) exercise-alone - Random effects model was used
Faulconbridge, et al.
symptoms of vs. control; and Publication bias: Obesity. 2009
depression at 6) pharmacologic - Funnal plot, results n.a.
baseline and Fontaine KR, et al.
agent vs. placebo
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 55
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
post-treatment outcome: Results (for weight): Qual LifeRes. 1999
Exclusion depression - Correlations between pre- and post-treatment values Galletly C, et al.
criteria were symptoms for weight and for depressive symptoms were Appetite. 2007
reported unattainable for 65.8 % of comparisons. The mean Hainer V, et al. Int J
observed correlation was 0.54. Obes. 2005
- Six between-groups analyses: Reductions in Halyburton AK, et al.
symptoms of depression were marginally greater Am Journal Clin Nutr.
with lifestyle modification than with dietary 2007
counseling (p = 0.053) and exercise-alone
Kerr J, et al. Depress
(p = 0.054)
Anxiety. 2008
- The largest effect size was found for the comparison
of exercise-alone with control (st. mean deviation: Kiortsis DN, et al. Nutr
0.54, p = 0.03), but high heterogeneity Metab Cardiovasc Dis.
2008
- Non-pharmacologic interventions were associated
with significant reductions in symptoms of depression Klem ML, et al. Int J
(p < 0.001) Eat Disord. 1997
Melanson KJ, et al.
Nutrition. 2004
Nieman DC, et al. J
Psychosom Res. 2000
Pi-Sunyer XF, et al.
JAMA. 2006
Rapoport L, et al. Int J
Obes Relat Metab
Disord. 2000
Sarsan A, et al. Clin
Rehabil. 2006
Sbrocco T, et al. J
Consul Clin Psychol.
1999
Scheen AJ, et al.
Lancet. 2006
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 56
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
Smith PJ, et al. J
Psychosom Res. 2007
Surwit RS, et al. Am J
Clin Nutr. 1997
Tanco S, et al. Int J
Eat Disord. 1998
Van Gaal LF, et al.
Eur Heart J. 2008
Vander Wal JS, et al.
Int J Food Sci Nutr.
2007
Wadden TA, et al. Int
J Obes. 1990
Wadden TA, et al. Am
J Clin Nutr. 2004
Williamson DA, et al.
Health Psychol. 2008
Wing RR, et al.
Diabetes Care. 1991
Systematic Papaion- Databases: Outcome : bone Included studies: Assessment 2- High heterogeneity, p
review nou A, et MEDLINE, minerale density - 25 observational studies: 7 longitudinal and 18 weight/weight loss: and/or 95 % CI for
al. (2009) Cochrane (BMD) cross-sectional studies; Cheung EY, et al. weight n. a.
[19] Database of - Weight/weight loss as risk factor: 7 longitudinal and Osteoporos Int. 2005
Systematic
10 cross-sectional studies were included Kung AW, et al.
Reviews,
Study quality (Randomization/Dropout rate/intention-to- Osteoporos Int. 2005
DARE,
CENTRAL, treat): Lau EM, et al.
CINAHL and - quality assessment checklist was used: rating Osteoporos Int. 2006
Embase, system of the United States Preventive Services Lynn HS, et al.
Health STAR; Task Force (USPSTF): 9 with good quality and 16 Osteoporos Int. 2005
between with fair quality were included Cauley JA, et al.
January 1,
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 57
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
1990 and Descriptive statistics: Osteoporos Int. 2005
January 2006, - target population: healthy men age 50 years or older, Bendavid EJ, et al. J
english, - study cohorts were mainly Caucasian participants, Bone Miner Res. 1996
Search terms - sample sizes ranged from 137 to 5 995 (median 458) Orwoll ES.
and inclusion Osteoporos Int. 2000
Heterogeneity:
criteria were Nguyen TV, et al. J
reported - high
Bone Miner Res. 2000
Publication bias:
Lunt M, et al.
- n. a. Osteoporos Int. 2001
Results (for weight): Yoshimura N, et al.
- In nine studies: weight or BMI were positively Osteoporos Int. 1998
associated with bone minerale density (BMD) at both Hannan MT, et al. J
sites; in one study at the lumbar spine only. Bone Miner Res. 2000
- In 4 studies: BMD was approximately 3 - 7 % higher Dennison E, et al.
at the hip and lumbar spine for every 10 kg increase Osteoporos Int. 1999
in weight.
Burger H, et al. Am J
- In 6 longitudinal studies: low baseline weight or BMI
Epidemiol. 1998
predicted subsequent bone loss at the hip.
Knoke JD, et al. Am J
- In 4 studies: weight loss was associated with an
Epidemiol. 2003
increased rate of bone loss at the hip and at the
lumbar spine Naves M, et al.
- In one study: weight loss of > 1 % per year may Osteoporos Int. 2005
substantially elevate the risk of lower BMD
- In one large cohort study: men who lost ≥ 5 % of
their baseline weight had approximately doubled the
rate of bone loss than men whose weight remained
stable.
- In one study: those who gained weight had very little
or no bone loss.
Systematic Suvan J, Databases: Outcome: Included studies: Studies included in 2+ High heterogeneity,
review/ et al. Ovid peridontitis 33 studies in total were included: 1 cohort, 32 case- meta-analysis: the most of studies
Meta- (2011) MEDLINE, are cross-sectional
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 58
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
analysis [20] EMBASE, control studies; 19 studies were included in meta- Al-Zahrani MS, et al. J studies, 1 abstract
LILACS, and analysis Periodontol. 2003 was included,
SIGLE, Study quality (Randomization/Dropout rate/intention-to- Alabdulkarim M, et al. publication bias
additionally treat): J Int Acad Periodontol. analysis n.a.
checking 2005
- 2 reviewers,
bibliographic
- cohort and case–control studies were assessed Dalla Vecchia CF, et
references
using the validated Newcastle-Ottawa Quality al. J Periodontol. 2005
Search to
Assessment Scale as recommended by the Ekuni D, et al. J
December
Cochrane Collaboration Guidelines; Periodontal Res. 2008
2009
- the quality of cross-sectional studies were assessed Genco RJ, et al. J
Search using questions from the Newcastle-Ottawa Quality Periodontology. 2005
strategy was Assessment Scale: in all studies: low risk of bias
reported Saito T, et al. J Dent
Descriptive statistics: Res. 2001
Inclusion and
exclusion - different confounders were reported, Saito T et al. J
criteria were - N = 1 362 and age 59-72 in cohort study; Periodontal Res. 2005
reported - in cross-sectional studies: different age, different Torrungruang K, et al.
sample sizes: from 60 to 13 665 individuals, J Periodontol. 2005
- different countries Nucci Da Silva L, et al.
Heterogeneity: Atheroscler Suppl.
- high (I2 > 70 %, p for heterogeneity sign.); random 2009
effects models analysis was performed Ylöstalo P, et al. J Clin
Publication bias: Periodontol. 2008
- n.a. Linden G, et al. J Clin
Periodontol. 2007
Results (for weight):
Buhlin K, et al. Eur
- SR: from 33 studies: 30 reported a positive Heart J 2003
association between peridontitis and BMI, 3 reported
no association; Prevalence data ORs ranging from Han DH, et al. J Clin
0.93 to 5.31. Periodontol. 2010
- In meta-analysis (forrest plot): significant Kushiyama M, et al. J
associations between periodontitis and BMI: Periodontol. 2009
- 12 studies: in obese individuals OR 1.81(95 % Nishida N, et al. J
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 59
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
CI 1.42, 2.30), Periodontol. 2005
- 11 studies: overweight individuals OR 1.27 Haffajee AD, et al. J
(95 % CI 1.06, 1.51); Clin Periodontol. 2009
- 6 studies: obese and overweight combined OR Saito T, et al. New
2.13 (95 % CI 1.40, 3.26) England J Medicine.
1998
Khader YS, et al. J
Clin Periodontol. 2009
Kongstad J, et al. J
Periodontol. 2009
Systematic Aucott L, Databases: lifestyle Included studies: Haskell WL, et al. 2- Quality assestment n.
review/ et al. Medline, interventions/ 16 studies: nine related to seven trial studies and seven Circulation 1994 a.
Meta- (2011) Embase, programmes for cohort studies Ditschuneit HH, et al.
analysis [21] PsycINFO, weight loss Am J Clin Nutr 1999
Descriptive statistics:
CINAHL, The (dietary, exercise,
- Follow-up was between 24 and 72 months; two Flechtner-Mors M, et
Evidence behavioural or
studies had large proportions of participants on lipid- al. Obes Res 2000
Based environmental) or
Medicine lowering medication Kuller LH, et al.
intentional weight
Reviews - Intervention trials: Six of the seven intervention trials Circulation 2001
loss (and weight
Collection, cycling) had diet and physical activity as their main Heshka S, et al. JAMA
CAB Nutrition components, Most had clinical or academic settings 2003
Abstracts and - Cohort trials: All had diet components and most Lindstrom J, J Am Soc
Reviews; included exercise; fünf studies included lifestyle Nephrol 2003
along with behavioural advice or behavioural therapy
hand Lindstrom J, et al
programmes; different settings (from residential Diabetes Care 2003
searching of clinics to free-living work places); the frequency and
International duration of contact for each intervention differed Mensink M, et al
Journal of .Obesity 2003;
Heterogeneity:
Obesity and Niebauer J, et al
Obesity - random effects models
Circulation 1997
Research Publication bias:
Sedgwick AW, et al.
Search up to - n. a. Int J Obes 1990
October 2007,
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 60
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
updated in Results (for weight): Eriksson KF, et al
April 2008 - weight loss at 2 - 3 years follow-up, produced Diabetologia 1991
MeSH terms significant beneficial lipid profile changes; weight loss Kauffmann R, et al.
and text words sustained longer than 3 years was not associated Rev Med Chil 1992
for ‘trials’, with beneficial lipid changes Martinez-Gonzalez
‘obesity’, Intervention trials: MA, et al. Eur J
‘overweight’, Epidemiol 1998
‘weight - SCRIP trial: cholesterol improvement of 0.99 mmol
L-1 was on the, but this is confounded with the Sjostrom M, et al .Eur
differences’
previously mentioned lipid-lowering medication; LDL: J Clin Nutr 1999
appropriately
combined significant reductions (-0.95 mmol L-1) Pawlowski Tet al. Pol
- meal replacement trial: Significant cholesterol Arch Med Wewn 2003
Inclusion
reductions of between 0.3 and 0.4 mmol L-1 were Welty FK, et al. Am J
criteria: ≥ 2-
reported (not statistically significant); improvement in Cardiol 2007
year follow-up
triglycerides was 0.94 mmol
for studies
with lifestyle - HDL: 3 studies. improvements: (+0.14 mmol L-1)
interventions/p - Not all studies reported LDL
rogrammes for - Netherlands IGT intervention study: significant
weight loss or weight and triglyceride reductions, but significantly
intentional raised levels of cholesterol and LDL
weight loss Cohort studies:
along with
- 1 study (Pawlowski): While cholesterol decreased for
records of
long-term lipid relevant groups in this study, there was no major
profile weight loss, and so lipid improvement was probably
change(s) for medication-induced.
adult - 1 study (Welty): reported the largest average weight
participants loss (7.8 kg after 31 months) of the cohorts along
with HDL (+0.12 mmol L-1) and LDL (-0.34 mmol L-
Exclusion:
1) improvements, none of these were significant; the
mean BMI ≥
mean triglyceride showed the largest decrease of the
35 kg m2,
whole review (1.14 mmol L-1) (statistically
eating
significant); cholesterol was not reported for this
disorders,
cohort
pregnant, or
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 61
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
mentally or - 2 studies (Sedgwick; Kauffmann): subgroups with
physically weight loss of 2 - 5 kg, with all subgroups showing
handicapped significant benefits for cholesterol
ethnic groups: - Other cohort studies had inconsistent weight lipid-1
UK- change relationships
compatible. Meta-Analysis
Small studies - Combining the results from all papers (excluding the
(appr. 50
SCRIP and Polish studies): average significant
participants
differences of -1.20 kg (95 % CI, -1.90, -0.50) for
per subgroup weight, -0.10 mmol L-1 for triglycerides (95 % CI, -
at recruitment
0.17, -0.03) and 0.05 mmol L-1 for HDL (95 % CI,
and/or appr. 0.01, 0.08) However, the differences of -0.08 mmol
20 at follow-
L-1 for cholesterol (95 % CI, -0.20, 0.05) and -0.07
up)
mmol L-1 for LDL (95 % CI, -0.23, 0.08) were not
significant.
- Subgroup analysis was reported
Meta- Torloni Observational gestational Included studies: 70 studies were 1+ Quality assestment
analysis MR, et al. studies diabetes (GDM) = 70 studies were included (59 cohorts and 11 case- included (see study (high or medium
(2009) Search: 1977- outcome, control studies) references) quality of most
[22] 2007 BMI = exposure studies)
Study quality:
4 databases: This SR followed the
- most studies with the high (14) or medium (43)
Medline, Cochrane
quality, two rewievers, created quality checklist
Embase, methodology and
Descriptive statistics: MOOSE
Cinahl, Lilacs
- 671 945 participants, recommendations (for
No language
- 53 studies form developed countries, MA of observational
or contries
- in 22 studies - measured BMI, in 33 self-reported, in studies)
restrictions
15 studies - no information Search strategy was
Included:
Heterogeneity: reported
studies with
women with - significant heterogeneity (I2 > 50 %) random effects High heterogeneity
information on model was used, sensitivity analysis was performed
prepregnancy
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 62
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
or first Publication bias:
trimester BMI, - n. a.
women with
previously Results (for weight):
diagnosted - the risk of gestational diabetes (GDM) is positively
diabetes associated with prepregnancy BMI
mellitus were Compared with women with normal BMI the unadujsted
excluded pooled OR:
Excluded - For underweight women (results from 16 cohort
studies: no OR studies): 0.78 (95 % CI 0.69 vs. 0.82)
or RR, no - For overweight women (17 cohort studies with
definition of 395 338 participants): 1.97 (95 % CI 1.77 vs. 2.19)
BMI
- For obese women (6 cohort studies with 23 938
categories,wo
participants): 3.01 (95 % CI 2.34 vs. 3.87)
men with high
risk of - For morbidly obese women (7 cohort studies with
diabetes, BMI 22 742 participants): 5.55 (95 % CI 4.27 vs. 7.21)
was registred - For every 1 kg/m2 increase in BMI: the prevalence of
after GDM increased by 0.92 % (95 % CI 0.73 to 1.10)
significant Compared with normal BMI women with at least BMI 25
prepregnancy had the risk of GDM of 2.95 (95 % CI 2.68 vs. 3.24),
weight gain based on 34 cohort studies
Search words Compared with women with BMI < 30 women with
were reported BMI > 30 had OR of GDM of 3.36 (95 % CI 3.01 vs.
3.74) based on 40 cohort studies
Systematic Nordmann Search in Mediterranean Included studies: Estruch R, et al. Ann 1+ Limitations : only 6
review/ AJ, et al. MEDLINE, and low-fat diets 6 RCTs were included Intern Med. included trials (3 trials
Meta- (2011) EMBASE, on cardiovascular 2006;145(1):1-11 published by the same
Study quality:
analysis [23] Biosis, Web of risk factors and Esposito K, et al. group of authors),
Science, and inflammatory - 2 reviewers, quality assestment (no blinding, Four of sign. heterogeneity
JAMA.
the markers the 6 included trials had a loss to follow-up <10%; no (sensitivity analysis is
2003;289(14):1799-
trial was stopped early for benefit) available) ; none of
Cochrane 1804
Central Descriptive statistics: the included trials was
Esposito K, et al..
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 63
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
Register of - 2650 individuals (50% women), JAMA. 2004; powered to detect any
Controlled - Mean age ranged from 35 to 68 years, mean BMI - 292(12):1440-1446 differences in clinical
Trials from from 29 to 35 kg/m2 Shai I, et al. N Engl J outcomes between the
their inception - Follow-up of included trials was 2 years in 4 trials, 4 Med. 2008; 2 diets
until January years in one trial, 6 years in one trial 359(3):229-241.
2011 using the
- Persistence on diet varied between 85% and 95% in Tuttle KR, et al. Am J
terms “diets,
subjects assigned to Mediterranean diets and from Cardiol.
fat restricted
78% to 93% in subjects assigned to low-fat diets 008;101(11):1523-
[Mesh]“
Heterogeneity: 1530.
and
- Q and I2 statistics , signifikant (see results) Esposito K, et al. Ann
“Mediterranea
Intern Med.
n diets.” ; No Publication bias:
2009;151(5):306-314.
language - assestment by means of funnel plots, no evidence
restrictions for publication bias (p<0.1)
Included Results: (2 years of follow-up)
studies : RCTs - weighted mean differences of body weight (-2.2 kg;
(search term : 95% confidence interval [CI], -3.9 to -0.6 ; P for
random) heterogeneity < 0.001, I2=97%) in favour to a
comparing Mediterranean diet
Mediterranean
- BMI (-0.6 kg/m2; 95% CI, -1 to 0.1 ; P for
to
heterogeneity < 0.001, I2=94%) in favour to a
low-fat diets in Mediterranean diet
overweight/ob - systolic blood pressure (-1.7 mm Hg; 95% CI, - 3.4 to
ese individuals -0.1 ; P for heterogeneity < 0.001, I2=89%), diastolic
with with at blood pressure (-1.5 mm Hg; 95% CI, -2.1 to -0.8 ; P
least one for heterogeneity = 0,03, I2=60%) in favour to a
additional Mediterranean diet
cardiovascular
risk factor or - fasting plasma glucose (-3.8 mg/dL, 95% CI, -7 to -
patients with 0.6 ; P for heterogeneity = 0,18 I2=98%) in favour to
a Mediterranean diet
established
coronary - total cholesterol (- 7.4 mg/dL; 95% CI, -10.3 to - 4.4 ;
artery disease, P for heterogeneity = 0,002, I2=73%) in favour to a
Mediterranean diet ; no statistically significant
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 64
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
with a differences in LDL (-3.3 m g/dL; 95% CI, -7.3- -0.6; P
minimum for heterogeneity =0,3, I2=23%) or HDL cholesterol (-
follow-up of 6 0.9 mg/dL; 95% CI, -1.9-3.8, P for heterogeneity
months, <0.001, I2=99%)
reporting - high-sensitivity C-reactive protein (- 1.0 mg/L; 95%
intention-to- CI, -1.5 to -0.5 ; P for heterogeneity <0,001 I2=82%)
treat data on in favour to a Mediterranean diet
cardiovascular
risk factors
Meta- Poobalan Databases: Primar outcome: Included studies: Baeten JM et al. 2001 2- Clearly focused
analysis AS, et al. Medline, OR for cesarian 11 cohort studies (3 prospective) Barau G et al. 2006 question, description
(Milestone (2009) Embase, section of methodology, the
Study quality: Bergholt et al. 2007
paper) [24] Cinahl literature search and
- 2 reviewers, methododlogical quality assestment Bhattacharya S. et al. flow chart were
Search from
using the NOS scala: all studies scored high quality 2007 reported, quality
1996 to May
2007 Descriptive statistics: Cnattingius R et al. assestment is
- Setting: USA (50 % of studies), Denmark, UK, 1998 reported
MESH term
and key word Sweden; Dietz PM et al. 2005 Heterogeneity n. a.
were reported - period from 1976 to 2005; Jensen H et al. 1999 Publication bias n. a.
(combined - in 3 studies: referent group ≠ norm. BMI; Kiran TCU et al. 2005
with Cochrane - in total 143 875 women in the normal BMI catogorie,
Collaboration Stotland NE et al.
43 025 in overweight, 20 419 in obese and 1 874 in 2004
strategy) morbidly obese group
Included: Vahratian A et al.
Heterogeneity: 2005
studies with
- n. a., random effects model was used, Young TK et al. 2002
nulliparous
pregnant - sensitivity analysis n. a.
women Publication bias:
conducted in - n. a.
any setting.
Results (for weight):
Excluded:
Crude pooled OR (95 % CI) for cesarian section
studies with
compared with women with normal BMI:
multiparous
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 65
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
women, case - In overweight women: 1.53 (1.48 to 1.58)
studies or - In obese: 2.26 (2.04 to 2.51)
case series, - In morbidly obese (BMI > 35 kg/m2): 3.38 (2.49 to
multiple 4.57)
pregnancies or
pregnant Pooled odds of having an emergency cesarian section:
women with - In overweight: 1.64 (95 % CI 1.55 to 1.73)
comorbidities, - In obese: 2.23 (95 % CI 2.07 to 2.42)
studien Pooled rates of cesarean section were:
reported an
association - In norm: BMI group: 15.22 %
between - In overweight: 20.52 %
cesarean - In obese: 29.02 %
delivery and - In morbidly obese: 38.37 %
other health Subgroup analysis was reported
care outcomes
Meta- Strazzullo Databases: Primary outcome: Included studies: Abbott RD, et al. 2+ Clearly focused
analysis P, et al. PUBMED, incidence of stroke Twenty-five prospective studies were included in Meta- Stroke. 1994;25 question, methodology
(Milestone (2010) EMBASE, Analysis, total number 33 prospective studies Walker SP, et al. Am J is described, literature
paper) [25] HTA, Epidemiol. 996;144 search is reported,
Study quality:
from January Shaper AG et al. BMJ. Quality assestment is
- 3 investigators, study quality was evaluated by the
1966 through 1997;314:1311-7 reported,
Downs and Black score system, all the studies had a
May 2009; High heterogeneity
quality score of at least 15 out of 19 Wassertheil-Smoller
key words: S, et al. Arch Intern (sensitivity analysis is
Descriptive statistics:
“BMI,” “body Med. 2000;160:494- reported)
mass index,” - 2 274 961 participants from 10 countries (10 studies
500 CI were reported
“overweight” form Europe, 9 from Asia, 6 from US),
Kurth T, et al. Arch publication bias were
AND stroke,” - 30 757 events (11 722 ishamic and 8 380
Intern Med. 2002;162 investigated
“cerebrovascul hemorrhagic score),
ar disease,” or - average follow up time 17.5 years Jood K, et al. Stroke.
combinations 2004;35:2764-9
Heterogeneity (tested by I2 and Q-Statistik):
In addition: Cui R, et al. Stroke.
- significant heterogeneity (p < 0.0001; I2 > 90 %), 2005;36:1377-82
manual search
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 66
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
of references - random effects model was used, Kurth T, et al.
from recent - sensitivity analysis was performed Circulation.
reviews and Publication bias (funnel plot, Egger Test and trim-and- 2005;111:1992-8
relevant fill method were performed): Tanne D, et al. Stroke.
published 2005;36:1021-5
original - no evidence of publication bias forpooled RR of total
stroke for overweight and obese subjects (Egger Murphy NF, et al. Eur
studies.
Test: p = 0.98) Heart. 2006;27:96-106
Inclusion
- but evidence of publication bias for stroke rate in Batty GD, et al. Heart.
criteria were
obese vs. normal-weight (Egger test, p = 0.01), but 2006;92:886-92
original article
in English, no missing study was identified by the trim-and-fill Chen HJ, et al. Stroke.
prospective method 2006;37:1060-4
study design, - no evidence for p. b. for stroke rate in overweight vs. Li C, et al. Int J Obes
follow-up ≥ 4 normal-weight (Lond). 2006;30
years, Results (for weight): Lu M, et al. J Intern
indication of - Pooled RR of total stroke for overweight and obese Med. 2006;260:442-50
number of subjects combined vs normal-weight individuals was
subjects Oki I, et al.
1.05 (95 % CI, 0.89 - 1.24; p = 0.56) Cerebrovasc Dis.
exposed, and
- total stroke rates in obese vs normalweight 2006;22:409-15
number of
individuals: pooled RR 1.26 (95 % CI, 1.07 - 1.48; Park HS, et al. Int J
events across
p = 0.005) Epidemiol. 2006;35
body mass
index - total stroke rates in overweight vs. normalweight Hong JS, et al. Ann
categories individuals: non significant, pooled RR 1.05 (95 % CI,
Epidemiol. 2007;17
0.93 - 1.17; p = 0.42)
Hu G, et al. Arch
- RR for ischemic stroke: 1.22 (95 % CI, 1.05 - 1.41)
Intern Med. 2007;167
for overweight and 1.64 (95 % CI, 1.36 - 1.99, but
publication bias sign.) for obesity, for overweight und Song Y, et al. Am J
obese RR = 1.30 (95 % CI, 1.06 - 1.60; p = 0.01) Cardiol. 2007;100
- RR for hemorrhagic stroke: 1.01 (95 % CI, 0.88 - Funada S, et al. Prev
1.17) and 1.24 (95 % CI, 0.99 - 1.54) for obese; for Med. 2008;47:66-70
overweight and obese individuals pooled RR was Sauvaget C, et al. Int
1.06 (95 % CI, 0.83 - 1.36; p = 0.64) J Epidemiol. 2008;37
Subgroup analysis was performed Zhou M, et al. Stroke.
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 67
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
2008;39:753-9
Eeg-Olofsson K, et al.
Diabetologia. 2009;52
Silventoinen K, et al.
Int J Epidemiol.
2009;38
Zhang X, et al. Stroke.
2009;40:1098-104
Meta- Renehan Literature Primary outcome: Included studies: 141 Studies were 2+ Clearly question,
analysis AG, et al. search in risk of cancer - 141 articles (221 datasets) of prospective included (see study methodology and
(Milestone (2008) Medline and associated with a observational studies (flow chart): reported on 76 references) literature search and
paper) [26] Embase (1966 5 kg/m2 increase studies (67 cohort studies, six nested case-control quality assestment
to November in BMI studies, and three randomised trials) were reported,
2007), no Heterogeneity range:
Study quality:
language 0 up to 84 %
restrictions, - 2 investigators,
p. b. results n. a.
Search - assessed according to three study components:
strategy: terms length of follow-up; whether BMI was self-reported or
related to measured; and the extent of adjustments for
bodyweight potential confounding factors
(“obesity”, Descriptive statistics:
“adiposity”, - 282 137 incident cases (154 333 men and 127 804
“body mass women),
index”, and - half the papers were published since 2004,
“body size”),
- 28 studies were from North America, 35 from Europe
combined with
specific terms and Australia, and 11 from Asia-Pacific;
for each - one cohort was multi-ethnic (three papers), and two
cancer site cohorts analysed black American populations;
included: - follow-up per cancer site varied from 8.4 years
cohort studies (breast cancer) to 14.4 years (multiple myeloma)
if they Heterogeneity:
determined
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 68
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
BMI at - I2 statistik: heterogeneity range 0 – 84 % (particular
baseline and sign.): heterogeneity was high for thyroid and liver
then recorded cancers, and moderate or low for the other sites
incident random effects model was used, sensitivity analysis
cancer cases was reported
during follow– Publication bias:
up; reported
- results?
risk estimates
with 95 % CIs Results (for weight):
across at least In men:
three - increaseed BMI (5 kg/m2) was strongly associated
categories of with oesophageal adenocarcinoma (RR 1.52,
BMI or must p < 0.0001) thyroid (1.33, p = 0.02), colon (1.24,
report p < 0.0001), and renal (1.24, p < 0.0001) cancers;
sufficient data - weaker positive association between increased BMI
to estimate and malignant melanoma (1.17, p = 0.004), multiple
these; case- myeloma (1.11, p < 0.0001), rectal cancer (1.09,
control studies p < 0.0001), leukaemia (1.08, p = 0.009), and non-
nested in such Hodgkin lymphoma (1.06, p < 0.0001).
cohort studies
In women:
and control
arms from - strong associations between a 5 kg/m2 increase in
clinical trials; BMI and endometrial (1.59, p < 0.0001), gallbladder
studies with (1.59, p = 0.04), oesophageal adenocarcinoma
self-reported (1.51, p < 0.0001), and renal (1.34, p < 0.0001)
or measured cancers
height and - Weaker positive associations for: leukaemia (1.17,
weight p = 0.01), and cancers of the thyroid (1.14,
p = 0.0001), postmenopausal breast cancer (1.12,
p < 0.0001), pancreas (1.12, p = 0.01), colon (1.09,
p < 0.0001), and non-Hodgkin’s lymphoma (1.07,
p = 0.05)
Increased BMI was negatively associated with the risk
of lung cancer (0.76, p < 0.0001 in men and 0.80,
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 69
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
p = 0.03 in women); but seperatly for smoking status:
no association for non-smokers (RR 0.91; 95 % CI
0.76 - 1.10)
Subgroup analysis was reported
Meta- Oreopou- Databases: Primary outcome: Included studies: Hall J, et al. J Am 2+ Clearly question,
analysis los A, et Cochrane all-cause mortality - 9 studies: 5 post hoc analyses of RCT-study Acad Nurse Prac. methodology, literatur
(Milestone al. (2008) Central Secondary populations, 1 prospective cohort study, 3 2005;1711 search, studies quality
paper) [27] Register of outcome: retrospective analyses of cohort data collected for Kristorp C, et al. («good» for all
Controlled cardiovascular another research question Circulation. studies) were reported
Trials (1990- mortality 2005;112:1756-62 High heterogeneity,
Study quality:
June 2007), but sensitivity analysis
- 2 reviewers, Davos C, et al. J
MEDLINE was performed,
Cardiac Fail.
(1966 - June - all studies were of high methodological quality (score
8-9/9) as assessed by the Ottawa-Newcastle criteria 2003;9:29-35 publication bias n. a.
2007),
EMBASE Descriptive statistics: Kenchaiah S, et al.
(1988 - June Circulation. 2007;116
- mean length of follow-up was 2.7 years,
2007), Scopus Bozkurt B, et al. Am
(1966 - June - total N = 28 209 individuals Heart J.
2007) and Heterogeneity: 2005;150:1233-9
Web of - significant for all cause mortality (I2 > 50 %, Gustafsson F, et al.
Science p = 0.02), non-significant heterogeneity for Eur Heart J. 2005;
(1900 - June cardiovascular mortality, random effects model was 26:58-64
2007) were used, sensitivity analysis was reported
searched, Cicoira M, et al. Eur J
Publication bias: Heart Fail 2007;9
No language
- n. a. Butler J, et al. Ann
or age
restrictions Results (for weight): Thorac Surg.
all-cause mortality: 2005;79:66-73
Databases
were searched - individuals without elevated BMI vs. overweight: RR Lavie C, et al. Am J
using “heart 0.84, 95 % CI 0.79 - 0.90 Cardiol. 2003;91:891-
4
failure” or - individuals without elevated BMI vs. obesity: all-
“cardiac cause mortality RR 0.67, 95 % CI 0.62 - 0.73
failure” and cardiovascular mortality (versus normal BMI):
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 70
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
“obes$” or - overweight (RR 0.81, 95 % CI 0.72 - 0.92)
“body mass - obesity (RR 0.60, 95 % CI 0.53 - 0.69)
index” as key - Underweight/low-normal-weight (RR 1.20, 95 % CI
words, text 1.04 - 1.38)
words or
MESH Sensitivity analysis (mortality): obese individuals
headings in (adjusted HR 0.88, 95 % CI 0.83 - 0.93); overweight
combination individuals (adjusted HR 0.93, 95 % CI 0.89 - 0.97)
with
“mortality,”
“survival,”
“reverse
epidemiology,”
and “obesity
paradox.”
Inclusion
criteria:
reporting
mortality in HF
patients
according to
BMI category
excluded were
studies
comparing
obese vs
nonobese
Meta- Buchwald Literatur Interventions: Included studies: 134 studies were 2- Study question is
analysis H, et al. search: gastric banding - (flow chart) in total of 134 studies were included and included (see study wide, methodology
(Milestone (2004) MEDLINE, (including extracted: 5 RCT, 28 nonrandomized controlled trials references) and litersture search
paper) [28] Current adjustable and or series with comparison groups, and 101 were descripted,
Contents, and nonadjustable uncontrolled case series. quality assestment of
the Cochrane bands), gastric studies n. a.
Study quality:
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 71
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
Library bypass (principally - quality assestment n. a. sign. heterogeneity
databases. Roux-en-Y Descriptive statistics: (for most of analysis)
MEDLINE variations), publication bias n. a.
- a total of 22 094 patients, 19 % (N = 3 769) men and
(1990-2003, gastroplasty
72.6 % (N = 14 082) women, mean age of 39 years
cutoff date (principally vertical
(range, 16 - 64 years), sex was not reported for 8 %
June 5, 2003) banded
patients,
search terms: gastroplasty),
biliopancreatic - baseline mean BMI for 16 944 patients was
obesity/
diversion or 46.9 kg/m2 (range, 32.3 - 68.8),
surgery,
gastric duodenal switch - Fifty-six of the extracted studies were based in North
bypass, (including a variety America, 58 in Europe, and 20 were conducted in
gastroplasty, of modifications), other locations throughout the world (Australia, New
bariatric, and mixed and Zealand, South America, Japan, Israel, Saudi Arabia,
gastric other (biliary and Taiwan),
banding, intestinal bypass, - majority of studies were conducted at single centers
“anastomosis, ileogastrostomy, (N = 126) and only a few were multicenter studies
Roux-en-Y,” jejunoileal bypass, (N = 5)
biliopancreatic and unspecified Heterogeneity:
diversion bariatric).
- sign. for weight reduction (p < 0.01), random effects
(including Procedures that model was used, sensitivity analysis n. a.
duodenal included a gastric
Publication bias:
switch), or bypass
jejunoileal component (eg, - n. a.
bypass. gastroplasty with Results (for weight):
gastric bypass, - mean weight loss (95 % confidence interval): 61.2 %
biliopancreatic (58.1 % - 64.4 %) for all patients; 47.5 % (40.7 % -
diversion with 54.2 %) for patients with gastric banding; 61.6 %
gastric bypass, (56.7 % - 66.5 %)with gastric bypass; 68.2 %
and banding with (61.5 % - 74.8 %)with gastroplasty; and 70.1 %
gastric bypass) (66.3 % - 73.9 %) with biliopancreatic diversion or
were classified as duodenal switch
gastric bypass
surgery Adverse events:
- Operative mortality (≤ 30 days): 0.1 % for the purely
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 72
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
Primary outcome: restrictive procedures (2 297 patients undergoing
weight loss, banding and 749 patients undergoing gastroplasty),
operative mortality 0.5 % for gastric bypass (5 644 Patients), and 1.1 %
outcome, and 4 for biliopancreatic diversion or duodenal switch
obesity (3 030 patients)
comorbidities Other outcomes:
(diabetes,
- Diabetes was completely resolved in 76.8 % (95 %
hyperlipidemia,
CI, 70.7 % - 82.9 %) of of patients and resolved or
hypertension, and
improved in 86.0 % (95 % CI, 78.4 % - 93.7 %)
obstructive sleep
apnea) - Hyperlipidemia improved in 70 % or more of patients;
the maximum improvements in hyperlipidemia by
meta-analysis occurredwith the biliopancreatic
diversion or duodenal switch procedure (99.1 %;
95 % CI, 97.6 % - 100 %) and with gastric bypass
(96.9 %; 95 % CI, 93.6 %-100 %)
- Hypertension was resolved in 61.7 % (95 % CI,
55.6 % - 67.8 %) of patients and resolved or
improved in 78.5 % (95 % CI, 70.8 % - 86.1 %)
- Obstructive sleep apnea was resolved in 85.7 %
(95 % CI, 79.2 % - 92.2 %) of patients and was
resolved or improved in 83.6 % (95 % CI,71.8 % -
95.4 %) of patients.
Meta- Buchwald Databases: Diabetes Type 2 Included studies: 621 studies were 2- Clearly focused
analysis H, et al. MEDLINE, and weight loss - 621 studies were in SR included, 73 % of the studies included (see study question, methodology
(Milestone (2009) Current after bariatric were single-arm series, 58 % of those retrospective; references) and literature search
paper) [29] Contents, and chirurgie 4.7 % RCT and quality
the Cochrane assessment were
Study quality:
Library (in reported (bad quality),
addition - studies were assigned a level of evidence using the
high heterogeneity,
manually schema of evidence assignment developed by the
CEBM in Oxford; publication bias
reference
analysis n. a.
check) - In addition, RCT were rated for quality with Jadad
Studies score; only 10 studies (1.6 %) contributing class I
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 73
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
published in evidence; By Jadad scoring, 27 of the 29 RCT had a
English from quality score of 1 to 3 and 2 trials had a score of 4 to
January 1, 5.
1990, to April Descriptive statistics:
30, 2006
- in total 888 treatment arms and 135 246 patients,
Search terms 103 treatment arms with 3 188 patients reported on
used were as resolution of diabetes, 19 studies with 43 treatment
follows: arms and 11 175 patients reported both weight loss
obesity/ and diabetes resolution separately for the 4 070
surgery diabetic patients;
(MeSH) OR
- mean age 40.2 years,
gastric bypass
OR - BMI 47.9 kg/m2,
gastroplasty - 80 % were female, and
OR bariatric - 10.5 % had previous bariatric procedures;
OR gastric - Most studies were performed in Europe (44 %) or
banding OR North America (43 %),
anastomosis, - Multicenter studies made up 11 % of the dataset;
Roux-en-Y
Heterogeneity (Q-statistic and I2):
(MeSH) OR
biliopancreatic - Weight loss data (16 diabetes-only studies) less
diversion heterogeneous;
(MeSH) OR - data on diabetes resolution were for the most part
jejunoileal highly heterogeneous (> 75 %) for the entire dataset
bypass but was slightly less heterogeneous (< 75 %) for
(MeSH) OR some surgery groups in the pure diabetic population
([gastric - I2 statistic were often more than 80 % (significantly
pacing OR heterogeneity), the results across studies had I2
gastric more than 65 % in all but the smallest studies;
stimulation] random effects model was used, sensitivity analysis
AND obes*) was reported
Publication bias:
- n. a.
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 74
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
Results (for weight):
Weight loss:
- Total weight loss (all procedures, mean change) for
at least 50 % of study patients was 38.49 kg (95 %
CI 40.36, to 36.63) or 55.9 % of excess body weight
loss. Mean BMI loss was 13.97 (95 % CI 14.51 to
13.43)
- Weight loss at 2 years or more follow-up was 41.6 kg
or 59 % excess body weight loss.
- Weight loss was greatest for the biliopancreatic
diversion/duodenal switch groups followed by gastric
bypass, gastroplasty, and laparoscopic adjustable
gastric banding.
Diabetes resolution:
- 78.1 % of diabetic patients had complete resolution,
diabetes was improved or resolved in 86.6 % of
patients
- Diabetes resolution was greatest for patients
undergoing biliopancreatic diversion/duodenal switch
(95.1 % resolved), followed by gastric bypass
(80.3 %), gastroplasty (79.7 %), and then
laparoscopic adjustable gastric banding (56.7 %).
- Postoperative Insulin levels declined significantly
postoperatively, as did hemoglobin A1c and fasting
glucose values.
Subgroup analysis was reported
Systematic Gill RS, et In English Outcomes: Included studies: Richette P, et al. Ann 2- Clearly focused
review al. (2011) MEDLINE, Primary - 6 studies were included in qualitative analysis (five Rheum Dis. question, insufficient
(Milestone [30] EMBASE, outcome. were case series and one was a case controlled 2011;70:139-44 description of
paper) SCOPUS, study) Parvizi J, et al. J methodology and
change or
BIOSIS Arthroplasty. literature search,
improvement in Study quality:
Previews and
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 75
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
the Cochrane hip or knee joint - 2 reviewers, 2000;15:1003-8 High heterogeneity,
Library pain. This included - methodological quality assesstment using the Abu-Abeid S, et al. Insufficient reporting
The pain score by the Cochrane Risk of Bias tools, level of evidence 2b for Obes Surg. of quality
bibliographies visual analogue all included studies 2005;15:1437-42 assesstment,
of all included scale, knee
Descriptive statistics: Hooper MM, et al. Int Publication bias
articles were society score
- number of patients in the included studies ranged J Obes (Lond). alnalysis n. a.
examined to (KSS) or Harris
from 14 to 1 203 patients; 2007;31:114-20
identify hip score (HSS).
- mean patient age ranged from 37 to 56 years; Korenkov M, et al.
additional Secondary
- Patients undergoing bariatric surgery had a BMI Obes Surg.
relevant outcomes:
ranging from 41 to 51 kg/m2, 2007;17:679-83
publications. 1. Joint space
- the included studies varied in the assessment tools Peltonen M, et al.
Ongoing trials width;
used to evaluate the patient’s hip or knee joint pain Pain. 2003;104:549-
were identified 2. Patient overall 57
using satisfaction; Heterogeneity:
controlled trial - high
3. Severity of
registration
osteoarthritis; Publication bias:
websites,
including 4. Quality of life. - n. a.
ICRTP Search Results (for weight):
Portal for the improved hip and knee osteoarthritis following marked
World Health weight loss secondary to bariatric surgery
Organization.
Search terms
and data n. a.
Systematic De Groot PubMed, Primary Included studies: Fraser-Moodie CA, et 2- Focused study
review NL, et al. EMBASE and outcomes: - 32 studies (5 RCT; 27 cohort/case control studies) al. Scand J question, search
(Milestone (2009) the Cochrane the effect on Gastroenterol 1999 strategy was
Study quality:
paper) [31] Library, search GERD (measured Austin GL, et al. Dig insufficient reported,
terms: - The quality of studies was assessed according to the
by 24-h pH Dis Sci 2006 Middle-bad quality of
combining the Cochrane library definitions; 5 studies with level of
monitoring, Mathus-Vliegen EMH, included studies
words obesity evidence 2; 27 studies with level of evidence 3; 3
manometry, et al. Scand J Publication bias n. a.
and gastro- studies with level of evidence 4
endoscopy and⁄or Gastroenterol 2002
oesophageal radiological Descriptive statistics:
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 76
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
reflux with techniques, the - mean BMI ranged from 23.5 to 53 kg/m2, number of Mathus-Vliegen EMH,
bariatric reduction in reflux patients ranged from 8 to 587 et al. Digestion 2003
surgery, diet, symptoms was Heterogeneity: Frederiksen SG, et al.
lifestyle evaluated by Eur J Surg 2000
- n. a.
intervention questionnaires)
Publication bias: Kjellin A, et al. Scand
and weight Secondary J Gastroenterol 1996
loss outcome: - n. a.
Mathus-Vliegen LM, et
inclusion weight reduction Results (for weight):
al. Eur J Gastroenterol
criteria: (i) (measured in kg, Four of seven studies reported an improvement of Hepatol 1996
obese or in percentages of GERD. For Roux-en-Y gastric bypass: positive effect on
overweight Clements RH, et al.
original weight or GERD was found in 8 studies (mainly evaluated by
patients (ii) Obes Surg 2003
in decreased questionnaires)
Data on BMI); percentage Frezza EE, et al. Surg
gastro- For vertical banded gastroplasty: no change or an
of excess weight Endosc 2002
increase of GERD
oesophageal loss. Jones KB et al. Obes
reflux For laparoscopic adjustable gastric banding: conflicting
Surg 1991
symptoms results.
and⁄or an Jones KB, Obes Surg
established 1998
diagnosis of Nelson LG, et al. Am
GERD. (iii) Surg 2005
Treatment Perry Y, et al. JSLS
modalities 2004
included a Smith SC, et al. Obes
type of Surg 1997
bariatric
surgery Patterson EJ, et al.
(gastric Surg Endosc 2003
banding, VBG Korenkov M, et al.
or RYGB), diet Obes Surg 2002
and⁄or Merrouche M, et al.
diet⁄lifestyle Obes Surg 2007
intervention Ortega J, et al. Obes
excluded: Surg 2004
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 77
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
case reports Di Francesco V, et al.
and expert Obes Surg 2004
opinions Deitel M, Am J Surg
search date 1988
n. a. Papavramidis TS, et
al. Obes Surg 2004
Ovrebo KK, et al. Ann
Surg 1998
Naslund E, et al. Eur J
Surg 1996
Lundell L, et al. Eur J
Surg 1997
Angrisani L, et al.
Obes Surg 1999
Dixon JB, et al. Obes
Surg 1999
Iovino P, et al. Surg
Endosc 2002
de Jong JR, et al.
Obes Surg 2006
de Jong JR, et al.
Obes Surg 2004
Klaus A, et al. Arch
Surg 2006
Weiss HG, et al. Am J
Surg 2000
Weiss HG, et al. Obes
Surg 2002
Tolonen P, et al. Obes
Surg 2006
Suter M, Arch Surg
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 78
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
2005
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 79
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
other follow-up. Results (for weight):
interventions Surgical-related Regarding histological outcomes, 18 studies reported a
in patients with mortality. significant improvement in the degree of steatosis
NASH;
Surgical-related 11 studies reported improvement in histological
alternative morbidity. markers of inflammation
Quasi-
Hepatic-related 6 studies showed some improvement in fibrosis scores.
randomised
mortality. in 4 studies some deterioration in the degree of fibrosis
clinical studies
Hepatic-related was described.
morbidity. The studies included in this review did not directly
Cardiovascular- report adverse-events rates after bariatric surgery.
related mortality. 2 trials reported histological score deterioration in a
Cardiovascular- small percentage of patients: similarly, two studies
related morbidity. reported NASH global scores, and four studies reported
an increase in hepatic fibrosis.
Histological
response (number All other fourteen studies did not report any adverse
of patients without events.
histological
improvement in
the degree of fatty
liver infiltration,
inflammation, and
fibrosis) based on
any score systems
or their
modifications.
Systematic Flegal KM, Search in Outcome: Included studies: 97 studies were 1+ Publication bias
review and et al. PubMed and mortality - 97 prospective studies included: see study analysis n.a., high
Meta- (2013) EMBASE references heterogeneity in most
Study quality: 1 reviewer (1 screen), 3 reviewer - review
analysis [33] through categories ; large
September 30, - Adequately adjustment was assessed: studies if they included population,
(Milestone
2012 were adjusted for age, sex, and smoking and not only one reviewer for
paper)
adjusted for factors in the causal pathway between all studies
without
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 80
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
language obesity and mortality, or if they had reported or
restrictions demonstrated that adjustments or exclusions to
Inclusion: avoid bias had shown little effect on their findings
Articles that Descriptive statistics:
reported HRs - Regions of origin of participants included the United
for all-cause States or Canada (n=41 studies), Europe (n=37),
mortality using Australia (n=7), China or Taiwan (n=4), Japan (n=2),
standard BMI Brazil (n=2), Israel (n=2), India (n=1), and Mexico
categories, (n=1).
prospective - studies included more than 2.88 million participants
studies of
and more than 270 000 deaths
general
populations of - 93 studies for the BMI category of 25 to less than 30
adults (overweight), 61 studies for the BMI category of 30 or
greater (obesity), and 32 studies for the BMI
Exclusion : categories of 30 to less than 35 (grade 1 obesity)
Studies and 35 and greater (grades 2
nonstandard
- and 3 obesity)
categories or
Heterogeneity:
that were
limited to - random-effects model was used
adolescents, - Between-study heterogeneity was statistically
only in significant in most categories
institutional - sensitivity analysis was performed
settings or to Publication bias:
those with
specific - n.a.
medical Results:
conditions or - all-cause mortality HRs relative to normal weight:
to those 0.94 (95% CI, 0.91-0.96) for overweight, 1.18 (95%
undergoing CI, 1.12-1.25) for obesity (all grades combined), 0.95
specific (95% CI, 0.88-1.01) for grade 1 obesity, and 1.29
procedures (95% CI, 1.18-1.41) for grades 2 and 3 obesity
- results from adequately adjusted studies : the
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 81
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
summary HRs were 0.94 (95% CI, 0.90-0.97) for
overweight, 1.21 (95% CI, 1.12-1.31) for obesity (all
grades), 0.97 (95% CI, 0.90-1.04) for grade 1
obesity, and 1.34 (95% CI, 1.21-1.47) for grades 2
and 3 obesity
- Authors conclusion : Relative to normal weight, both
obesity (all grades) and grades 2 and 3 obesity were
associated with significantly higher all-cause
mortality. Grade 1 obesity overall was not associated
with higher mortality, and overweight was associated
with significantly lower all-cause mortality.
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 82
Thema: Prävention
Aggregierte Evidenz
a) Leitlinien
Quelle Text Evidenz- bzw. Literaturbelege Methodische
Empfehlungs- Bewertung
grad
SIGN (2010): Empfehlungen: Domäne 3 (DELBI)
Management of - Individuals consulting about weight management should B n. a. 19 Punkte
Obesity. A national be advised to reduce: Bei der Suche nach
clinical guideline - intake of energy-dense foods (including foods Evidenz wurden
[4] systematischen
containing animal fats, other high fat foods,
confectionery and sugary drinks) by selecting low Methoden angewandt
energy-dense foods instead (for example
wholegrains, cereals, fruits, vegetables and salads)
- consumption of ‘fast foods’ (eg ‘take-aways’)
- alcohol intake
- Individuals consulting about weight management should
B
be encouraged to be physically active and reduce
sedentary behaviour, including television watching.
- Adults consulting about weight management should be
encouraged to undertake regular self weighing. B
- Healthcare professionals should offer weight
management interventions to patients who are planning to B
stop smoking.
- Weight management measures should be discussed with
patients who are prescribed medications associated with B
weight gain.
- Where relevant, patients should be advised that use of B
combined contraceptives or hormone replacement
therapy is not associated with significant weight gain.
Zitierte Literatur:
- A World Cancer Research Fund (WCRF) systematic 2++ WCRF. Washington DC, AICR; 2009 (R. 71)
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 83
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 84
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 85
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 86
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 87
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 88
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 89
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 90
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
prevent weight gain in healthy normal-weight 9
adults within the community Diabetes Prevention
Outcome: weight, studies where the primary intention Program Research Group.
was not to lose weight N Engl J Med.
Dietary interventions vs. Control: 2002;346:393-403
- 2 RCTs: association between low-fat non-reducing Tuomilehto J, et al. N Engl
diet with weight change: -1.42 kg (95 % CI -2.10 to J Med. 2001;344:1343-50
-0.74), Duration: 24 months Lindstrom J, et al. Lancet.
- 2 RCTs: Duration 24 months, signifikant weight 2006;368:1673-9
change, Intervention group -1.6 kg vs. control +1.5 Heshka S, et al. JAMA.
kg 2003;289:1792-8
- intensive diet group: increased mean weight by Jones DW, et al. Am J
2.09 kg and the routine diet group increased Hypertens. 1999;12(Pt1-
weight by 1.57 kg, at a median of 51 months of 2):1175-80
follow-up.
Hypertension Prevention
Behavioural interventions vs. Control: Trial Research Group.
- 1 RCT: Duration 24 months: no significant effect Arch Intern Med.
on weight 1990;150:153-62
Diet and exercise vs. Control: Jeffery RW, Wing RR. J
- 1 Study (809 individuals): intervention did not Consult Clin Psychol.
prevent weight gain, duration 24 and 36 months 1995;63:793-6
Diet and behaviour vs. Control (8 Studies): Kristal AR, et al. Cancer
Epidemiol Biomarkers
- duration 36 months: significant weight change: Prev. 2005;14:2377-83
-1.01 kg (95 % CI -1.34 to -0.68 kg, 2 studies) at
24 months, -1.77 kg (95 % CI -1.94 to -1.59 kg, Kuller LH, et al.
3 studies), Circulation. 2001;103:32-7
- duration 48 months: -0.52 kg (95 % CI -0.85 to Mensink M, et al. Obes
-0.19 kg, 2 studies) Res. 2003;11:1588-96
- duration 90 months -0.70 kg (95 % CI -0.90 to Oldroyd JC, et al.
-0.50 kg, one study) Diabetes Res Clin Pract.
Diet, exercise and behaviour therapy vs. Control: 2006;72:117-27
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 91
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
- 284 individuals: non-significant weight changes, Page RC, et al. Diabet
duration 24 and 36 months Med. 1992;9:562-6
- not significant difference between clinic-and Jeffery RW, French SA.
home-based interventions Am J Public Health.
Diet plus exercise vs. Diet: 1999;89:747-51
- Low-fat diet Ramachandran A, et al.
- Exercise: walking or resistance training, amount Diabetologia.
3.6 - 8.4 MJ/wk 2006;49:289-97
- non-significant weight change, duration 29 - 33 Simonen P, et al. Am J
months Clin Nutr. 2000;72:82-8
Singh RB, et al. J Am Coll
Nutr. 1996;15:592-601
Davis BR, et al. Arch
Intern Med.
1993;153:1773-82
Davis BR, et al.
Hypertension.
1992;19:393-9
Davis BR, et al. Am J
Hypertens. 1994;7:926-32
Trials of Hypertension
Prevention Collaborative
Research Group. et al.
Arch Intern Med.
1997;157:657-67
Stevens VJ, et al. Ann
Intern Med. 2001;134:1-11
de Waard FD, et al. Eur J
Cancer Prev. 1993;2:233-
8
Sheppard L, et al. Am J
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 92
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
Clin Nutr. 1991;54:821-8
Insull W, et al. Arch Intern
Med. 1990;150:421-7
Chlebowski RT, et al. J
Clin Oncol. 1993;11:2072-
80
Howard BV, et al. JAMA.
2006;295:39-49
Ditschuneit HH, et al.
Obes Res. 2001;9(Suppl.
1):284s-9s
Diabetes Prevention
Program Research Group,
Crandall J, et al. J
Gerontol A Biol Sci Med
Sci. 2006;61:1075-81
Prentice RL, et al. JAMA.
2006;295:629-42
Beresford SA, et al.
JAMA. 2006;295:643-54
Dunn AL, et al. JAMA.
1999;281:327-34
Esposito K, et al. JAMA.
2004;292:1440-6
Fogelholm M, et al. Arch
Intern Med.
2000;160:2177-84
Hivert MF, et al. Int J
Obes. 2007;31:1262-9
King AC, et al. Circulation.
1995;91:2596-604
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 93
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
Lanza E, et al. Am J Clin
Nutr. 2001;74:387-401
Levine MD, et al. Obesity.
2007;15:1267-77
Sherwood NE, et al. Int J
Obes. 2006;30:1565-73
Tate DF, et al. Am J Clin
Nutr. 2007;85:954-9
Turner-McGrievy GM, et
al. Obesity. 2007;15:2276-
81
Wein P, et al. Aust N Z J
Obstet Gynaecol.
1999;39:162-6
Pierce JP, et al. JAMA.
2007;298:289-98
Ilanne-Parikka P, et al.
Diabetes Care.
2008;31:805-7
Lanza E, et al. Cancer
Epidemiol Biomarkers
Prev. 2007;16:1745-52
Prentice RL, et al. J Natl
Cancer Inst.
2007;99:1534-43
Tinker LF, et al. Arch
Intern Med.
2008;168:1500-11
Chlebowski RT, et al. J
Natl Cancer Inst.
2006;98:1767-76
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 94
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
Quinn Rothacker D.
Nutrition. 2000;15:344-8
Systematic Neville Included: Second or third Included studies: Booth et al., Health educ 1- Study quality:
review LM, et al. RCTs or generation Study quality: (Randomization/Dropout rate/intention- Res. 2008;23(3):371-81 insufficient
(2009) quasi- computerised to-treat): Cook et al., J Med Interner reporting
[35] experimental intervention in which Res, 2007:9(2):e17 (blinding,
- 6 RCTs
design tailored nutrition, allocation
- National Public Health Partnership guidlines were Spittaels et al. Health
published physical avtivity or consealment,
used for evaluating evience of intervention educ Res.
1996-2008, weight loss advice ITT)
- Internal and external vlidity criteria were reported 2007;22(3):385-96
was generated publications bias
due to Winett et al. Ann Behav
through a - Small or unrepresentative sample not analysed
intervention Med. 2007;33(3):251-61
computerised system - Only 2 studies reported a rationale for sample size
Language small patient
and delivery was - 3 studies described dropouts Hagemann et al. J Geriatr
restriction: groups
inclusive of, but not Phys Ther. 2005;28(1):28-
english exclusive to, the - 5 studies reported randomizations procedure
33
Medline, electronic technology Descriptive statistics:
Veverka et al. Mil Med.
Embase, - Duration: 5 RCTs 2-3 months, 1 RCT 6 months 2003;168(5):373-9
Cinahl et al. Heterogeneity:
Primary Outcome:
Keywords are body mass, body - n. a.
reported weight or waist Publication bias:
circumference
- n. a.
Results:
5 RCTs: short-medium term positive effects on
weight outcomes
- 3 RCTs (small groups: N = 57/39, long-term
follow-up not mantained): reported significant
positive effects between groups.
- 1 RCT (N = 31 women): conflicting results for
different fitness and weight reduction outcomes
- 2 RCTs: positive within groups effects
The evidence of effectiveness or efficacy of
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 95
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
computer-tailored primary prevention interventions
targeting weight reduction is limited to a small
number of studies which are heterogeneous.
Systematic Lombard Databases: Interventions: Included studies: Eiben G, Lissner L. Int J 1- High
review CB, et al. Medline, diet, physical activity, Study quality: (Randomization/ Dropout rate/ Obes (Lond). heterogeneity
(2009) Psychinfo, behaviour intention-to-treat): 2006;30:691-6 between studies
[36] Embase, EBM Hivert MF, et al. Int J (different
- 9 RCTs (one study used a modified
reviews, Obes (Lond). interventions,
Primary outcome: randomization)
CINHAL 2007;31:1262-9 individuals
to prevent weight - unit of randomization: individuals (seven studies), groups)
Keywords families (one study) or schools (one study) Jeffery RW, French SA.
were reported gain in adults Few trials are
- One study adjusted for clustering effect created by Am J Public Health.
Search 1999;89:747-51 available
the randomization method
strategy in Levine MD, et al. Obesity
- Five studies reported on intention-to-treat analysis
details was (Silver Spring).
extra reported - Two studies reported weight data using
multivariate models adjusted for confounding 2007;15:1267-77
Studies: RCTs Klem ML, et al. Int J Obes
baseline variables
Included due Descriptive statistics: Relat Metab Disord.
to: primary 2000;24:219-25
outcome, - Duration: varied from 13 weeks to 5 years:
Leermarkers EA, et al.
study design, - 3 studies 16 weeks or less, 2 studies for 1 Obes Res 1998;6:346-52
study duration, year, 2 studies were for 2 years, 1 study was
for 3 years and one was for 5 years Lombard C, et al. Int J
follow-up
Obes (Lond).
Excluded due - Overall: 375 men and 1 595 women
2008;32(Suppl.1):S34
to comorbidity, - process information was not always reported
Rodearmel SJ, et al.
outcome, - all studies inconporated diet, physical activity and Obesity (Silver Spring).
intervention behaviour components 2006;14:1392-401
Heterogeneity: Kuller LH, et al.
- n. a. Circulation 2001;103:32-7
Publication bias:
- n. a.
Results:
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 96
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
Weight:
- 5 RCTs showed a significant difference in weight
between groups:
- Weight change by group (intervention vs.
control): -1.9 vs. +2.6; -1.9 vs. +0.2; -0.2 vs.
+0.8; -0.54 vs. +0.5; -0.1 vs. +2.4
- 4 RCTs reported no significant difference
Diet:
- The nature of diet varied
- Only one study showed a significant decrease in
energy intake (-669 kJ, -160 kcal) and fat intake
measured by FFQ
Physical activity:
- 3 studies reported no significant difference in
physical activity between groups
- 1 study reported no change in fitness but a
change in self-reported physical activity.
- 3 studies showed limited change in physical
activity
Behaviour:
- 2 studies were showed an association between
frequent self-monitoring of weight and weight
change
Meta- Kremers Databases: lifestyle interventions Included studies: Gomel M, et al. Am J 1- 18 Studien an
analysis S, et al. Medline aimed at prevention 46 studies: Public Health. Frauen, 2
(2009) (PubMed) of overweight and 1993;83:1231-8 Studien an
- 5 studies in which workplace interventions were
[37] Keywords obesity in the adult Jeffery RW, et al. Am J Menschen mit
evaluated
were reported population Public Health. Down Syndrom
(> 18 years) with - 15 community-based intervention studies eingeschlossen
Studies: 1993;83:395-401
primary programme - 5 intervention studies were identified that targeted Publikations-
different a general patient population or high-risk patients Braeckman L, et al. Occup
objective: weight bias, sehr
design Med. 1999;49:549-55
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 97
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
Included mangement, for primary prevention Proper KI, et al. Am J heterogene
studies had to prevention of weight - 4 studies examined diverse ethnic groups e. g. Prev Med. 2003;24:218- Studien
be published gain or moderate Hispanics, African-American women 26
between weight loss - 4 studies were identified of prevention of Kwak LN. The NHF-NRG
January 1990 excessive gestational weight gain for pregnant in Balance Project
and the onset women Department of Human
of the review, Biology. Maastricht
- 2 studies Included women surrounding the
be written in University: Maastricht,
menopause
English or 2007
Dutch, be - 8 studies were identified that investigated the
effect of smoking cessation including weight- Murray DM, et al. Prev
primary
control interventions Med. 1990;19:181-9
studies and
include one or - 2 intervention studies were identified that targeted Shelley E, et al. Eur Heart
more at adults with learning disabilities and adults with J. 1995;16:752-60
anthropometri Down’s syndrome Baxter T, et al. BMJ.
cal outcome Descriptive statistics: 1997;315:582-5
measures - 28 studies (61 %) were executed in the USA, 14 in Jeffery RW, et al. Int J
(e.g. body Europe (five in UK), two in Australia and two in Obes. 1997;21:457-64
weight, body Canada Jeffery RW, French SA.
mass index or
skin-fold - participants ranged between 19 and 48 835 (mean AmJ Public Health.
thickness) 1 892; SD 7 328) 1999;89:747-51
- mean BMI at baseline was 27.3 (SD 3.4) O’Loughlin JL, et al. Am J
Excluded:
studies of - mean age was 42.1 years (SD 9.8) Public Health.
pregnant or - mean duration of the interventions was 18.9 1999;89:1819-26
[pre]menopau months (SD 22.4) Donnelly JE, et al. Arch
sal women Heterogeneity: Intern Med.
2003;163:1343-50
- n. a.
Schmitz KH, et al. Int J
Publication bias:
Obes Relat Metab Disord.
- n. a. 2003;27:326-33
Results: Dzator JA, et al. J Clin
- In 45.7 % significant intervention effects on BMI Epidemiol. 2004;57:610-9
- Effect sizes for changes in BMI was between Slentz CA, et al. Arch
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 98
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
-0.09 and 0.45, a mean effect size was 0.06 (95 % Intern Med. 2004;164:31-9
CI = 0.04 - 0.08) Jenum AK, et al. Diabetes
- univariate regressions: when the programme goal Care. 2006;29:1605-12
was specifically aimed at weight management, the Levitsky DA, et al. Int J
intervention was found to be more successful than Obes. 2006;30:1003-10
programme goals that were aimed at preventing
cardiovascular disease or improving general Schuit AJ, et al. Am J
health status (standardized b = 0.37; p = 0.01). Prev Med. 2006;30:237-
42
- Positive assiciation of intervention duration with
intervention effectiveness at a level p ≤ 0.15 Hivert MF, et al. Int J
Obes. 2007;31:1262-9
Salyer J, et al. Prog
Transplant. 2007;17:315-
23
Family Heart Study
Group. BMJ.
1994;308:313-20
Andersen RE, et al.
JAMA. 1999;281:335-40
Riebe D, et al. Prev Med.
2003;36:45-54
Jackson C et al. J Adv
Nurs. 2007;58:23-34
McConnon A, et al. BMC
Health Serv Res.
2007;7:206
Howard-Pitney B, et al.
Am J Public Health.
1997;87:1971-6
Yanek LR, et al. Public
Health Rep.
2001;116(Suppl.1):68-81
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 99
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
Hall WD, et al. Ethn Dis.
2003;13:337-43
Winett RA, et al. Ann
Behav Med. 2007;33:251-
61
Clapp JF III, Little KD.
Med Sci Sports Exerc.
1995;27:170-7
Polley BA, et al. Int J
Obes Relat Metab Disord.
2002;26:1494-502
Olson CM, et al. Am J
Obstet Gynecol.
2004;191:530-6
Kuller LH, et al.
Circulation. 2001;103:32-7
Simkin-Silverman LR, et
al. Ann Behav Med.
2003;26:212-20
Howard BV, et al. JAMA.
2006;295:39-49
Hall SM, et al. Am J Public
Health. 1992;82:799-803
Pirie PL, et al. Am J Public
Health. 1992;82:1238-43
Danielsson T, et al. BMJ.
1999;319:490-3
Marcus BH, et al. Arch
Intern Med.
1999;159:1229-34
Jonsdottir D, et al. Scand
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 100
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
J Caring Sci.
2001;15:275-82
Perkins KA, et al. J
Consult Clin Psychol.
2001;69:604-13
Spring B, et al. J Consult
Clin Psychol.
2004;72:785-96
Copeland AL, et al. Addict
Behav. 2006;31:115-27
Rimmer JH, et al. Am J
Ment Retard.
2004;109:165-74
Chapman MJ, et al. J
Intellect Disabil.
2005;9:131-44
Systematic Enwald Databases: second generation Included studies: Oenema A, et al. Ann 1- Die meisten
review HP, et al. MEDLINE, tailored health - 21 RCTs and 2 quasi-experimental design Behav Med. Outcomes sind
(2010) Science communication (nonrandomized controlled Trials) 2005;29(1):54-63 nicht relevant
[38] Direct, Google (using interactive Kroeze, et al. J Nutr Educ (Verhaltensän-
- 10 studies focused on behavior change in
Scholar, CSA, media e. g. E-Mail, nutrition, 7 on change in physical activity, 2 on Behav. 2008;40(4):226-36 derungen usw.),
EBSCO, Internet) nur in 4 Studien
change in both nutrition and physical activity, and Booth, et al. Health Educ
LISTA, 4 on behavior change related to weight relevante
Res. 2008;23(3):371-81
Emerald Outcomes
management Oenema A, et al. Health
Journals, Web Gruppen sehr
of Science - 14 studies did not include a no-information control Educ Res.
group heterogen bzgl.
(ISI), and 2001;16(6):647–60
Intervention-
ABI/Inform Descriptive statistics: Block, et al. Prev Chronic Design, Dauer,
(ProQuest); - 8 studies included more than 500 participants, 6 Dis. 200415;1(4):A06 Geschlecht,
Keywords studies included less than 100 participants Dunton, et al. Prev Med. Abbrechquoten,
were reported; - Duration: most (20) studies were short (6 months 2008;47(6):605-11 Ethnien,
not limited by or less) Frenn, et al. Appl Nurs Bildungsgrade
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 101
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
publication Results: Res. 2005;18(1):13-21 Selektionsbias
date Nutrition interventions: more positive results Hageman, et al. J Geriatr
Included: RCT (possible cause: fruit and vegetable consumption is a Phys Ther. 2005;28(1):28-
or quasi- relatively easy behavioral change) 33
experimental physical activity interventions: less positive results Irvine, et al. Health Educ
designs with Res. 2004;19(3):290-305
pretest and - many studies ended up with negative outcomes
from the perspective of tailoring Luszczynska, et al. Health
posttest;
- physical activity measurements were conducted Educ Res.
focused on 2007;22(5):630-8
both objectively and by self-report
second
- In 4 physical activity studies, the outcomes were Marcus, et al. Arch Intern
generation
mixed or negative from the perspective of tailoring Med. 200714;167(9):944-
interventions;
Tailoring: In 6 studies (2 on nutrition, 3 on physical 9
focused on
health activity and 1 on weight management), tailoring did Napolitano, et al. Ann
behavior not increase the effectiveness of the intervention. Behav Med.
related to - In some studies the effectiveness of the 2003;25(2):92-9
nutrition, intervention was reported as mixed from the Di Noia, et al. Am J Health
physical perspective of tailoring: some measured indicators Promot. 2008;22(5):336-
activity, or may have been better and others worse when 41
weight compared with the control group. Papadaki, et al. Patient
management, Educ Couns.
4 Weight management-studies:
alone or in 2008;73(2):256-63
combination; - in 3: significantly decreases in weight loss, but 1
measured or with a high attrition rate; Park, et al. J Nutr Educ
assessed - in 1 study: self-reported and objectively measured Behav. 2008;40(5):288-97
behavioral, results might not always be in line. The tailored Rothert, et al. Obesity
psychological, intervention group ended up with significantly (Silver Spring).
or greater objectively measured weight loss and 2006;14(2):266-72
physiological greater reduction in waist circumference. Spittaels, et al. Health
outcomes; Educ Res.
included 2007;22(3):385-96
design; full Tate, et al. Arch Intern
text available Med. 2006;166(15):1620-
Excluded:
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 102
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
measured only 5
the feasibility Tate DF, et al. JAMA.
and 2001;285(9):1172-7
acceptability of
de Vet Emely, et al.
computer-
Health Educ Res.
delivered
2008;23(2):218-27
tailored health
communica- Walker, et al. Nurs Res.
tion; focused 2009;58(2):74-85
on diabetes Wanner, et al. J Med
self- Internet Res.
management; 2009;11(3):e23
gave advice in Oenema, et al. Ann Behav
computer Med. 2008;35(2):125-35
kiosk or in an
online Internet Spittaels, et al. Prev Med.
shopping site 2007;44(3):209-17
Meta- Anderson RCTs, non- Worksite Included studies: Abrams DB, Follick MJ. J 1- Heterogeneity:
analysis LM, et al. randomised interventions Study quality: (Randomization/ Dropout rate/ Consult Clin Psychol. Results of Q-test
(2009) studies, cohort (nutrition and intention-to-treat): 1983;51(2):226-33 n.a., only “not
[39] designs, time physical activity Anderson J, Dusenbury L. significant”
- 47 studies: 31 RCTs, 12 non-randomised studies,
serie programs) AAOHN J. 1999;47(3):99-
3 cohort designs, 1 time series
Following Outcomes: different - Quality assessment: “Community Guide” was used 106
Randomization
Databases weight related Briley ME, et al. J Am Diet
- Studies with greatest or moderate design procedure,
were used: outcomes including Assoc. 1992;92(11):1382-
suitability and good or fair quality of execution allocation
Medline, weight in pounds or 4
were included concealment,
Embase, kilograms, BMI and
- Random effect model Cook C, et al N Z Med J. blinding, drop
Cinahl, percentage body fat
2001;114(1130):175-8 outs,
Cochrane - Only 2 RCTs reported intention-to-treat analysis
DeLucia J, et al. J Subst publications bias
library et al. - Many of the studies reported insufficient statistical
Abuse. 1989;1:203-8 not reported
Up to 2005 information for statistical pooling with CIs
- Randomization procedures, allocation Forster JL, et al. J Occup
Keywords
concealment, blinding, drop outs n. a. Med. 1985;27(11):8084-8
were reported
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 103
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
Language Descriptive statistics: Furuki K, et al. J Occup
restriction: - Outcome measure at least 6 - 12 months from the Health. 1999;41:19-26
only English start of intervention program Gomel M, et al. Am J
Included due - any weight status: normal, overweight, obese Public Health.
to: design, 1993;83(9):1231-8
- Intervention: worksite health promotion programs
duration, Jeffery RW, et al. Am J
including nutrition or physical activity programs or
weight status, both with different implementations-strategies Public Health.
intervention, 1993;83(3):395-401
outcome - Separate analysis of studies comparing
intervention to untreated control and intervention Karlehagen S, Ohlson
to multiple treatment arm CG. Prev Med.
- The behaviour focus of 27 studies was on diet and 2003;37(3):219-25
physical activity, 10 diet only, 10 physical activity Lovibond SH, et al. J
only Behav Med. 1986;9:415-
- Duration was < 6 months in 19 studies, 6 - 9 37
months in 14 studies, 12 - 18 months in 8 studies, Muto T, Yamauchi K. Prev
> 18 months in 6 studies Med. 2001;33(6):571-7
- Different data were not reported (age in 70 % of Nilsson PM, et al. Scand J
studies, socioeconomic data and information Work Environ Health
about jobs in 40 % of studies, the size of worksite 2001;27(1):57-62
in 64 % of studies)
Nisbeth O, et al. Patient
Heterogeneity: Educ Couns.
- Q-Statistik was used 2000;40(2):121-31
- Analysis part II: 9 RCTs (outcome weight in Oden G, et al. Fitness
pounds): Q-Test for heterogeneity was not Bus. 1989;4:198-204
significant Pohjonen T, Ranta R.
Publication bias: Prev Med.
- n. a. 2001;32(6):465-75
Results: Pritchard JE, et al. Nutr
Diet. 2002;59(2):87-96
- Analysis part I: all study design were used;
Anderson JV, et al. J
- Analysis part II: effects separately by study
design: Occup Med.
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 104
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
- Analysis part II: RCTs: 1993;35(8):800-4
- 9 RCTs; outcome weight in pounds: pooled Cockcroft A, et al. Occup
effect was -2.8 pounds (95 % CI -4.63 to Med (Lond).
-0.96) in favour of intervention 1994;44(2):70-6
- 3 RCTs: physical activity behaviours alone: Elberson KL, et al.
effect was -2.24 pounds (95 % CI -6.49 to Outcomes Manag Nurs
+2.00) Pract. 2001;5(2):82-6
- 5 RCTs: physical activity and diet: effect was Gerdle B, et al. J Occup
-3.18 pounds (95 % CI -5.88 to -0.5)
Rehabil. 1995;5(1):1-16
- One study: diet alone: weight loss was -1.71
(95 % CI -8.38 to +4.95) Hedberg GE, et al. Occup
Environ Med.
- 6 RCTs; outcome BMI: pooled effect was
1998;55(8):554-61
-0.47 (95 % CI -0.75 to -0.19) in favour of
intervention Wier LT, et al. Aviat
- 3 cluster RCTs reported BMI outcomes in 6 Space Environ Med.
months: pooled effect was -0.25 (95 % CI 1989;60:438-44
-0.64 to +0.14) Anderson J, Dusenbury L.
- Subgroup analysis: no association between AAOHN J. 1999;47(3):99-
program effectiveness and focus of program 106
or behavioral focus Fukahori M, et al. J Occup
- But: small number of studies in each category Health. 1999;41(2):76-82
Juneau M, et al. Am J
Cardiol. 1987;60:66-77
Krishnan N, et al. Indian J
Ind Med. 2004;8(2):29-33
Peterson G, et al. Behav
Ther. 1985;16(A2):213-22
Shimizu T, et al. J Occup
Health. 2004;46(3):205-12
Steinhardt M, et al. J
Psychol. 1999;133(5):495-
513
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 105
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
Borenstein M, Englewood
NJ. Biostat. 2006,(33)
Briley ME, et al. J Am Diet
Assoc. 1992;92(11):1382-
4
Bruno R, et al. Prev Med.
1983;12(4):523-32
Crouch M, et al. Prev
Med. 1986;15:282-91
Erfurt JC, et al. Am J
Health Promot.
1991;5(6):438-48
Linenger JM, et al. Am J
Prev Med 1991; 7(5):298–
310
Okayama A, et al. Environ
Health Prev Med 2004;
9(4):165–9
Elliot DL, et al. Am J
Health Behav 2004;
28(1):13–23
Drummond S, Kirk T. J
Hum Nutr Diet
1998;11:473–85
Robison JI, et al. Med Sci
Sports Exerc
1992;24(1):85–93
Talvi AI, et al. Occup Med
(Lond) 1999 Feb;49(2):
93–101
Barratt A, et al. Am J
Public Health
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 106
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
1994;84(5):779–82
Aldana SG, et al. J Occup
Environ Med
2005;47(6):558–64
Grandjean PW, et al. J
Sports Med Phys Fitness
1996;36(1):54–9
Harvey HL. Dissert Abstr
Int B: Sci Eng 1998;60
(2B)
Proper KI, et al. Am J
Prev Med 2003;
24(3):218–26
Thorsteinsson R, et al.
Scand J Prim Health Care
1994;12(2):93–9
Systematic Lin JS, et Included: counseling for both Included studies: 13 studies of good quality: 1- High hetero-
Review al. (2010) - trials with physical activity and Study quality: (Randomization/ Dropout rate/ Elley CR, et al. BMJ. geneity
[40] primary dietary change with a intention-to-treat): 2003;326:793
care– focus on the
- 66 studies, most of them RCTs Kallings LV, et al. Eur J only 13 were
relevant prevention of
- only 13 were good- quality trials Cardiovasc Prev Rehabil. good- quality
counseling cardiovascular
Descriptive statistics: 2009;16:80-4 trials
on physical disease
- minimum follow-up of 6 months after Kolt GS, et al. J Am
activity or
Geriatr Soc. 2007;55:986- Randomization
healthful randomization
92 procedure,
diet Heterogeneity:
intervention Lawton BA, et al. BMJ. allocation
- Statistical heterogeneity was high (I2= 70%) 2008;337:a2509 concealment,
s
Publication bias: Marcus BH, et al. Health blinding, drop
- minimum
follow-up - n. a. Psychol. 2007;26:401-9 outs,
publications bias
- priori Results: Martinson BC, et al. Prev
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 107
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
outcomes Medium- to high-intensity dietary behavioral Med. 2008;46:111-9 n. a.
counseling, with or without physical activity Morey MC, et al. J Am
counseling : small but statistically significant Geriatr Soc.
improvements in adiposity, blood pressure, and 2009;57:1166-74
cholesterol level
Hypertension Prevention
The evidence for changes in physiologic outcomes Trial Research Group.
was strongest for high-intensity counseling Arch Intern Med.
interventions. 1990;150:153-62
Medium- to high-intensity dietary interventions (with The Trials of Hypertension
or without concomitant physical activity counseling) Prevention Collaborative
decreased body mass index at about 12 months. Research Group. Arch
2/3 of ttrials of high-intensity dietary interventions Intern Med. 1997;157:657-
reported statistically significant group differences, 67
suggesting that although the amount of weight Tinker LF, et al. Arch
change varied greatly from study to study, these Intern Med.
interventions are likely to reduce weight (decrease in 2008;168:1500-11
body mass index of approximately 0.3 to 0.7 kg/m2).
Mosca L, et al. Circ
Physical activity counseling trials were limited to Cardiovasc Qual
primarily medium-intensity interventions for this Outcomes. 2008;1:98-106
outcome and generally did not reduce adiposity.
Simkin-Silverman LR, et
Five trials evaluating high-intensity counseling had al. Womens Health.
follow-up longer than 12 months; the reduction in 1998;4:255-71
body mass index persisted up to 72 months,
Wister A, et al. CMAJ.
although this result was slightly attenuated.
2007;177:859-65
Systematic Spring B, Search Smoking treatment Included studies: Danielsson T, et al. BMJ. 1+ Zusammen-
review et al. strategy was vs. combined Study quality: 1999; 319:490–4 fassung:
(2009) reported smoking treatment Hall SM, et al. Am J Public Gute
- 10 RCTs
[41] Databases: and weight control Health. 1992; 82:799–803 methodische
- 2 authors for inclusion by reviewing the titles and
Cochrane Marcus BH, et al. Arch Qualität des SR
abstracts (the proportion of agreement was 93 %):
Database of Intern Med. 1999; Vor allem
2-4 authors for data extraction
SR, 159:1229–34 weibliche
CENTRAL, - Quality assessment was reported: quality of
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 108
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
PubMed, Ovid studies was assessed using the validated PEDro Marcus BH, et al. Am J Probanden
MEDLINE, scale (ranged from 5 to 8) Cardiol. 1991; 68:406–7
CINAHL, Descriptive statistics: Marcus BH, et al. Addict
EMBASE, and Behav. 1995; 20:87–92
- 154 male and 2079 female adults
PsycInfo
- “regular” smokers Marcus BH, et al. Nicotine
Period: up to Tob Res. 2005; 7:871–80
August 2007 - Any ethnic origin
- Interventions: non-pharmacological, non- Perkins KA, et al. J
Studiendesign: Consult Clin Psychol.
chirurgical treatment
RCTs 2001; 69:604–13
- Classification of smoking cessation: short ≤ 3
months, long-term ≥ 6 months Pirie PL, et al. Am J Public
Heterogeneity: Health. 1992; 82:1238–43
- tests for heterogeneity were statistically significant Spring B, et al. J Consult
Clin Psychol. 2004;
- sensitivity analysis was performed 72:785–96
- subgroup analysis was performed
Ussher M, et al. 2007;
- Random effects model was used 32:3060–4
Publication bias:
- Funnel plots and standardized Hedge's g against
standard error were used
- Eggers p-values: 0.06-0.33: possibility that small
negative studies were excluded
Results:
Smoking cessation:
Combined smoking plus weight treatment produced
significantly higher short-term abstinence (OR=1.29,
95% CI=1.01,1.64 p=.041)
But: no longer significant for long-term abstinence
(OR=1.23, 95% CI=0.85,1.79 p=0.27)
Post-cessation Weight Gain:
Combined smoking plus weight treatment also
reduced short-term weight gain significantly
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 109
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
compared to smoking treatment alone (g=-0.30 95%
CI=-0.57,-0.02 p=.035)
But: The advantage was no longer significant for
long-term weight control (g=-0.17 95% CI=-0.42,0.07
p=.16)
Subgroup analysis: similar effects in all groups
Systematic Farley AC, Search Pharmacological Included studies: Cooper 2005; Copeland 1+ Zusammen-
review et al. strategy was interventions versus - 73 Studies 2006; Danielsson 1999; fassung:
(Coch- (2012) reported placebo for post Hall 1992; Hankey 2009; Gute
Heterogeneity:
rane) [42] Database: cessation weight Klesges 1990; Klesges methodische
control ; - significant statistical heterogeneity. 1999; Levine 2010;
Cochrane Qualität des SR;
Tobacco Behavioural weight Results: Norregaard 1996; Heterogene
Addiction management - pharmacological interventions for post cessation O’Malley 2006; Parsons Studien
Group’s interventions versus weight gain (PCWG): significant reduction in WG 2009; Perkins 2001; Pirie
Specialized advice or no at the end of treatment (dexfenfluramine (Mean 1992; Spring 1995 ;
Register of intervention ; difference (MD) -2.50kg, 95% confidence interval Spring 2004; Toll 2010;
trials, included (CI) -2.98 to -2.02, 1study), phenylpropanolamine Gonzales 2006; Hurt
CBT to accept
reports of trials (MD -0.50kg, 95% CI-0.80 to -0.20, N=3), 1997; Jorenby 2006;
moderate weight
indexed in naltrexone (MD -0.78kg, 95% CI-1.52 to -0.05, Niaura 2002, Nides 2006;
gain versus no
MEDLINE to N=2); evidence that treatment reduced weight at Piper 2007; Rigotti 2006;
behavioural weight
update 6 or 12 months (m). No pharmacological Saules 2004; Simon 2004;
advice ; All types of
20110826, intervention significantly affected smoking Simon 2009; Uyar 2007;
antidepressant
EMBASE to cessation rates; Zellweger 2005; Bize
versus placebo for
2011week 33, 2010; Marcus 1999;
smoking cessation ; - Weight management education only was
PsycINFO to Marcus 2005; Ussher
Exercise associated with no reduction in PCWG at end of
20110822 and 2003; Abelin 1989;
interventions versus treatment (6 or 12m); these interventions
Web of Blondal 1999; Bohadana
no exercise for significantly reduced abstinence at 12m (RR 0.66,
Science; 2000; CEASE 1999;
smoking cessation ; 95% CI 0.48 to 0.90, N=2).
CENTRAL Cooper; Dale 1995;
All types of NRT - Personalised weight management reduced PCWG Ehrsam 1991; Fiore
Inclusion versus placebo for at 12m (MD -2.58kg, 95% CI -5.11 to-0.05, N=2) ; 1994A; Fiore 1994B;
criteria were smoking cessation ; was not associated with a significant reduction of Garvey 2000 ; Gourlay
reported abstinence at 12m (RR 0.74, 95% CI 0.39 to 1.43,
Varenicline versus 1995; Gross 1995;
N=2).
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 110
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
placebo for smoking - A very low calorie diet (VLCD) significantly Hjalmarson 1984;
cessation ; reduced PCWG at end of treatment (MD -3.70kg, Hjalmarson 1994;
Varenicline versus 95% CI-4.82 to-2.58, N=1), but not significantly so Hjalmarson 1997; Lerman
bupropion ; at 12m (MD -1.30kg, 95% CI-3.49 to 0.89, N=1) ; 2004; Pack 2008; Pirie
Varenicline versus VLCD increased chances of abstinence at 12m 1992; Puska 1995;
NRT (RR 1.73, 95% CI 1.10 to 2.73, N=1). Richmond 1994; Sachs
- Cognitive behavioural therapy to allay concern 1993; Shiffman 2002A;
about weight gain (CBT) : no evidence for Shiffman 2002B;
reduction of PCWG ; some evidence of increased Stapleton 1995;
PCWG at 6m (MD 0.74, 95% CI 0.24 to 1.24); Sutherland 1992; TNSG
was associated with improved abstinence at 6m 1991; Tonnesen 1991;
(RR 1.83, 95% CI 1.07 to 3.13, N=2) but not at Tonnesen 1993;
12m (RR 1.25, 95% CI 0.83 to 1.86, N=2). Wallstrom 2000; Aubin
- no evidence that exercise interventions 2008; Gonzales 2006;
significantly reduced PCWG at end of treatment Jorenby; Nakamura 2007;
(MD -0.25kg, 95% CI-0.78 to 0.29, N=4), Niaura 2008; Nides 2006;
significant reduction at 12m (MD -2.07kg, 95% CI- Oncken 2006; Rigotti
3.78 to-0.36, N=3). 2010; Tashkin 2011;
Tonstad 2006, Tsai 2008;
- bupropion and fluoxetine limited PCWG at the end
Wang 2009
of treatment (bupropionMD-1.12kg, 95%CI-1.47
to-0.77,N=7) (fluoxetine MD -0.99kg, 95% CI-1.36
to-0.61, N=2) ; no evidence that the effect
persisted at 6m (bupropion MD -0.58kg, 95% CI-
2.16 to 1.00, N=4), (fluoxetine MD -0.01kg, 95%
CI-1.11 to 1.10, N=2) or 12m (bupropion MD -
0.38kg, 95% CI-2.00 to 1.24, N=4). ; no data on
WG at 12m for fluoxetine.
- treatment with NRT attenuated PCWG at the end
of treatment (MD -0.69kg, 95% CI-0.88 to-0.51,
N=19), with no strong evidence that the effect
differed for the different forms of NRT (the
difference in weight change at end of treatment
was -0.45kg (95% CI-0.66 to-0.27, N=18); no
evidence of an effect on PCWG at 12m (MD -
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 111
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
0.42kg, 95% CI-0.92 to 0.08, N=15).
- evidence that varenicline significantly reduced
PCWG at end of treatment (MD -0.41kg, 95% CI-
0.63 to-0.19, N=11), but this effect was not
maintained at 6 or 12m. No significant difference
in PCWG between varenicline and NRT.
Systematic Lopez LM, Search progestin-only pills, Included studies: Relevant studies: 1+ Zusammen-
review et al. strategy was Norplant, and - 15 studies: 9 = prospective (5 RCTs and 4 other Ball 1991 fassung:
(Coch- (2011) reported depotmedroxyproges prospective); 6 = retrospective Gute
Bonny 2009
rane) [43] Database: terone acetate methodische
- From multiple continents Castle 1978
MEDLINE, (DMPA) versus other Qualität des
pills or placebo - 3 of 5 RCTs did not have any information on
CENTRAL, Espey 2000 SR ;
randomization method or allocation concealment;
POPLINE, other 2 RCTs reported the method of Moore 1995 Verschiedene
EMBASE, randomization and allocation concealment; 2 Pantoja 2010 Interventionen
LILACS, RCTs had information on blinding. 1 studie was wurden
Salem 1984
ClinicalTrials.g reportedly “single-blind.” For the trials used in vergliechen ;
ov, ICTRP Salem 1988
Westhoff 2007, the evaluators were blinded. 8 von 15 studien
- Quality of evidence was assessed quality of Sivin 1998 haben schlechte
Inclusion evidence using the GRADE approach Sule 2005 bzw. Sehr
criteria were - 3 studies: high quality; 3 studies: moderate quality; Taneepanichskul 1998 schlechte
reported 4 studies: low quality; 4 studies: very low quality Tankeyoon 1976 qualität
Heterogeneity: Tuchman 2005
- was analysed, sensitivity analysis was reported Westhoff 2007
Results: WHO 1983
- Three RCTs compared two POCs
- Three retrospective studies compared a POC to a
nonhormonal IUD
- The retrospective study of Espey 2000 showed
two DMPA groups to be similar in weight gain at
one and two years
- DMPA in adolescents: greater increase in body
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 112
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
fat versus a group using no hormonal method
(mean difference 11.00 %; 95% CI 2.64 to 19.36)
and lean body mass (%) (mean difference -4.00;
95% CI -6.93 to -1.07).
- DMPA group comparing IUD group: weight gain
(kg) was greater (mean difference) 2.28, 2.71,
3.17, respectively).
- Norplant group versus non-hormonal IUD group:
greater weight gain (kg) (mean difference 0.47 kg
(95% CI 0.29 to 0.65)
- Norplant group versus group using non-hormonal
or no method: greater weight gain (mean
difference 0.74; 95% CI 0.52 to 0.96).
- Norplant group versus IUD group: greater weight
gain (kg) (mean difference 1.10 kg; 95% CI 0.36 to
1.84).
Meta- Oken E, et Database: children whose Included studies: Adams AK et al, Am J Clin 2+ Meta-analysis of
analysis al. (2008) Medline: mothers smoked Study quality: Nutr 2005;82:393–398 observational
(Milestone PubMed, Ovid; during pregnancy Al Mamun A, et al, Tob studies
- 14 observational studies were included
paper) studies compared with Control 2006;15:452–457
[44] published children whose - Two authors (EO and EL) performed independent
data extractions of the eligible studies, in Bergmann KE, et al, Int J p.b., but
between 1966- mothers did not
accordance with the ‘MOOSE’ guidelines Obes Relat Metab Disord ‘missing’ were
June 2006; smoke during
Descriptive statistics: 2003;27:162–172. imputed;
Keywords pregnancy
- 14 observational studies on 84 563 children Chen A, et al, Int J
were reported;
Epidemiol 2006;35:121–
Included - populations in Australia, North America, and 130.
studies: Europe
Dubois L, et al, Int J Obes
reported an - prevalence of smoking during pregnancy in the
(Lond) 2006;30:610–617.
association - studies populations ranged from 7.5 to 51%
between Oken E et al, Obes Res
Heterogeneity: 2005;13:2021–2028.
maternal
smoking - tests for heterogeneity (I2=49%) were statistically Power C, et al, Int J
during significant Epidemiol 2002;31:413–
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 113
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
pregnancy and - random-effects models were used 419
risk of Publication bias: Reilly JJ, et al, BMJ
overweight 2005;330:1357.
evidence for publication bias: asymmetry of the
among
funnel plot and by rank correlation testing (P<0.001) Salsberry PJ et al,
children at
but: ‘missing’ studies to simulate a dataset without Pediatrics
least 2 years
publication bias were imputed; resulting pooled odds 2005;116:1329–1338.
of age;
ratio (OR 1.40, 95% CI: 1.26, 1.55) was somewhat Toschke AM, et al, Eur J
excluded
lower, but still indicated a substantial detrimental Pediatr 2002;161:445–
were: studies
effect of prenatal smoking 448.
that provided
only a Results: Toschke AM, et al, Am J
continuous children whose mothers smoked during pregnancy: Epidemiol
measure of 2003;158:1068–1074
elevated risk for overweight at ages 3–33 years,
adiposity, compared with children whose mothers did not von Kries R, et al, Am J
although those smoke during pregnancy (pooled adjusted OR 1.50, Epidemiol 2002;156:954–
studies are 95% CI: 1.36, 1.65) 961
discussed Whitaker RC. Et al,
separately unadjusted ORs = adjusted ORs
Pediatrics 2004;114:e29–
e36.
Wideroe M, et al, Paediatr
Perinat Epidemiol
2003;17:171–179
Systematic Mattes Search: first, Considered outcome Included studies: 12 RCTs Tordoff MG, et al Am J 1+ analysis of
Review/ RD, et al. other recent measures: any Study quality: Study-level risk of bias was assessed: Clin Nutr. 1990; publication bias
Meta- (2011) evidence- indices of or proxies see summary table and graph 51(6):963–9. n.a.;
analysis [45] based for adiposity, DiMeglio et al, Int J Obes The most of
Descriptive statistics (see also results): adults and
reviews; including weight, Relat Metab Disord. 2000; included studies
children studies were included;
second, BMI, percent body 24(6):794–800 were not blinded
searches of fat, or dichotomous Heterogeneity: available (see results)
James J, et al. BMJ. 2004; two authors
PubMed, indicators of Publication bias: unpublished literature was included
328(7450):1237. independently
PsycINFO, the overweight or to avoid publication bias, other analysis of publication
Ebbeling CB et al reviewed the
Cochrane obesity. bias n.a.
.Pediatrics. 2006; included studies
Collaborative Results (meta-analysis): using the
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 114
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
Website, Web - comparing studies of added NSB consumption (4 117(3):673–80. guidelines
of Science, studies): Addington, E. Doctoral contained in the
and added daily energy loads ranged from ~180 kcal to Dissertation. Manhattan Cochrane
Dissertation 530 kcal (~754 kJ to 2219 kJ); time periods ranged (KS): Kansas State Handbook for
Abstracts from 3 wk to 1 y; Sample sizes ranged from less than University; 1988. Systematic
through 30 to133 Reviews of
Haub MD, et al. Nutr J.
January 2009. Interventions;
the results were statistically significant in only 2 2005; 4:21.
No language Disagreements
studies Munoz, D. Doctoral
restriction. in ratings were
meta-regression revealed a dose-response relation Dissertation. Albany (NY): discussed until
Search terms:
(Pearson’s r, with observations weighted by the State University of New consensus was
“sugar
inverse of their variances = 0.92, P = 0.029) with a York; 2006. reached
sweetened
slope of .0022 (SE = 0.00057) and an intercept of James J, et al .BMJ. 2007;
beverage,”
−0.357 (SE = 0.249) 335(7623):762.
“soda,” “liquid
calories,” and - comparing studies of reduced NSB consumption Reid M, et al. Br J Nutr.
“chocolate (6 studies): 2007; 97(1):193–203.
milk,” among test of heterogeneity was not significant (P = 0.643; Williams CL, et al .Int J
others. I2=0%) Food Sci Nutr. 2007;
Included: studies ranged in duration from 4 wk to 52 wk with a 58(3):217–30
studies – RCT follow-up at 3 y from baseline. Sample sizes ranged Sichieri R, et al .Public
- those 1) from 103 to 1140; Health Nutr. 2009;
conducted in meta-analysis-outcome variable=change in BMI 12(2):197–202
humans; 2) because it was commonly reported across all 6
lasting at least Albala C, et al .Am J Clin
studies Nutr. 2008; 88(3):605–11.
3 weeks; 3)
incorporating the overall estimate of standardized mean difference
random in BMI was extremely close to zero (−0.037; SE =
0.042; P = 0.378); confidence interval was −0.120 to
assignment of
subjects to 0.046
conditions that
differed only in Authors conclusion: Metaanalysis of 6 studies that
the added NSBs to persons’ diets showed dose-
consumption dependent increases in weight. Contrarily, meta-
of NSBs; and analysis of studies that attempted to reduce NSB
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 115
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
4)including an consumption consistently showed no effect on BMI
adiposity when all subjects were considered. Meta-analysis of
indicator as an studies providing access to results separately for
outcome subjects overweight at baseline showed a significant
effect of a roughly 0.35 standard deviations lesser
BMI change (i.e., more weight loss or less weight
gain) relative to controls. The current evidence does
not demonstrate conclusively that NSB consumption
has uniquely contributed to obesity or that reducing
NSB consumption will reduce BMI levels in general.
Systematic Malik VS, English- Included studies: Studies in adult: 2+ Included in
Review et al. language Study quality: cross-sectional studies: SIGN guideline;
(2006) articles; Large observ.
- Total 30 studies: 15 are crosssectional studies, 10 (1) French et al; Int J
(Milestone Searching in studies
are prospective cohort studies, and 5 are clinical Obes Relat Metab Disord
paper) the MEDLINE trials and interventions. Two studies report both 1994;18:145–54.
[46] database; prospective and cross-sectional findings (2) Liebman et al; Int J
articles
Descriptive statistics: Obes Relat Metab Disord
published
- male and female adults, children and adolescents 2003;27:684 –92
between 1966
and May 2005; - endpoints evaluating body size or weight Prospective studies:
Design: cross- measurements in humans, BMI, weight in (3) Bes-Rastrollo et al; Am
sectional, kilograms or in pounds J Clin Nutr 2006;83:362–
prospective - cross-sectional studies: 2 involved adults; =both 70
cohort, and from USA: (1) included 3552 Adults (1913 female, (4) French et al; Int J
experimental 1639 male); soft drink: soda (2) 1817 Adults (889 Obes Relat Metab Disord
studies of the female, 928 male); soft drinks: Sugar-sweetened 1994;18:145–54.
intake of beverages, soda, diet soda
(5) Kvaavik et al; Public
sugar- - 4 prospective studies have examined the relation
sweetened Health Nutr 2005;8:149 –
between the intake of sugar-sweetened beverages
beverages and 57.
and weight gain in adults: (3) 7194 Adults;
weight gain, duration 28.5 mo; Sugar-sweetened soft drinks, (6) Schulze et al; JAMA
obesity, or diet soda, milk; (4) 3552 Adults (1913 females, 2004;292:927–34
both; 1639 males); USA; duration 2 y.; soft drink: soda; Experemental trials and
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 116
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
Key words (5) 422 Adults (215 female, 207 male); Oslo; interventions:
were used in duration 8 y; soft drink: soda (6) 51 603 Females; (7) DiMeglio et al; Int J
the primary duration 8 y; soft drinks: Sweetened soft drinks, Obes Relat Metab Disord
search diet soft drinks, fruit juice 2000;24:794–800
strategy, as - Experemental trials and interventions: (7) 15 (8) Raben et al; Am J Clin
well as in a Adults (8 female, 7 male), crossover design; (8) 41 Nutr 2002;76:721–9.
subsequent Adults (35 female, 6 male), design: parallel (9) 30
search using Adults (9 female and 21 male) crossover design (9) Tordoff and Alleva; Am
medical J Clin Nutr 1990;51:963–9
Heterogeneity:
subheading
(MeSH) terms; - n.a.
Additional Publication bias:
reports were - n.a.
obtained by Results: ´
cross-
positive association between greater intakes of SSBs
matching
and weight gain and obesity in and adults.
references of
selected cross-sectional studies:
articles; - Significant (P = 0.03) association between soda
Duration: at consumption and weight in females, non
least 6 months significant in males (P= 0.13)
for prospective - Probability of overweight and obesity greater in
cohort studies subjects who drank at least 1 soda/wk than in
those who drank < 1 soda/wk (P< 0.05)
Prospective studies:
- Association between sugar-sweetened beverage
intake and weight gain in subjects with at least 3
kg weight gain in 5 y before baseline (OR =1.6;
95% CI: 1.2, 2.4; P = 0.02)
- Positive but non significant association between
soda consumption and weight change
- No significant association between soda intake
and change in BMI
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 117
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
- Association between soft-drink intake and weight
Experemental trials and interventions:
- Significant increase in body weight and BMI after
liquid load (P<0.05)
- Body weight, fat mass, and BMI increased in
sucrose group and decreased in sweetener group;
respective difference between groups (2.6 kg;
95% CI: 1.3, 3.8; 1.6 kg, 95% CI: 0.4, 2.8; and
BMI 0.9, 95% CI: 0.5, 1.4)
- Relative to no soda, HFCS soda significantly (P=
0.01) increased weight in females and NS
increase in males; APM soda decreased weight in
males and NS increase in females
Meta- Streuling I, Datebases: Interventions to Included studies: Asbee SM, et al,Obstet 1-/ 2+ RCTs and
analysis et al. MEDLINE reduce gestational - 4 RCT, 5 nonrandomized trials (flow chart) Gynecol 2009;113(2 Pt nonrand.
(2010) (1950–2009), weight gain (GWG) 1):305–12. Studies;
- Study quality: (Randomization/ Dropout rate/
[47] EMBASE by modulating diet Olson CM, et al. Am J Four studies
intention-to-treat): 2 reviewer, Cochrane
(1974–2009), and physical activity Handbook and CONSORT (Consolidated Obstet Gynecol were not of high
Cochrane during pregnancy 2004;191:530–6. methodologic
Standards of Reporting Trials) were used;
CENTRAL consealment allocation: in only 1 study, in 3 study: Polley BA, et al. Int J quality;
Library Issue 4 no explanation about mathod of randomisation; 4 Obes Relat Metab Disord no accepted
( 2009), and studies reported losses to follow-up of <10%; no 2002;26:1494–502. standard
Web of blinding; 3 cohort studies: reported potential approach on
Shirazian T, et al Am J
Science confounders how to measure
Perinatol 2010;27:411–4.
(1900–2009) - Descriptive statistics: 4 trials from the United
Gray-Donald K, et al Can GWG
Search terma States, 2 from Canada,1 from Finland , 1 from
Med Assoc J
were reported Sweden , and 1 from Belgium. 2000;163:1247–51.
Inclusion - 1886 women were eligible for the studies, 1549
Hui AL, et al Can J
criteria: written women completed the trials.
Diabetes 2006:169–75.
in English or - 3 trials: only overweight or obese women
German Kinnunen TI, et al. Eur J
- main target of all trials: to test interventions to
language; Clin Nutr 2007;61:884–91.
prevent excessive GWG and adverse pregnancy
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 118
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
focusing on utcomes. Claesson IM, et al. BJOG
healthy - GWG: 3 authors defined GWG as the difference 2008;115:44–50.
women; between prepregnancy weight and body weight at Guelinckx I, et al. Am J
singleton delivery , in 2 studies GWG was assessed as the Clin Nutr 2010;91:373–80.
pregnancies; difference between body weight in early
intervention pregnancy and body weight at delivery, 4 trials did
comprised not report how they defined GWG
modification of - Intervention: in 8 studies: modification of physical
diet and activity and diet was supplemented by regular
physical weight monitoring, attempts to achieve GWG
activity; within the recommended Institute of Medicine
subjects were (IOM) ranges; in 3 trials: specific exercise
compared with programs for their subjects, in other trials:
a control intervention to oral and written information and
group recommendations for exercise; in 6 studies:
receiving individual nutrition counseling by professional
routine nutritionists or study coordinators; in 1 trial: weekly
prenatal care; motivational talks were initiated with the aim of
and GWG was motivating the study subjects to change their
documented behavior and obtain information relevant to their
for control and needs; 2 studies offered written and oral
intervention information about healthful eating during
groups pregnancy
separately.
Heterogeneity:
- I2-Statistik: moderate/high
- random-effects model
- sensetivity analyses were reported
Publication bias: n.a
Results (for weight):
Lower GWG in Interventional groups: in 3 studies
significant, in 3 studies n.s.
Forrrest plot:
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 119
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
All trials: sign. GWG-reduction (P=0.01): 20.22 units
(95% CI: 20.38, 20.05 units), corresponding to an
average reduction of GWG of 1.2 kg (data not
shown).
Only RCTs: nonsignificant reduction of GWG on
average in the intervention groups (SMD =20.13;
95% CI: 20.41, 0.15).
Only nonrandomized trials: sign. (P = 0.02) lower
GWG in the intervention groups (SMD = 20.27; 95%
CI: 20.49, 20.04)
Meta- Streuling I, Databases: Intervention: Included studies: 12 RCTs Clapp JF III, et al. Am J 1- Quality of
analysis et al. MEDLINE increased physical - Study quality: (Randomization/ Dropout rate/ Obstet Gynecol included studies
(2011) (1950–2009), activity intention-to-treat): 2 reviewers, Cochrane’s 2000;183:1484–8. (middle)
[48] EMBASE handbook and CONSORT statement; in 6 studies: Collings CA, et al. Am J ITT in only 2
(1974–2009), blinded allocations assigment was reported, in 6 Obstet Gynecol studies
Cochrane studies less losses to follow-up (< 15 %), in 5 1983;145:702–7.
CENTRAL studies high losses (>15 %), ITT in 2 studies was Marquez-Sterling S, et al.
library Issue 3, reported Med Sci Sports Exerc
2009, ISI Web
Descriptive statistics: 2000;32:58–62.
of Knowledge,
containing - 4 trials from the USA, 2 from Iran, 1 from Spain, 1 Yeo S. et al. Res Nurs
Web of from Australia, 1 from New Zealand, 3 from Brazil. Health 2009;32:379–90.
Science - 1073 women, 906 participants had completed the Garshasbi A, et al. Int J
(1900–2009), trials. Gynaecol Obstet
BIOSIS - All studies: women with low-risk pregnancies only. 2005;88:271–5.
Previews - 7 studies no exercise regularly before pregnancy. Sedaghati P, et al. Gazz
(1926–2009), - Intervention: duration 10-32 weeks, exersise 3 Med Ital- Arch Sci Med
Current times a week at least 20 minutes up to 1 hour 2007;166:209–13.
Contents performing aerobics, running, cycling, water Barakat R, et al. Int J
Connect aerobics or muscle strengthenin; stsrt at the 1-2 Obes (Lond)
(1998–2009) trimester; in 9 studies: with supervision, 3 studies: 2009;33:1048–57.
and Journal home-bases exercise
Citation Ong MJ, et al. Diabetes
- Gestational weight loss (GWG)- not the main
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 120
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
Reports outcome, definition was different Metab 2009;35:418–21.
(1999–2008). - Prepregnancy weight/BMI: norm. Hopkins SA, et al. J Clin
Key words Heterogeneity: Low Endocrinol Metab
were reported - random-effects model 2010;95:2080–8.
Inclusion Cavalcante SR, Reprod
Publication bias:
criteria: RCT, Health 2009;6:1.
healthy - No indication for p.b. (funnel plot)
Results (for weight): Prevedel T, et al. RBGO
women;
2003;25:53–9.
Intervention= 7 trials: lower GWG in the exercise group, but in only
solely physical Santos IA, et al.Obstet
1 – significant (p<0.05); 5 trials: women in the
activity; exercise groups did not gain Gynecol 2005;106:243–9.
compared with
significantly less weight.
no intervention
promoting meta-analysis: significant GWG-reduction in the
physical exersise group (p=0.03), MD of GWG of -0.61 (95%
activity; GWG CI: -1.17, -0.06),
was sensitivity analyses were reported
documented
for both
groups
separately.
Systematic Streuling I, Databeses: Diets (low Included studies: 12 observational studies Aaronson LS 1989 2- No quality ass.,
Review et al. MEDLINE caloric/portein or - Study quality: 6 studies adjusted for confounders Ancristi G 1977 only 6 studies –
(2011) (1950-2009), other) adjustment for
- Descriptive statistics: Bergmann MM 1997
[49] EMBASE confounders,
(1974-2009) - 9 studies from USA, 3 studies from Europe Deierlein AL 2008 different
(English, - sample sizes; varied from 50 to 2087 women Lagiou P 2004 definition for
German - 2 studies: low-income pregnant teeagers, 10 Langhoff-Roos J 1987 GWG
languages) studies – adult women
Oken E 2008
search terms - different dietary assestment between the studies
(FFQ or recall methods) Picone TA 1982
were reported
inclusion - Gestational weight loss (GWG) was defined in Scholl TO 1991
criteria: different ways Sloan NL 2001
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 121
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
english or - Heterogeneity: n.a. Stevens-Simon C 1992
german, - Publication bias: n.a. Stuebe AM 2009
health women Results (for weight):
with singleton
pregnancy, 5 studies: significantly (p<0.05) association between
population- energy intake and GWG (3 of them – adjusted for
based or confounders), 3 studies (2 – adjusted) – no
hospital-based significant association
cohort studies
industrialized
countries,
without
repeated
pregnancy
Meta- Gardner B. Databeses: Intervention: Included studies: Claesson IM, et al.. Br J 1-/2- Different design,
analysis et al, 2011 PsycInfo, recommended - 7 RCTs, 5 – others (Quasi-experimental control Obstet Gynaecol 2007; Allocation cons.
[50] Medline, behaviour: diet or trials and historical cohort designs in two trials; 115: 44–50. In only 1 trial,
Embase, physical aktivity or one trial used a time series design); 2 trials in 10 Hui AL, et al. Can J Only 3 trials –
AMED, HMIC, both studies were reported Diabetes 2006; 30:169– ITT
Cochrane 175.
- Study quality: (Randomization/ Dropout rate/
Central intention-to-treat): 2 reviewers, Cochrane validity Polley BA, et al. Int J
Controlled
criteria (allocation concealment, intention-to-treat Obes(Lond) 2002; 26:
Trials analysis and losses to follow-up), scoring system 1494–1502.
Register,
was used; Gray-Donald K, et al
Cochrane
Health - Allocation was concealed in one trial, concealment CMAJ 2000; 163: 1247–
Technology unclear - 6 trials. 1251.
Assessment, - 3 trials – ITT, Kinnunen TI, et al Eur J
peer-reviewed - 7 trials reporting attrition rates of more than 10%. Clin Nutr 2007; 61: 884–
English- Descriptive statistics: 892.
language - Treatment characteristics were coded for both Wolff S, et al Int J Obes
journal articles intervention and control treatments where (Lond) 2008; 32: 495–501.
published possible. Weight gain – primary outcome. Asbee SM, et al Obstet
between 1990
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 122
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
and 2010 - 1656 participants (744 intervention, 912 control), Gynecol 2009;113: 305–
3 search filters Sample sizes ranged from 21 to 560 (mean 138 311.
were used: participants per trial). Shirazian T, et al Am J
interventions - Seven trials were conducted in North America, five Perinat 2010; 27: 411–
to prevent USA, two Canada, and 5 in Europe (2 in Belgium, 414.
excessive and one in each of Denmark, Finland and Guelinckx I, et al. Am J
GWG; Sweden). Clin Nut 2010; 91: 373–
controlled trial - 11 trials: both diet and PA; 1 trial - diet only 380
designs; - behavioural outcomes (intake of specific foods or Olson CM, et al Am J
samples with PA) were assessed in six trials. Obstet Gynecol 2004;
chronic health Heterogeneity: significant, moderate (P = 0.0008; I2 191: 530–536.
conditions = 66%)
were
Publication bias: no p.b (funnel plot)
excluded.
Results (for weight):
Inclusion
criteria: Pooled results: Significantly less weigth loss in the
quantitative interventionla group: (WMD = -1.19 kg, [95% CI: -
data, 1.74, -0.65], P 0.0001).
intervention to 4 trials - statistically significant effects, intervention
improve diet recipients gaining between 2.60 and 7.36 kg less
and/or than controls.
increase PA
Eight trials - no effect on weight
so as to
prevent gain, 1 of these observed negative effect (P = 0.09),
excessive overweight intervention participants (mean gain 13.6
weight gain in kg) tended to gain more weight than overweight
pregnant adult controls (mean gain 10.1 kg)
women aged Moderator analyses were reported
differences
between an
intervention
and a control
group
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 123
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
Systematic Campbell 11 databases Diet and physical Included studies: RCTs: 1- Significant
Review F, et al. December activity interventions - 13 studies: 5 RCTs, 8 qualitative studies (flow Guelinckx I, et al. 2010, heterogeneity,
(2011) 2008, second chart) 91:373-380. small number of
[51] search - Study quality: (Randomization/ Dropout rate/ studies
Wolff S, et al.. Int J Obes
(update) in intention-to-treat): quality assestment: Cochrane (Lond) 2008,32:495-501.
January 2010. Collaboration’s tool; 3 trials: method of Asbee SM, et al.
(1990-2010); randomisation was reported, 1 trial – allocation Obstetrics and
concept of consealment, no blinding, only 2 trials reported Gynecology
excessive loss to follow-up 2009,113:305-311.
gestational Descriptive statistics: Polley BA, et al., Int J
weight gain by
- number of participants Obes Relat Metab Disord
the IoM
- in RCTs- from 52 to 195 with a total of 577. 2002, 26:1494-1502.
(1990).
- mean age from 25.5 to 29 years. Hui AL, et al. CAN J
Inclusion
- Mean pre-pregnancy BMI from 22.6 to 34.7 kg/m2 DIABETES 2006, 30:169-
criteria and
(2 studies recruted only obese women) 175.
key words
were reported - mean gestational age from 9.8 to 15.5 week
(adults, no - countries: Canada, USA, Europe
medical - complex interventions (several components)
comlikations
Heterogeneity: significant (I2 = 67%)
etc)
Results (for weight):
Meta-Analysis of 5 RCTs: No significant difference in
gestational weight gain (GWG) (mean difference -
0.28; 95% CI -0.64 to 0.09)
Subgroup and sensitivity analyses were performed
Cochrane Gallo MF, Databases Combination Included studies: Aden 1998 1+ Poor study
Review et al. CENTRAL hormonal - 49 RCTs (compared 52 different pairs) Agoestina 1989 quality
(2011) (The contraceptives
Study quality: (Randomization/ Dropout rate/ Brill 1991
[52] Cochrane compared to a
intention-to-treat): Brill 1996
Library), placebo, no
MEDLINE, intervention or to a - 2 reviewers (double check), no summary quality Burkman 2007
POPLINE, combination score, appraisal of potential biases concentrated
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 124
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
EMBASE, and contraceptive on the study design, blinding, randomization Cachrimanidou 1993
LILACS, (differed in drug, method, group allocation concealment, and loss to Coenen 1996
asClinicalTrial dosage, regimen, or follow up and early discontinuation;
Coney 2001
s.gov and study length) - Generally poor quality of trials, associated with
InternationalCl empirical evidence of bias Dionne 1974
inical Trials - 31 trials: generating the randomization - not Endrikat 1997
Registry reported Endrikat 1999
Platform
- 45 trials - allocation concealment not reported, 3 Endrikat 2001a
(ICTRP).
trials reported sufficient allocation consealment Endrikat 2001b
Up to to May - Only 4 trials reported the number of women
2011. Foulon 2001
recruited for the trial
Search Franchini 1995
- Blinding: 2 studies - single-blinded, 10 - double-
strategy was blinded, 1- triple-blinded; not mentioned in 15 Goldzieher 1971
reported. trials. Gruber 2006
Inclusion - ITT – described for 3 trials Halbe 1998
criteria:
- 33 trials did not specify the analytic method used Kashanian 2010
English-
language, - for the weight change data Kaunitz 2000
RCTs, at least - Loss to follow up: 0-17 %: only in 19 trials Kirkman 1994
3 treatment Descriptive statistics: Knopp 2001
cycles, - sample sizes ranged from 20 to 5654 participants,
compared to Koetsawang 1977
median - 196 participants.
placebo or to Koetsawang 1995
- study location - was not described for 13 trials; the
different Lachnit-Fixson 1984
other studies were conducted in locations
combination
worldwide. Liukko 1987
contraceptive
- duration of the trials: from 3 to 24 treatment cycles Loudon 1990
with most trials – 6 or 12 treatment cycles Miller 2001
- Main outcome: change in body weight Milsom 2006
Heterogeneity: n.a Oddsson 2005
Publication bias: n.a. Oelkers 1995
Results (for weight): Oelkers 2000
In 4 trials (comparison to placebo or bo intervention):
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 125
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
no association with weight change Procter-Gray 2008
Other trials: no significant association with weight Rosenbaum 2000
change Sang 1995
Three studies: differences in the numbers of women Serfaty 1998
with a weight change of more than 2 kg.
Sibai 2001
Four studies: differences in the mean weight change
Spellacy 1970
between groups.
Spona 1996
Athers conclusion: Available evidence was
insufficient to determine the effect of combination Stewart 2005
contraceptives on weight, but no large effect was Teichmann 1995
evident. Van der Does 1995
Weisberg 1999
Wiegratz 1995
Wiegratz 2002
Wiik 1993
Winkler 1996
Worsley 1980
Meta- Verweij Databases: Physical activity or Included studies: See study references 1- low quality of
analysis LM, et al. Medline, dietary behaviours or - 43 RCTs met inclusion criteria, 22 RCTs were studies.
(2011) Embase, both included in meta-analysis Moderate-high
[53] PsychInfo heterogeneity
Study quality: (Randomization/ Dropout rate/
Cochrane
intention-to-treat):
Library,
SportDiscus, - double-check, Chochrane Handbook was used,
Current GRADE was used; 1 studie – excellent quality, 11
Controlled – good, 20 – poor and 11 – fair quality
Trials; Descriptive statistics:
Between - 26 studies: Physical activity and dietary
1980- behaviours
November - 14 studies: only physical activity
2009
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 126
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
Search - 3 studies: only dietary behaviours
strategy was - Participants: number varied: 33-18,210
reported participants; age: 18-67; 7 studies included only
Inclusion men, 4 studies – only women, 32 studies – men
criteria: and women; 16 studies included white color
English, workers, 9 – blue color workers, 19 studies – n.a.,
RCTs, 9 studies included participants with high
targeting cardiovascular risk
physical - Different outcomes (cardiovascular risk reduction
activity or or disease prevention – 17 studies, 17 studies –
dietary improve physical activity, 8 – health promotion,
behaviours or only 2 studies aimed obesity prevention or weight
both of control)
employers, - Lenth of intervention: 4 week to 3 years, 11
weight releted studies – short follow-up (< 6 month) and 32
outcome studies – long follow up.
measures
Heterogeneity: moderate-high
Publication bias: n.a.
Results (for weight):
Reduce of body weight, BMI, body fat
- Moderate Evidenz for both (Physical activity and
dietary behaviours): significant reduce body
weight (9 studies, 5 – good quality, mean
difference (MD): -1.19 kg/m2, 95% CI -1.64 to -
0.74, but in 3 good quality studies – non significant
differences); significant reduce BMI (11 studies,
MD -0.34 kg/m2, 95% CI -0.46 to -0.22);
significant reduce body fat (3 studies; MD –
1.12%, 95% CI -1.86 to -0.38); WC n.s. (MD -1.08,
95% CI -4.18 to 2.02)
- Low evidence for only physical activity: (reduce of
body weight: MD – 1.08 kg, 95% CI – 1.79 to –
0.36); BMI (MD – 0.50 kg/m2; 95% CI -0.65 to -
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 127
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
0.34); body fat (MD -0.56%; 95% CI -2.53 to 1.42),
WC n.s. (MD – 1.31, 95% CI – 3.62 to 1.00)
- Sensitivity analyses were reported (only fair-low
quality of studies, small studies)
Systematic Vuillemin Studies Work site physical Included studies: 33 studies were included 1- Only one study
Review A, et al. published from activity interventions - 33 european studies: 20 RCT, 2 with cluster- (See study references) with obesity-
(2011) January up to (counselling, randomised design, 2 – non-randomised tirals, 2 – related outcome
(the Hope December exercise training, before-after studies, 9 with pre-post design as primary
project) 2099 active commuting, outcome :
- 15 studies with obesity-related outcome, Only one
[54] Databases: walking) quality
study with obesity-related outcome as primary
PubMed, outcome assestment n.a.
Embase, Heterogeneity
Study quality: (Randomization/ Dropout rate/
Cinahl, n.a.
intention-to-treat):
Psychinfo, publicationbias
SportDiscus, - dobble-check,quality assestment (11 criteria
n.a.
Web of score), 17 studies with high quality
Science, Descriptive statistics:
Cochrane - setting – Europe (1 study from Germany),
Only search intervention: counseling – 2 RCT, exercise training
elements were – 10 RCT, active commuting – 4 RCT, walking – 4
reported RCT
Inclusion Heterogeneity: n.a
criteria were Publication bias: n.a.
reported (date,
Results (for weight):
aim =
increasing no evidence or only incolclusive evidence for a effect
physical on obesity-related outcomes
activity, adult
participants,
specifically
carried out in a
worksite
setting,
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 128
Studien- Autoren, Untersuchte Welche Charakteristik eingeschlossener Studien/ Literaturbelege Evidenz- Meth.
typ Jahr Studien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Materialien wurden geprüft (SIGN)
Europe,
primary
prevention
studies)
c) Einzelstudien
Artikel Anzahl der Intervention/ Vergleichs- Outcomes Ergebnisse Evidenz- Bemerkungen
(Autor, Patienten/ ggf. intervention niveau
Jahr)/ Patienten- Nachverfolgung (z.B. SIGN)
Studien- merkmale
typ
Ter Bogt 457 patients Intervention group: Control group: Changes in body Intervention group: more 1+ Randomisation procedere,
NC, et al. overweight or visits to a nurse usual care from weight, waist weight losers and stabilizers exclusion criteria, dropouts were
(2009) obese practitioner (NP) their general circumference, blood compared to control group: reported
[55] and one feedback practitioner (GP- pressure, and blood (77% vs 65%; p<0.05) There are statistically significant
mean age: 56
session by group) lipids Men: mean weight losses difference between women for
years
RCT telephone for were 2.3% for the intervention and control groups :
sex : 52% women
lifestyle counseling intervention group and 0.1% in age, hypertention, physical
with either with guidance of for the control group activity,but in follow-up
Ter Bogt hypertension or NP using a (p<0.05) study (authors conclusion)
NC, et al. dyslipidemia, or standardized Lifestyle counseling by NPs did
Women: mean weight losses
(2011) both computerized not lead to significantly better
were in intervention und
[56] from 11 general software program. prevention of weight gain
control groups 1.6%
practice locations compared with GPs. In the
Control group: obese people
RCT (3- in the Netherlands majority in both groups, lifestyle
lost more weight (-3.0%)
years- counseling succeeded in
than the non-obese (-1.3%;
follow-up) preventing (further)weight gain.
p<0.05)
Not significant: Mean waist
circumference decreased by
2.4 cm in intervention group
and by 1.2 cm in control
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 129
Mediano 203 women Intervention group Control received weight loss and others Intervention group: 1- Randomisation procedere was
MF, et al. from Brazil (=home-based only dietary (HDL-cholesterol, - greater weight loss in the reported, the study was not
(2010) exercise) received counseling aimed triglycerides, glucose, first 6 months (−1.4 vs. blinded, relevant outcome
middle age: 25–45
[57] booklet on aerobic at a energy HOMA-IR) −0.8 kg; p=0.04), (weight loss) was measured,
years
exercise that could restriction of 100– but intention-to-treat analysis was
be practiced at 300 calories per after 12 months: no reported
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 130
Haakstad 105 sedentary, Exercise group Control group Main outcomes: aternal Sign. difference between 1+ Assessor blinded
LA, et al. nulliparous (n=52): 60 min. (n=53): weight gain and the exersise and control groups; Randomisation: simple
(2011) pregnant women supervised aerobic participants were proportion of women only participants who computerised randomisation
[58] Mean age: 30.7 dance and strength asked not to whose weight gain attended 24 exercise programm
(SD +/-4) training for 60 min, change their exceeded the IOM sessions (n=14) differed
ITT
at least twice per usual physical recommendations sign. from controls
RCT Pre-pregnancy High drop out rate
week for a pattern (p=0.006):
BMI: 23.8 (+/- 4.3
minimum of 12 Weight gain during
kg/m2)
weeks pregnancy 11.0 kg. (SD +/-
The majority from
2.3 kg) vs. 13.8 kg. (+/- 3.8
Norway (n=94)
kg), p=0.01;
Participants with
disease that could No difference between the
interfere with groups in the proportion of
participation were women gaining more weight
excluded than recommended by the
IOM
Phelan S, Pregnant (3.5 Behavioral Standard care Primary outcome. In NW women, in 1+ Assessor (clinical and staff)
et al. week gestation), intervention (social (n=201): regularly Proportion of women intervention group: blind
(2011) normal-weight learning theory) to visits to they with the excessive decreased % who exceeded The retention at the 6 months
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 131
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 132
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 133
Thema: Therapie
Aggregierte Evidenz
a) Leitlinien
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 134
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 135
3
Zitierte Literatur: Verheijden, 2005 (R. 109)
- Assessing motivation for behaviour change:
- In order to target interventions appropriately, healthcare
professionals need to consider the willingness of a patient to 1++
Bridle, 2005 (R. 110)
undertake the necessary behaviour change required for effective
weight management.
- A systematic review of RCTs examined the effectiveness of health
behaviour change interventions (eg around smoking cessation,
dietary change, alcohol intake reduction, and increasing physical
activity), based on the Transtheoretical ‘Stages of Change’ model. 1+, 3
The review found only limited evidence for the effectiveness of Marshall, 2003 (R. 111)
stage-based interventions for behaviour change.
- Despite the common-sense appeal of the assessment of ‘readiness
to change’ using the Transtheoretical ‘Stages of Change’ model,
current evidence does not support this approach to intervention. An
RCT examined the effectiveness of using stages as a basis for
physical activity intervention. Both stage-matched and mismatched
materials led to significant differences in level of physical activity at 1+, 3
six months compared to no intervention at all. Booklet-based
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 136
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 137
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 138
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 139
Thema: Basisprogramm
Quelle Text Evidenz- bzw. Literaturbelege Methodische
Empfehlungs- Bewertung
grad
ICSI (2011): - Weight management includes physical activity, nutrition and behaviour n. a. Domäne 3 (DELBI)
Health Care management strategies. Franz, 2007 [M]; Freedman, 2001 [R] 12 Punkte
Guideline: - Successful weight-loss maintenance is sustained by a combination of Bei der Suche nach
M, R, C Wing, 2001 [R]; McGuire, 1998 [C]
Prevention and lower calorie intake and increased physical activity. Analysis of data from Evidenz wurden
Management of the National Weight Control Registry indicates weight-loss maintainers keine
Obesity (Mature have an average intake of 1,400 kcal/day and get one hour of moderate systematischen
Adolescents and activity per day, and eat breakfast daily. n. a. Methoden
Adults) - Daily, weekly and short-term goals are important. High-intensity weekly angewandt
[5] face-to-face meetings produce the best results. Keine
Literaturangaben bei
Overview, nur bei
Annotations
SIGN (2010): Empfehlungen: Domäne 3 (DELBI)
Management of - Weight management programmes should include physical activity, dietary A n. a. 19 Punkte
Obesity A change and behavioural components. Bei der Suche nach
national clinical Evidenz wurden
- Reducing inactivity should be a component of weight management best practice of n. a.
guideline programmes. systematischen
the guideline
[4] Methoden
development
group angewandt
Zitierte Literatur:
1+ NICE, 2006 (R. 64); Avenell, 2004 (R. 98); CAVE: siehe auch
- Diet plus physical activity: There is consistent evidence that combined
diet and physical activity is more effective for weight loss than diet alone. Curioni, 2005 (R. 132); Norris, 2004 (R. hier im Text 1.8
133) „Gewichtsreduk-
tionsprogramme“:
- Diet plus physical activity plus behavioral therapy: A combination of 1++ kommerzielle und
physical activity (varying in level from three supervised sessions plus NICE, 2006 (R. 64) internetbasierte
exercise information to recording of 30-45 minutes of activity four to five Programme
times week), behaviour therapy (components as listed below) and diet
(either calorie deficit or a low calorie diet) is more effective for weight loss
compared with diet alone. In a meta-analysis of five studies, median
weight change was –4.60 kg (range –3.33 kg to –5.87 kg) for the
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 140
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 141
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 142
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 143
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 144
Thema: Ernährungstherapie
Quelle Text Evidenz- bzw. Literaturbelege Methodische
Empfehlungs- Bewertung
grad
ICSI (2011): Empfehlungen: Domäne 3 (DELBI)
Health Care Overview of Management Recommendations: n. a. n. a. 12 Punkte
Guideline: Bei der Suche nach
Nutrition (balanced healthy eating plan or lower calorie balanced eating plan)
Prevention and Evidenz wurden
Management of - Encourage at least five servings of fruits and vegetables per day, whole
keine
Obesity (Mature grains with a fiber intake of 20-35 grams of fiber daily, less than or equal to
systematischen
Adolescents and 30% of calories from fat (7%-10% of calories from saturated fat, less than
Methoden
Adults) or equal to 1% from trans fat).
angewandt
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 145
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 146
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 147
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 148
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 149
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 150
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 151
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 152
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 153
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 154
Thema: Bewegungstherapie
Quelle Text Evidenz- bzw. Literaturbelege Methodische
Empfehlungs- Bewertung
grad
ICSI (2011): Empfehlungen: Domäne 3 (DELBI)
Health Care Overview of Management Recommendations: nur 12 Punkte
Guideline: Bei der Suche nach
Physical activity
Prevention and Evidenz wurden
Management of - Minimally, all patients should be encouraged to do at least 10 minutes of n. a. n. a.
keine
Obesity (Mature physical activity above what they are already doing each day and
systematischen
Adolescents and gradually increase the amount of time, followed by an increase in intensity.
Methoden
Adults) - Ideally, all patients should meet the current recommendations of 60 angewandt
minutes of moderate-intensity activity on most days per week. This can be n. a. n. a.
[5]
done in 10-minute increments. Keine
Literaturangaben
- Patients with chronic activity limitations (e.g., arthritis, respiratory n. a. n. a. bei Overview, nur
dysfunction, neuropathy, morbid obesity) should be evaluated and bei Annotations
managed to establish or enhance patient mobility.
- Small bouts of physical activity, not generally considered exercise, such as
n. a. n. a.
taking the stairs, parking farther away, exercising while watching TV,
standing rather than sitting and activity breaks from screens (TV,
computer, other media) are also important for healthy body weight.
Zitierte Literatur:
- Physical inactivity, or sedentary lifestyle, has been previously identified as R Fletcher, 1992 [R]
an independent risk factor for cardiovascular disease by the American
Heart Association
- Physical inactivity is currently seen as a key contributor to the obesity
problem. With approximately 60% of adults in the United States D Flegal, 2002 [D]
overweight
- While physical activity has long been recognized as an important B Paffenbarger, 1986 [B]
component of a healthy lifestyle and longevity
- Some of the confusion arises from inherent individual variability in C Skinner, 2001 [C]
response to exercise
- Evidence still remains that increasing calorie expenditure by increasing
physical activity is necessary for improved weight-loss outcomes and A, R, M Esposito, 2003 [A]; Rejeski, 2002 [A];
weight maintenance National Heart, Lung and Blood Institute,
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 155
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 156
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 157
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 158
Home repair, Home repair, painting ––– Journal of the American Medical
carpentry Association, 1995 Feb 1; 273(5):404.
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 159
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 160
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 161
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 162
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 163
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 164
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 165
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 166
Thema: Verhaltenstherapie
Quelle Text Evidenz- bzw. Literaturbelege Methodische
Empfehlungs- Bewertung
grad
ICSI (2011): Empfehlungen: n. a. n. a. Domäne 3 (DELBI)
Health Care Overview of Management Recommendations: 12 Punkte
Guideline: Bei der Suche nach
- Identify behaviors that may lead to increased weight gain: for example,
Prevention and Evidenz wurden
stress, emotional eating, boredom and poor sleep.
Management of keine
Obesity (Mature - Help patients set specific, measurable, time-limited goals to decrease
calorie intake and increase physical activity as appropriate. systematischen
Adolescents and Methoden
Adults) - Suggest patients weigh themselves at least weekly and record the amount angewandt
[5] and type of food/beverages consumed and physical activity completed.
Keine
- Provide support and encourage patients to also seek support from family,
Literaturangaben
friends and support groups in order to assist them with their eating, activity
bei Overview, nur
and weight goals.
bei Annotations
Zitierte Literatur:
- A key component of successful weight loss and maintenance is regular A, D Boutelle, 1999 [A]; Boutelle, 1998 [D]
self-monitoring of energy intake, expenditure and body weight. Participants
in weight-loss trials who regularly self-monitor their diet and activity tend to
lose more weight compared to those who don't
- Evidence from the National Weight Control Registry (NWCR), which was D Klem, 1997 [D]
created to compile data on individuals who were successful at losing at
least 13.6 kg and maintaining that loss for one year or more, shows that
over 75% of these successful weight-loss maintainers report weighing
themselves at least once a week
- Siehe auch langfristige Gewichtsreduktion
Follow up:
- Weight loss requires frequent follow-up (initially weekly) with planned A, R Rejeski, 2002 [A]; Tuomilehto, 2001 [A];
education/counseling by health care providers to be most effective (i.e., Chao, 2000 [A]; National Heart, Lung and
improve adherence) Blood Institute, 2000 [R]
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 167
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 168
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 169
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 170
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 171
Thema: Gewichtsreduktionsprogramme
Quelle Text Evidenz- bzw. Literaturbelege Methodische
Empfehlungs- Bewertung
grad
SIGN (2010): Commercial diets: Domäne 3 (DELBI)
Management of - A variety of commercial weight reduction programmes (Atkins, low 19 Punkte
Obesity A carbohydrate; Ornish, LEARN, very low fat; and Zone macronutrient Bei der Suche nach
1 ++ Gardner, 2007 (R. 155)
national clinical ratios), are associated with a modest reduction in body weight and a Evidenz wurden
guideline reduction in several cardiac risk factors in overweight and obese systematischen
[4] premenopausal women at 12 months. Zone, LEARN and Ornish produce Methoden
comparable results. Atkins was associated with significantly greater weight angewandt
loss and more favourable metabolic effects at 12 months than Zone.
- In an RCT of commercial weight loss programmes in the UK (Dr Atkins’ CAVE:
new diet revolution, Slim-Fast plan, Weight Watchers pure points
programme, and Rosemary Conley’s eat yourself slim diet and fitness 1 ++ Truby, 2006 (R. 156) - Kapitel 9 der
plan), all groups lost weight and body fat at six months compared to Leitliie zum
control (average weight loss 5.9 kg) but there was no difference between Thema: „Weight
management
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 172
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 173
Zitierte Literatur:
R Klein, 2002 [R]
- Pharmacotherapy, when used for six months to one year, along with
lifestyle modification including nutrition and physical activity, produces
weight loss in obese adults. Behavioral modification programs including
dietary and exercise counseling typically result in a 5% weight loss
- The average weight loss with pharmacological agents is 10%-15% of initial D Frank, 2004 [D]
weight
- Patient monitoring:
R National Heart, Lung and Blood
- To be considered successful weight maintenance, weight regain Institute/NIH, 1998 [R]
should be less than 3 kg (6.6 lb.) in two years and there should be a
sustained reduction in waist circumference of at least 4 cm
- Phentermine:
- Primary pulmonary hypertension has been identified in relation to the M, C McCann, 1997 [M]; Abenhaim, 1996 [C]
use of several anorexiant medications, especially when the duration
of therapy exceeded three months Bray, 2004 [R]
R
- These included aminorex and fenfluramine (therefore, the
combination medication of phenterminefenfluramine)
- In the case of aminorex, this serious side effect led to the withdrawal X Apovian, 1999 [X]
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 174
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 175
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 176
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 177
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 178
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 179
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 180
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 181
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 182
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 183
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
30. June 2007 weight - one study mentioned that they did have blinding of 140 one study
Language outcome measurement (12) (13) Hellenius ML et al; ITT reporting
selection: only - only two studies had a 0% dropout rate (12,13), in Atherosclerosis
English which intent-to-treat analysis was conducted; the 1993;103:81–91
Keywords rest of the studies did not conduct intention-to-treat (23) Williams PT et al;
were reported analyses Metabolism 1994;43:655–
- dropout rates for the interventions were lower than 663
Population:
obese or 30%, except one study (19) with 50–65% dropout (9) Anderssen SA et al; J
rate
overweight Intern Med 1996;240:203–
adults - sensitivity analysis (excluded studies with high 209
dropout rate): the overall results died not change
compared (19) Skender ML et al; J
Diet-plus- Descriptive statistics: Am Diet Assoc
exercise (D + - mean age of the study population ranged from 36 1996;96:342–346
E) vs. diet-only to 55 years (17) Pan XR et al;
(D) - mean weight ranged from 70 to 100 kg Diabetes Care
dietary - mean BMI from 25 to 38 kg m2 1997;20:537–544
programme - ten studies included both men and women, and (22) Wadden TA et al; J
being identical three included only women (11,21,22), four Consult Clin Psychol
in both included only men (13,15,18,23) 1998;66:429–433
intervention - length of intervention varied from 3 months to 6 (25) Wing RR et al;
groups
years Diabetes Care
Duration - length of the subsequent follow-up without active 1998;21:350–359
minimum 6 intervention varied from 0 to 2.5 years (20) Stefanick ML et al; N
months
- ten studies reported results as change in weight Engl J Med 1998;339:12–
and seven studies as change in BMI 20
Heterogeneity: (11) Fogelholm M et al;
- there are no significant heterogeneity P-values (for Arch Intern Med
heterogeneity) were mentioned 2000;160:2177–2184
(18) Reseland JE et al;
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 184
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
- random effect model was used Am J Clin Nutr
Publication bias: 2001;73:240–245
- formal statistical testing (funnel plots, Begg and (14) Kiernan M et al; Obes
Egger test) did not suggest publication bias Res 2001;9:770–777
Results: (10) Brekke HK et al;
Diabetes Res Clin Pract
- D + E programme produced greater long-term
2005;70:225–234
weight loss than only D programme:
(15) Kukkonen-Harjula KT
- pooled weight loss: 1.14 kg (95% CI 0.21 to
et al; Prev Med
2.07) or 0.50 kg m-2 (95% CI 0.21 to 0.79)
greater for D + E group than only D group 2005;41:784–790
- pooled standardized mean difference (12) Heilbronn LK et al;
between D + E and D groups was -0.25 (95% JAMA 2006;295:1539–
CI -0.36 to -0.14) 1548
- Subgroup analysis: (26) Messier SP et al;
- Intervention time: difference in weight loss Arthritis Rheum
was significantly greater (p-value 0.03) for - 2004;50:1501–1510
interventions with a duration longer than 1
year (mean differences= - 0.35) than that for
interventions of shorter duration (mean
differences= - 0.07)
- No statistical significant differences in results
by baseline age, obesity, sex, population,
comorbidities and duration of follow-up after
the active intervention
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 185
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
Meta- Anderson RCTs, non- Worksite Included studies: (27) Abrams DB, Follick 1- Heterogeneity:
analysis LM, et al. randomised interventions Study quality: (Randomization/ Dropout rate/ MJ. J Consult Clin Psychol Results of Q-test
(2009) studies, cohort (nutrition and intention-to-treat): 1983; 51(2):226 –33. n.a., only “not
[39] designs, time physical activity (31) Anderson J, significant”
- 47 studies: 31 RCTs, 12 non-randomised studies,
serie programs) Dusenbury L. AAOHN J
3 cohort designs, 1 time series
Following Outcomes: 1999; 47(3):99–106.
- Quality assessment: “Community Guide” was Randomization
Databases different weight used; (34) Briley ME, et al.J Am procedures,
were used: related outcomes Diet Assoc 1992;
- Studies with greatest or moderate design suitability allocation
Medline, including weight in 92(11):1382– 4.
and good or fair quality of execution were included concealment,
Embase, pounds or
- Random effect model (37) Cook C, et al N Z blinding, drop
Cinahl, kilograms, BMI
Med J 2001; outs,
Cochrane and percentage - Only 2 RCTs reported intention-to-treat analysis
(35, 47) 114(1130):175–8. publications bias
library et al. body fat
(39) DeLucia J, et al. J not reported
Up to 2005 - Many of the studies reported insufficient statistical
information for statistical pooling with CIs Subst Abuse 1989;1:203–
Keywords 8.
were reported - Randomization procedures, allocation
concealment, blinding, drop outs n. a. (44) Forster JL, et al. J
Language Occup Med 1985;
restriction: Descriptive statistics:
27(11):8084–8.
only English - Outcome measure at least 6-12 months from the
(46) Furuki K, et al. J
start of intervention program
Occup Health 1999; 41:19
- any weight status: normal, overweight, obese –26.
- Intervention: worksite health promotion programs (48) Gomel M, et al. Am J
including nutrition or physical activity programs or Public Health
both with different implementations-strategies 1993;83(9):1231– 8.
- Separate analysis of studies comparing
(52) Jeffery RW, et al. Am
intervention to untreated control and intervention to
J Public Health
multiple treatment arm
1993;83(3):395– 401.
- The behaviour focus of 27 studies was on diet and
physical activity, 10 – diet only, 10 – physical (54) Karlehagen S, Ohlson
CG. Prev Med 2003;
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 186
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
activity only 37(3):219 –25.
- Duration was < 6 months in 19 studies, 6-9 months (57) Lovibond SH, et al. J
in 14 studies, 12-18 months in 8 studies, > 18 Behav Med 1986;9:415–
months in 6 studies 37.
- Different data were not reported (age in 70 % of (58) Muto T, Yamauchi K.
studies, socioeconomic data and information about Prev Med
jobs in 40 % of studies, the size of worksite in 64 2001;33(6):571–7.
% of studies) (59) Nilsson PM, et al.
Heterogeneity: Scand J Work Environ
- Q-Statistik was used Health 2001; 27(1):57–
- Analysis part II: 9 RCTs (outcome weight in 62.
pounds): Q-Test for heterogeneity was not (60) Nisbeth O, et al.
significant Patient Educ Couns 2000;
Publication bias: 40(2):121–31.
- N. a. (61) Oden G, et al. Fitness
Bus 1989;4:198 –204.
Results:
(64) Pohjonen T, Ranta R.
- Analysis part I: all study design were used;
Prev Med 2001 Jun; 32(6):
- Analysis part II: effects separately by study design: 465–75.
- Analysis part II: RCTs: (65) Pritchard JE, et al.
- 9 RCTs; outcome weight in pounds: pooled Nutr Diet 2002 Jun;
effect was - 2.8 pounds (95% CI -4.63 to - 59(2):87–96.
0.96) in favour of intervention
(29) Anderson JV et al. J
- 3 RCTs (47, 49, 53): physical activity Occup Med 1993;35(8):
behaviours alone: effect was - 2.24 pounds
(95% CI -6.49 to +2.00) 800–4.
- 5 RCTs (38, 58, 60, 62, 65): physical activity (36) Cockcroft A, et al.
and diet: effect was - 3.18 pounds (95% CI Occup Med (Lond) 1994;
-5.88 to -0.5) 44(2):70–6.
- One study (40): diet alone: weight loss was (41) Elberson KL, et al.
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 187
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
-1.71 (95% CI -8.38 to +4.95) Outcomes Manag Nurs
- 6 RCTs; outcome BMI: pooled effect was Pract 2001; 5(2):82– 6.
-0.47 (95% CI -0.75 to -0.19) in favour of (47) Gerdle B, et al. J
intervention Occup Rehabil 1995;
- 3 cluster RCTs (37, 42, 48) reported BMI 5(1):1–16.
outcomes in 6 months: pooled effect was (51) Hedberg GE, et al.
-0.25 (95% CI -0.64 to + 0.14) Occup Environ Med 1998;
- Subgroup analysis: no association between 55(8):554–61.
program effectiveness and focus of program or
(72) Wier LT, et al .Aviat
behavioral focus
Space Environ Med 1989;
- But: small number of studies in each category 60: 438–44.
(30) Anderson J,
Dusenbury L. AAOHN J
1999; 47(3):99 –106.
(45) Fukahori M, et al. J
Occup Health
1999;41(2):76–82.
(53) Juneau M, et al. Am J
Cardiol 1987; 60:66 –77.
(55) Krishnan N, et al.
Indian J Ind Med
2004;8(2):29 –33.
(63) Peterson G, et al.
Behav Ther
1985;16(A2):213–22.
(68) Shimizu T, et al .J
Occup Health
2004;46(3):205–12.
(79) Steinhardt M, et al. J
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 188
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
Psychol 1999;133(5):495–
513.
(26) Borenstein M,
Englewood NJ: Biostat,
2006.
(33) Briley ME, et al. J Am
Diet Assoc
1992;92(11):1382– 4.
(35) Bruno R, et al. Prev
Med 1983;12(4):523–32.
(38) Crouch M, et al. Prev
Med 1986;15:282–91.
(43) Erfurt JC, et al. Am J
Health Promot 1991;5(6):
438–48.
(56) Linenger JM, et al.
Am J Prev Med
1991;7(5):298 –310.
(62) Okayama A ,et al.
Environ Health Prev Med
2004; 9(4):165–9
(42) Elliot DL, et al. Am J
Health Behav
2004;28(1):13–23.
(40) Drummond S, Kirk T.
J Hum Nutr Diet
1998;11:473–85.
(67) Robison JI, et al. Med
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 189
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
Sci Sports Exerc
1992;24(1):85–93.
(69) Talvi AI, et al. Occup
Med (Lond) 1999
Feb;49(2):93–101.
(32) Barratt A, et al. Am J
Public Health
1994;84(5):779–82.
(28) Aldana SG, et al. J
Occup Environ Med
2005;47(6):558–64
(49) Grandjean PW, et al.
J Sports Med Phys
Fitness 1996;36(1):54 –9.
(50) Harvey HL. Dissert
Abstr Int B: Sci Eng
1998;60(2B)
(66) Proper KI, et al. Am J
Prev Med 2003;24(3):218
–26.
(70) Thorsteinsson R, et
al. Scand J Prim Health
Care 1994;12(2):93–9.
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 190
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
Systematic Witham MD, RCTs Diet, physical Included studies: (15) Glasgow RE et al; 1- Significant
Review/ et al. (2010) Search activity and mixed Study quality: (Randomization/ Dropout rate/ Patient Educ Couns 1997; statistical
Meta- [62] strategy: 13 approaches intention-to-treat): 32: 175–84. heterogeneity
analysis electronic Outcomes: weight, (14) Whelton PK et al ; Publications bias
- 9 RCTs
databases BMI, total JAMA 1998; 279: 839–46 analysis not
- all studies reported random allocation
(Medline, cholesterol, high- (10) Mengham LH et al; exist
Cochrane, density lipoprotein - insufficient detail were in most trials regarding
adequate allocation concealment Pract Diab Int 1999; 16: insufficient detail
Embase et al.) (HDL) cholesterol, 5–8 about allocation
low-density - some studies specified intention-to-treat analysis
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 191
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
Search date lipoprotein (LDL) in their protocols (16) Toobert DJ et al; Ann concealment
was reported cholesterol, - 2/9 studies clearly performed intention-to-treat Behav Med 2000; 22: 1–9 Post hoc
Search terms triglycerides, analyses; insufficient detail was given in 3/9 (13, 22) Messier SP et al; subgroup
were reported fasting glucose, - most studies gave numbers of withdrawals, but Arthritis Rheum 2004; 50: analysis
HbA1c and blood only four gave reasons for withdrawal or dropout 1501–10
weight loss
pressure, deaths,
was a primary - baseline treatment and control groups were well Rejeski WJ et al; Health
hospitalization,
aim of the balanced in all nine studies Psychol 2002; 21: 419–26
morbidity, quality
intervention - Blinding: only one study clearly reported that the (11) Mayer-Davis EJ et al;
of life, measures
follow-up data of physical team in charge of patients’ usual care was blinded Am J Public Health 2004;
at a minimum function and to the intervention, or that those measuring 94: 1736–42
of 1 year were exercise capacity outcomes were blinded to treatment group (17, 18 = PATH (Positive
available Descriptive statistics: Action for Todays Health)
mean age of - with one exception [10], the included trials were all Trial)
groups was carried out in the USA Irwin ML et al; JAMA
≥60 years - most studies targeted patients with a specific 2003; 289:323–30;
mean baseline disease entity (diabetes mellitus, coronary artery Frank LL et al; Obes Res
BMI was ≥30 disease, osteoarthritis) 2005; 13: 615–25
kg/m2 - studies were a mixture of single-centre and multi- (19) Crandall J et al; J
trials with centre trials Gerontol A Med Sci 2006;
placebo or no - some interventions were conducted in community 61A: 1075–81
intervention for or primary care settings and some in secondary (12) Villareal DT et al; J
the control care settings Clin Endocrinol Metab
group and - all studies examined patients who were living in 2008; 93: 2181–7
trials the community rather than in institutional settings
comparing
- two studies had a mean baseline BMI of >35
active
kg/m2 [11, 12]
intervention
groups - one trial [11] targeted black and white adults with
diabetes living in medically underserved rural
communities
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 192
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
- all trials provided dietary advice, with the exception
of PATH trial, which provided physical activity
advice [17, 18]
- in two trials, it was not clear whether this was low-
fat dietary advice [10, 14].
- two trials did not report giving physical activity
advice [10, 15], and three trials provided facilities
for undertaking physical activity [12, 13, 17, 18].
Heterogeneity:
- random effects model was used
- I2 tests for heterogeneity across analyses were
performed, and possible sources of heterogeneity
were explored
- For weight: Significant statistical heterogeneity (I2
= 89%; P < 0.001)
Publication bias:
- n. a. in analysis
- “it is possible that unpublished studies exist that
have not been included”
Results (for weight):
- overall weighted mean difference change
comparing intervention and control groups at 12
months was −3.0 kg (95% CI −5.1 to −0.9, P =
0.005)
- Post hoc subgroup analysis (according to the type
of intervention):
- trials that provided physical activity advice
with dietary advice appeared to provide
greater weight loss (change in weight of −3.8
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 193
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
kg; 95% CI −6.22 to −1.38, P = 0.02)
- two studies for which weight change was
extrapolated from BMI change [15, 16] gave a
change in weight of −3.3 kg (95% CI −5.8 to
−0.8, P = 0.009)
- Studies with a clearly defined weight loss goal
such as defined weight loss or calorie
restriction [10–12, 14] showed a change in
weight of −4.0 kg (95% CI −7.3 to −0.7),
compared with −1.3 kg (95% CI −2.9 to 0.3, P
< 0.001 for difference) in those without a
defined goal [15–17]
Systematic Kastorini Databases: Mediterranean diet Included: 21 RCTs and 14 prospective/cross- Tuttle KR, et al. Am J 1- Reporting quality
Review CM, et al. Pubmed, (vs. low fat, low sectional studies Cardiol 2008 of studies n.a.
(2010) Scopus and carbohydrates et Study quality: n.a. Fung TT, et al. Am J Clin
[63] Embase al. Diet) Nutr 2005
Heterogeneity:n.a.
Studies in Publication bias:n.a. Panagiotakos DB, et al.
English, until Nutrition 2006
Results (for weight):
December Panagiotakos D, et al.
2009, Not all studies show protective effects on body
Nutr Metab Cardiovasc
reporting data weight;
Dis 2009
Search terms: Observational studies (adherence to the
Tzima N, et al. Lipids
combinations Mediterranean diet, obesity and cardiovascular risk
Health Dis 2007
of key words factors): indicate that subjects closer to the
Mediterranean diet decreased both their body weight Sanchez-Tainta A, et al.
relating
and CVD risk factors Eur J Cardiovasc Prev
to disease Rehabil 2008
(coronary
Panagiotakos DB, et al.
heart disease, Clinical trials evaluating the relationship between
Asia Pac J Clin Nutr 2007
obesity, body adherence to the Mediterranean diet, obesity and
weight) and cardiovascular risk factors: are in accordance with Tyrovolas S, et al. Int J
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 194
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
Mediterranean results from observational studies. Food Sci Nutr; 2009
diet de Lorgeril M, et al. Lancet
1994
Esposito K, et al. JAMA
2003
Esposito K, et al. JAMA
2004
Esposito K, et al. Ann
Intern Med 2009
Buscemi S, et al. Eur J
Clin Invest 2009
Vincent-Baudry S, et al.
Am J Clin Nutr 2005
Shai I, et al. N Engl J Med
2008
Elhayany A, et al.
Diabetes Obes Metab
2010
Rallidis LS, et al. Am J
Clin Nutr 2009
Toobert DJ, et al.
Diabetes Care 2003
Ambring A, et al. Clin Sci
(Lond) 2004
Bos MB, et al. Nutr Metab
Cardiovasc Dis; 2009
Goulet J, et al.
Atherosclerosis 2003
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 195
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
Andreoli A, et al. Eur J
Clin Nutr 2008
Estruch R, et al. Ann
Intern Med 2006
Michalsen A, et al. Eur J
Clin Nutr 2006
Rodriguez-Villar C, et al.
Diabet Med 2004
Lerman RH, et al. Nutr
Metab (Lond) 2008;5:29.
Systematic Södlerlund Databases: Physical exercise. Included studies: Fogelholm M, et al. 1+ Small studies,
Reviews A, et al. Medline, Diet, behaviour 12 RCTs were included Journal of Obesity and publication bias
(2009) Cochrane, therapie Related Metabolie analysis n.a.
Descriptive statistics: see results
[64] Cinahl ect. Disorders 1999
Heterogeneity: n.a.
RCTs King AC,et al. Health
Publication bias: n.a. Psychology 1997
Adults
Results: Kukkonen-Harjula K, et al.
Physical
training = part Weight loss: Preventive Medicine 2005
of treatment in seven studies body weight decreased significantly Skender ML, et al. Journal
Healthy in Intervention groups. of the American Dietetic
overweight or At the end of the Intervention period the effect size of Assoecation 1996
obese the average weight lass was greatest in two studies Wadden TA, et al. Journal
subjects that combined diet with aerobic training. of Consuling and Clinical
At least one ln one study the effect sizewas negative at the end of Psychology 1998
year follow the Intervention period, signlfying a weight gain Weinstock RS, Archives of
up/likelihood Follow-ups in eight of the studies: for two years; the Interna! Mediclne 1998
of rest of the studies had Interventions that continued Jakicic JM, et al. Journal
maintenance one year or more. The follow- ups showed of the American Medical
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 196
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
English significantly lower weight gains after Interventions Association 1999
Between that included moderately intense aerobic trainlng and Jefferey R, et al. Journal
1995-2006 emphasized increased, individual, daily activity of Consultingand Clinical
lnclusion in three studies there was no significant dlfference in Psychology 1998
criteria: RCT; welght gain among the Intervention groups during Perri MG, et al. Journal of
the subjects follow-up. Consulting and Clinical
had to be The biggest effect size at follow-up (1.09) occurred in Psychology 1997
adults; a study in which diet, behaviour therapy and Andersen RE, Jotrrnal or
treatment: individual aerobic trainlng were combined in one of the Arnerican Medical
physical the Intervention groups (52 weeks training and follow- Association 1999;
tralning or up = three months)
exercise; The smallest effect size at follow-up (-0.79 (largest
overweight or increase in weight)) occurred in a study in which only
obese aerobic training took place four to six hours per week
subjects but with an HRR lntensity of 60% in one of the two
otherwise Intervention groups (raining period was 40 weeks
healthy; the lang; follow-up - a little over a year
Intervention
groups include
at least 15 Conclusion:
subjects; at The biggest effect size: at follow up: at the group in
least one-year which diet, individual aerobic training and behaviour
follow-up alter therapy were combined
the The smallest effect size: in the group this only
Intervention or aerobic training
if there was no
follow-up then
the
intervention
had to be at
least 12
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 197
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
months in
order to
increase the
likelihood of
maintenance
of the results;
published in
English
between 1995
and 2006.
Cochrane Tuah NA, et Databases: Intervention: Included studies: Dinger 2007 1+ Gute
Review al. (2011) The Cochrane Theoretical model Study quality: (Randomization/ Dropout rate/ Johnson 2008 methodische
[65] Library (until “Stages of intention-to-treat): Qualität
Jones 2003
10, 2010), Change”=TTM 1 low risk of bias
- 5 RCTs Logue 2005
MEDLINE SOC trial and 4 High
(until - Only one study: reported allocation concealment Steptoe 2001
Theoretical risk of bias trials
Dezember framework or - Blinding: 1 study (reporting bias,
2010), guideline in - No selective reporting: 1 study selection bias)
EMBASE (until designing lifestyle - Flow chart available
January 2011) modification - Two authors assessed each trial independently
and strategies, mainly
PSYCHINFO - Inter-rater agreement for key bias indicators (e.g.
dietary and allocation concealment, incomplete outcome data)
(until Januar physical exercise
2011) was calculated using the kappa statistic
versus a
Descriptive statistics:
Inclusion comparison
criteria: intervention of - 3910 participants (1834 in interventions group and
RCT using usual care 2076 in control group)
TTMSOC as a Control: Usual - Adults, aged 18 years and over, who are
model, advice on diet or overweight or obese
theoretical advice on physical - Participants with co-morbidities, such as diabetes,
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 198
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
framework or exercise heart diseases and hypertension will be included in
guideline in the review
designing - length of intervention from six weeks to 24 months,
Primary outcomes:
lifestyle with a median length of nine months
weight loss,
modification - AE: Death and weight gain are the two adverse
health-related
strategies, events reported by the included trials
quality of life;
mainly dietary
and physical Other outcomes: Heterogeneity:
exercise change in physical - I2 statistic
versus a activities Publication bias:
comparison behaviour and
dietary intake, - Funnel plot
intervention of
usual care; adverse events Results (for weight):
one of the including relapse - Intervention: limited impact on weight loss (about 2
outcome into unhealthy kg or less)
measures of behaviour and - no conclusive evidence for sustainable weight loss
the study was weight gain;
- other outcomes: significant change in physical
weight loss; morbidity; death
activities behaviour and dietary intake in
and from any cause;
combination with TTM SOC
participants costs.
- TTMSOC was used inconsistently as a theoretical
were
framework for intervention in the trials
overweight or
obese adults
Meta- Thorogood RCTs Moderate-intensity Included studies: Nishijima H, et al. Med Sci 1+ Publication bias
analysis A, et al. Inclusion aerobic exercise Study quality: (Randomization/ Dropout rate/ Sports Exerc. 2007; analysis n.a.
(2011) criteria: Trials programs intention-to-treat): Alves JG, et al. Am J
[66] with isolated Public Health
- 14 RCTs were included in SR, 6 RCTs were
aerobic included in M-A 2009;99(1):76-80.
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 199
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
exercise - 1847 patients were included Irwin ML, et al. JAMA.
longer 12 - Flow diagram 2003;289(3):323-330.
week and at - PRISMA Statement was used Anderssen S, et al. Nutr
least 120 Metab Cardiovasc Dis.
- 4 studies reported blinding
minutes per 1995;
week were - 3 studies did not conceal allocation after
randomisation Lambers S, et al. Clin
included.
- ITT = inclusion criterion Rehabil. 2008;22(6):483-
Obese and
492.
overweight Descriptive statistics:
individuals, Blumenthal J, et al. Arch
- Includes studies/Duration: 2 studies (265 patients) Intern Med.
intention-to- had a 12-month exercise intervention, 4 studies
treat analysis 2000;160(13):1947.
(861 patients) had a 6-month intervention, and 8
was used studies (414 patients) had a 12-16-week Hellenius M, et al.
Through intervention Atherosclerosis. 1993;
January 2010 - 4 studies had patient populations with a mean Posner J, et al. J Am
Medline and age>60 years and 1 study recruited only young Geriatr Soc. 1992;40(1):1.
Cochrane date patients aged between 19 and 23 years Bonanno JA, et al. Am J
bases - 2 studies were located in Japan, 1 – in Brasil, 11 – Cardiol. 1974;33(6):760-
in Europe or North America 764.
Heterogeneity: Raz I, et al. Isr J Med Sci.
- random effects model was used 1994;30(10):766-770.
DiPietro L, et al. J Am
Publication bias:
Geriatr Soc.
- n. a. 1998;46(7):875.
Results (for weight): van Aggel-Leijssen DP, Int
- Six-month programs were associated with a J Obes Relat Metab
modest reduction in weight (weighted mean Disord. 2001;25(1):16-23
difference 1.6 kg; 95% confidence interval [CI], Abe T, et al. Med Sci
1.64 to 1.56) and waist circumference (weighted Sports Exerc.
mean difference 2.12 cm; 95% CI, 2.81 to1.44) 1997;29(12):1549-1553.
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 200
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
- Twelve-month programs were associated with
modest reductions in weight (weighted mean
difference 1.7 kg; 95% CI, 2.29 to 1.11) and waist
circumference (weighted mean difference 1.95 cm;
95% CI, 3.62 to 0.29)
Meta- Ismail I, et Electronic aerobic exercise Included studies: Donelly J, et al. Med Sci 2+ High
analysis al. (2012) database (AEx) and - 35 studies Sports Exerc 2009 heterogeneity;
[67] searches were progressive Brochu M, et al. J Clin
Study quality:
performed in resistance training Endocrinol Metab 2009
AMED, - flow chart reported
(PRT) on visceral Cuff DJ, et al Diabetes
MEDLINE, adipose tissue - two reviewers
Care 2003
MEDLINE (VAT) - Included studies met a minimum quality threshold
defined as having met all inclusion criteria; Study Giannopoulou I, et al. J
Daily Update,
quality was further assessed by two researchers in Clin Endocrinol Metab
PREMEDLINE
a blinded manner using a modified assessment 2005
(via
scale created by Downs & Black Hunter GR, et al.Obesity
OvidSP),
- All included studies specified their hypotheses, 2010
SPORTDiscus
, CINAHL (via main outcomes, participant characteristics, Ibáñez J, et al. Obesity
EBSCO), interventions, main findings, variability estimates, 2010
EMBASE statistical tests, accuracy of measures and Irving BA, et al. Med Sci
randomization procedure. Eight studies did not Sports Exerc 2008
and Web of
report adverse events while five studies did not
Science from Irwin ML, et al J Am Med
provide an adequate description of the control
earliest record Assoc 2003
group. Eighteen studies
to November Janssen I, et al. Diabetes
- reported the reliability of the VAT measure. Only
2010. The two studies made an attempt to blind study Care 2002
search Kim E, et al. Jpn J Phys
participants to the intervention they received, and
strategy Fitness Sports Med 2008
only two studies made an attempt to blind those
combined measuring the main outcome of the intervention
terms covering Ku YH, et al. J Int Med
the Descriptive statistics: Res 2010
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 201
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
areas of - 2145 individuals (702 male; 1422 female; 21 not Kwon HR, et al. Korean
strength reported) participated in the trials Diabetes J 2010
training, - Seventeen studies exclusively recruited female Kwon HR, et al. Korean
aerobic participants, five studies exclusively recruited male Diabetes J 2010
exercise participants, with 11 studies recruiting both men Nicklas et al. Am J Clin
training and and women; Sex was not reported in one study Nutr 2009
visceral fat ( - The mean age of participants ranged from 28–83
Park SK, et al .J Physiol
Included years, and 11 studies did not report mean age Anthropol Appl Human Sci
studies: RCTs - 18 studies had participants who were classified on 2003
in which average as obese, 15 as overweight and two
aerobic Poehlman ET, et al J Clin
within normal range
exercise or Endocrinol Metab 2000
- Fourteen studies specifically recruited obese
progressive Ross R, et al. Obes Res
participants, nine studies recruited participants
resistance 2004
with type 2 diabetes, three studies with metabolic
training in syndrome and two studies recruited Asian-only Schmitz KH, et al. Am J
isolation or Clin Nutr 2007
cohorts
combination
were - 27 studies that conducted AEx training, the Boudou P, et al. Eur J
employed for 4 frequency of AEx was most commonly 3 d per Endocrinol 2003
weeks or more week (10 of 27 studies) followed by 5 d per week Rice B, et al. Diabetes
in adult - frequency for PRT was most commonly 3 d per Care 1999
humans, week (9 of 13 studies), with three studies training Ross R, et al. Ann Intern
where with PRT 2 d per week Med 2000
computed - Six studies combined AEx and PRT training, three Ross R, et al. J Appl
tomography of which conducted training on 3 d per week and Physiol 1996
(CT) or one study conducted on 4 d, 5 d and 6 d per week
magnetic Thong FSL, et al .Am J
Heterogeneity: Physiol Endocrinol Metab
resonance
- see results 2000
imaging (MRI)
was used for Publication bias: Binder EF, et al. J
quantification - Funnel plot and Eggers test, result n.a. Gerontol A Biol Sci Med
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 202
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
of visceral Results (for weight): Sci 2005
adipose tissue - significant pooled effect size (ES) for the Garr DB, et al. Diabetes
pre- and post- comparison between AEx therapy and control (ES 2005
intervention = -0.23, 95% CI: -0.35 to -0.12; P < 0.001). Coker RH, et al. Metab
Significant heterogeneity among studies was Syndr Relat Disord 2009
observed (I2 = 71.0%, P < 0.001); After re-
DiPietro L, et al .J Am
analysis via random effects model with this outlier
Geriatr Soc 1998
removed, there remained a significant pooled ES (-
0.33, 95% CI: -0.52 to -0.14; P < 0.01) Janssen I, et al .Int J Obes
1999
- non-significant pooled ES for the comparison
between PRT therapy and control (ES = 0.05, 95% McTiernan A, et al.
CI: -0.10 to 0.20; P = 0.52); random effects model: Obesity 2007
0.09, 95% CI: -0.17 to -0.36; P = 0.49); Short KR, et al. Diabetes
- in nine studies which directly compared AEx with 2003
PRT, the pooled ES did not reach statistical Sigal RJ, et al. Ann Intern
significance (ES = 0.20, 95% CI: -0.02 to 0.42; P = Med 2007
0.08; random effects model ES = 0.23, 95% CI: - Slentz CA, et al. Appl
0.02 to 0.50; P = 0.07 favouring AEx); I2 = 20.1%, Physiol 2005
P = 0.26
Stewart KJ, et al .Am J
- pooled ES did not reach statistical significance for
Prev Med 2005
interventions that combined AEx and PRT therapy
vs. control (ES = -0.27, 95% CI: -0.46 to -0.08; P < Mourier A, et al. Diabetes
0.01; random effects model: -0.28, 95% CI: -0.69 Care 1997
to 0.14; P = 0.19); I2 = 87.1%, P < 0.01
Meta- Shikany JM, Databases: Modified Included studies: Aude et al., Arch intern 1- 4 RCTs, data
analysis et al. (2011) PubMed, Web carbohydrate diet Study quality: (Randomization/ Dropout rate/ med 2004 from three RCTs
[68] of Science (MCD)=South intention-to-treat): Maki et al, Am J Clin were obtained
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 203
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
Studies Beach diet - 4 RCTs were included nutrition 2007 from sponsor
published from compared with - Flow diagram Only 1 RCT was
1950 up to various control - ITT identified
April 2010 diets on weight through search
loss Descriptive statistics:
Key word: process
“south beach” - Included studies/Duration: 12-36 week
Only two
- 24 week follow up: available from 3 studies
Inclusion included studies
criteria: - 506 adult patients were included were published
design, Heterogeneity: The raw data
intervention = - Heterogeneity of studies from study 1
MDS, weight - Fixed and random effects models were used were n.a.
loss and
Publication bias: p.b analysis n.a.
related
anthropometri - n. a. results after 36
c measure are Results (for weight): week (=duration
outcomes of one included
Forest plot was used study) n.a.
Exluded: non
4 RCTs: weight loss was in all 4 studies after 12 and High drop out
RCTs, trials
24 week better in MCD group; results for BMI and and missing rate
focused on
waist circumference were different: BMI was better in
weight Study question
MCD group after 12 week and better after 24 week in
mantainance, is clearly
only 3 studies;
trials in focussed
patients Waist circumference was better in MCD group after
12 and 24 week in only one study Different control
undergoing diets
gastric bypass Fixed effects model:
surgery ITT analysis
Significant greater weight loss (after 12 week:-1.66;
CI -1.98, -1.34; after 24 week: -1.20; CI -1.73, -0.68), Multiple
BMI (after 12 week: -0.53; CI -0.66, -0.41; after 24 imputation to
week: : -0.43; CI -0.62, -0.23) and waist handle missing
circumference (after 12 week: -1.02; CI -1.49, -0.54; data
Heterogeneity of
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 204
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
after 24 week: : -0.69; CI -1.29, -0.09) reduction after studies
12 and 24 week (Fixed and
Random effects model: random effect
Results only minimal different to Fixed effects model, model were
but not significant difference in waist circumference used)
after 24 week (-0.91; CI -2.42,0.60) CI were reported
Meta- Esposito K, Databases: Mediterranean diet Included studies: Esposito et al, 2003, 1+ High
analysis et al. (2011) PubMed, (=MD) versus Study quality: (Randomization/ Dropout rate/ JAMA methodological
[69] Embase, control diet intention-to-treat): Mc Manus et al, 2001, Int Quality of Study,
Scopus, J Obes Relat Metab But: The
- 16 RCTs were included
Cochrane Disord interventional
- PRISMA checklist was used
Trials from Esposito et al, 2004, mediterranean
inception to - Flow diagram is available diet and control
JAMA
January 2010 - Two investigators independently assessed the diet varied
eligibility of studies, consensus procedure was Esposito et al, 2009, Ann
Search between the
used Intern Med
strategy was trials
- Jadad scala of methodology quality was used Shai et al, (low fat) 2008,
reported, no High
- CI were reported N Engl J Med
language heterogeneity
restrictions Descriptive statistics: Elhayany et al, (LCM)
Sensitivity
were used 2010, Diabetes Obes
- 3436 adult participants (1848 assigned to analysis was
Metab
Inclusion mediterranean and 1588 assigned to control diet) reported
criteria: were included De Lorgeril et al 1994,
Were are no
design, Lancet
- 4 trials did not reported weight in kilogram evidence for
outcome: body Rodriges Villar et al, 2004, Publication bias
- Countries: USA, Europe, Israel
weight, BMI Diabetes med
Heterogeneity:
Exclusion Bos et al, 2009, Nutr
criteria were - High Heterogeneity of studies (Q2 and I2 statistic) Metab Cardiovask Dis
reported (lack - random effects model was used Fernandez Puebla et al,
of - subgroup analyses were performed to explore 2003, Nutr Metab
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 205
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
randomisation, heterogeneity Cardiovask Dis
lack of control Publication bias: Estruch et al (olive oil),
diet group, 2006, Ann intern med
- Begg funnel plot and Egger test were used
samples with
- There are no evidence for Publication bias Toolbert et al 2003,
less as 15
Diabetes Care
patients, follow Results (for weight):
up less as 4 Vincent-Baudry, Am J clin
Forest plot was used
week et al) nutr, 2005
Random effects analysis:
Michalsen Eur J clin Nutr
Significant greater effect on weight in MD group
Tuttle et al, Am J Cardiol
(Mean difference between groups –1.75 kg, CI -2.86
to -0.64 kg) and on BMI (Mean difference between 2008
groups –0.57 kg/m2, CI Rallidis et al, 2009 Am J
-0.93 to -0.21 kg/m2), the effect was greater in Clin Nutr
association with energy restriction (mean weight: -
3.88 kg) or increased physical activity (mean weight -
4.01 kg)
Sensitivity analysis: the effect of MD was no longer
statistically significant then diet was no associated
with energy restriction or increased physical activity
and in trials with a shorter follow up (less as 6 month)
Meta- Burke LE, et Databases: Three components Included studies: Linde.JA. ,et al. Ann 2- No restrictions
analysis al. (2011) Medline, of self monitoring Study quality: (Randomization/ Dropout rate/ Behav Mfed.2005 on design or
[70] PsychInfo in behavioural intention-to-treat): Baker RC, 1et al. Behav size
Published weight loss Ther 1993 homogenous
- 22 observational studies
between 1993- studies: diet, samples
- 8 were reports from randomized clinical trials Helcel DL et al. ,J Am Diet
2009 exercise and self
testing behavioural weight loss interventions 2007; Flow chart
weighing
Key words Tate DF, et al. JAMA.
Descriptive statistics:
were reported 2001;
Primary outcome: - 15 studies focused on dietary self monitoring, 1 –
Search Gokee-LaRose J, et al. lnt
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 206
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
limiters: weight loss and on self monitoring exercise, 6 – on self weighting J Behav Nutr Phys Act.
English weight - 6 studies were secondary data analysis or ancillary 2009:
language, maintenance studies of existing weight loss programs Van Wormer Am J Prev
human beings - The use of technology (Internet, personal digital Med 2009;
Manual search ass., electronic digital scales)- reported in 5 Burke LE, et al. 2006;
of reference studies
Yon ßA, et al J Behav
sections of the - Population: predominantly white and women Med. 2007
included
- 4 studies did not report the racial and ethnic Welsh EM 2009;
studies were
composition
performed Boutelle KN 1998;
Heterogeneity:
Inclusion Boutelle KN 1999
criteria: - N. a.
Baker RC, et al. 1998:
conducted in Publication bias:
the USA, Nothwehr F 2005;
- n.a.
reported Hollis JF et al. 2008;
Results:
between 1989 Carels RA, et al. 2005
and 2009, Significant association between self monitoring and
weight loss: Carels RA, et al. 2008
investigated
the effect of - Self monitoring dietary intake: all 15 studies found Burke LE, et al. 2009
self monitoring significant associations between self monitoring Shay LE, et al. 2009;
on weight loss and weight loss Butryn ML. et al. 2007;
and reported - Self monitoring physical activity: only one of three Wing RR. Et al. 2006;
the use of self studies specifically examined the role of self-
monitoring Tate DF, et al. 2006:
monitoring exercise in relation to weight loss
diet, physical Wadden TA. et al. 2005
- Self monitoring weight: one study showed that
activity or self- greater weight loss was associated with increased
weighing frequency of self weighting; in the weight gain
prevention trial only daily weighting was
associated with weight loss and less frequent
weighting was associated with weight gain; in 2
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 207
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
randomized trials: daily self
Systematic Pearson ES inclusion Goal setting (e.g. Included studies: Burnett KF, et al J Consult 2+ Publication bias
Review 2012 criteria: education Study quality: (Randomization/ Dropout rate/ Clin Psychol analysis n.a.
a) utilized goal sessions, self- intention-to-treat): 1985;33:698–703.
[71]
setting as the monitoring Chapman SL, et lal J
18 studies
primary records), Consult Clin Psychol
START evaluations criteria (Specificity, Timing,
intervention or 1978;46:1588–9.
Acquisition, Rewards and feedback, and Tools)
principal Jarvie GJ, et al Behav
component Descriptive statistics:
Therapist 1985;8:187–8.
thereof for The participants involved in the selected studies were
Dubbert PM, et al Behav
effecting included based on varying sets of overweight and/or
Res Ther 1984;21:221–
dietary and/or obesity criteria:
42.
physical participants were in 2 studies overweight as identified
activity Jeffery RW, et al Amer J
in pounds or kilograms
behavior Clin Nutr 2003;78:684–9.
change; (b) desired to lose 15 pounds (2 studies)
Baron P, et al. Can J
targeted an wanted to join a weight loss program (2 studies) Behav Sci 1981;13:161–
overweight The average age of participants ranged from 24 to 50 70.
and/or obese years old Baron P, et al. Int Rev
adult the majority of the study populations were female Appl Psychol
population 1982;31:369–82.
based on Mean percent overweight and BMI values were
relevant BMI between 15–50% and 29.7–35.2 kg/m2 Ureda JR. Et al Health
values, or 6 Studies examined the effects of goal setting on Educ Behav 1980;7:163–
dietary behaviors, 4 studies: physical activity 85.
adults who
self-identified behaviors, or a combination of the two (8 studies) VanWormer JJ. J Appl
a need for Intervention length within the studies occurred mostly Behav Anal 2004;37:421–
weight loss as 5.
between 4 and 8 weeks (7 studies); or 10–19 weeks
confirmed by (7 studies); Wing RR, et al Addict
the Behav 1981;5:139–44.
The length in three studies extended over the course
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 208
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
researchers; of 6, 9, and 18 months (3 studies) Booth AO et al Health
(c) occurred in Follow-up assessments occurred at differing intervals Educ Res 2008;23:371–
a non-primary among the studies and ranged from eight weeks to 81.
care setting 30 months post-intervention. Donaldson JM, et al
whereby Behav Intervent
S.T.A.R.T. evaluation criteria were applied
participants 2009;24:73–83.
were self- Heterogeneity: n.a.
Schneider PL, et al Sci
referred from Publication bias:
Health Promot
the local N. a. 2006;21:85–9.
community;
Results: Taylor CB et al Behav
Studies were
Developing specific goals that are in close proximity, Therapist 1991;22:229–
published in
involve the participant in acquisition, and incorporate 36.
English before
January 2010. regular feedback, are common features in this VanWormer JJ, et al Am
context; J Health Behav
Exclusion
- Specificity: Sixteen of the 18 studies employed 2009;33:445–54.
criterien were
reported specific goals as part of their behavior change Sperduto WA, et al Addict
protocols (e.g., restrict daily caloric intake by 750 Behav 1986;11:337–40.
Databases : calories; walk 7000 steps per day for one week);
Medline, Zegman M, et al Addict
two of these 16 interventions also combined goals
CINAHL, Behav 1983;8:319–22.
of a more general nature such as ‘reduce caloric
PsycINFO, intake’; Significant behavioral and physiological
SCOPUS, changes (e.g., decreased food consumption,
EMBASE, weight loss) were found in two studies that
Web of compared the impact of explicitly defined goal
Science, setting conditions with general or no goal
ProQuest treatment groups
Nursing
- Timing: With the exception of the two studies
Journals, and
where goal content was not specified, 16 studies
Physical
endorsed the use of proximal or daily goals either
Education
in isolation, or in combination with distal or weekly
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 209
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
Index. goal setting; When comparisons were made to
distal or no goal groups, findings revealed some
favourable outcomes for proximal goal setting as
evidenced by changes in eating behaviour s and
weight loss. Alternatively, was found greater
reductions in caloric consumption in the distal goal
setting group during treatment; however, attrition
rates in this same group were also higher
compared with the proximal group.
- Acquisition: Thirteen studies within this review
incorporated assigned goals, or goals that were
both assigned and self determined. No studies
assessed the impact of acquisition on outcome
variables independently.
- Rewards and feedback: 12 studies incorporated a
feedback component which was delivered in
person, over the telephone, or technologically via
e-mail or through a computer program; Types of
feedback included: reviewing goals and making
modifications as required; computer printouts and
graphs detailing goal progression; problem solving
discussions concerning difficulties with goal
attainment; encouragement to set more
challenging goals; praise, support, and reinforcing
messages for achieving goals; and the provision of
relevant education information. feedback on
progress was incorporated as a component within
the larger intervention and was not assessed
independently in any of the studies with respect to
behavioral outcomes.
- Tools: Participant education was a salient feature
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 210
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
in 13 studies and was delivered either as part of a
baseline period or the formal intervention. In an
effort to facilitate the self-monitoring process and
bring the attainment of behavioral goals to fruition;
multiple assistive devices were integrated into the
interventions. These included items such as
calorie-counting booklets, exercise and nutritional
manuals and diaries, self-monitoring ards,
mouthful counters, pedometers, heart-rate
monitors, home scales, social support, behavioral
contracts, portable computers, and internet-based
programs.
Systematic Gordon J, et No study Weight Included studies: Ahrens RA, et al. 2003 2- Quality
Review al. (2011) design, management - 1RCT, 1 non-randomized controlled trial, 8 Bescoby S, et al. 2006; assessment
[72] langugae, interventions in the uncontrolled studies Focused
Botomino A, et al. 2008
publication community question,
Study quality: (Randomization/ Dropout rate/ Bradley C. et al. 2009
status or age pharmacy setting
intention-to-treat): Publication bias
restrictions All studies had De Miguel E et al .2002
- All studies had reporting and methodological and
were imposed multy-component Lloyd KB et al. 2002;
weaknesses indicating risk of bias heterogeneity
Pre-specified interventions Lloyd KB, et al. 2007; n.a.
protocol based (unspecific lifestyle - 2/10 studies clearly performed ITT analyses
on Cochrane recommendations, - Withdrawal rates likely to cause bias in 4/10 Malone M et al. 2003;
Collaboration pharmacist advise, - Blinding measuring outcomes to treatment group Schwartz SM et al. 2008
methods pharmacist visits, was unclear in 2 controlled studies Toubro S, et al. 1999
Medline, nutritional advise - Adequacy of sequence generation and allocation Phrmakon. Denmark
Embase, etc.) concealment was unclear in RCT 2000.
Health Primary outcome; - 1/10 incorporated a representative sample of Winter H et al., 2007
Management change in weight service users
Information (and other Descriptive statistics:
Consortium, anthropometry,
- Countries: USA 4/10, UK 3/10, 1 Switzerland, 1
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 211
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
CINAHL, e.g. waist Spain, 1 Denmark
International circumference, if - 8/10 studies used self-recruitment methods
Pharmacy reported) - 5/10 were single-centre, 5/10 were multicentre
Abstracts, Secondary - 8/10 reported gender: women represented 70%.
Cochrane outcomes of any
Controlled - Only 1 study reported a mean baseline BMI of >35
type
Trials kg/m2
Register, - 6/10 studies reported a mean BM on study entryI,
Database of 5/10 reported a mean BMI of 25-35 kg/m2
Abstracts of - All studies had multi-component intervention
Reviews of - all had dietary component but clear description
Effects, Health only in 4/10
Information - 2 studies reported advise on physical activity
Resources
- 5 studies provided specific behaviour change
and Pharm-
line were used techniques (goal setting, self monitoring etc.)
Heterogeneity: n.a.
Jan 1999-June
2009 Publication bias: n.a.
Keywords Results (for weight):
were reported Long term mean weight loss (12 months) measured
in 3 uncontrolled studies ranged from 1.1 to 4.1 kg.
This weight loss differed significantly in 2 studies
(one of which compared high risk counselling group
with statdard care and intensive counselling group,
duration – 1 year); 4 uncontrolled studies reported
statistically significant weight loss
Short term weight loss: ranged from 0.5 to 5.6 kg at 6
months and 0.6 to 5.3 kg at 3 months; in 2 studies
was weight loss at 6 months non significant
Weight loss in 3 studies were unclear
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 212
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
Meta- Nordmann Databases: Mediterranean diet Included studies: Estruch R, et al.. Ann 1+ Sign.
analysis AJ, et al. MEDLINE, vs. low-fat diet - 7 RCT: 6 RCTs included in meta-analysis 1 RCT Intern Med. Heterogeneity
(2011) EMBASE, included only in sensitivity, analysis due to validity 2006;145(1):1-11;
[23] Biosis, Web of concerns (Flow chart) Esposito K, et al.. JAMA.
Science (all Study quality: (Randomization/ Dropout rate/ 2003;289(14):1799-1804;
from their intention-to-treat): Esposito K, et al. JAMA.
inception to 2004;292(12):1440-1446.
- 5 studies had reported consealed allocation, 4
January studies had blinded assessor, 6 studies had loss to Shai I, et al. N Engl J Med.
2011), and the follow up < 10 %, ITT-reporting is an inclusion 2008;359(3):229-241;
Cochrane criterion Tuttle KR, et al.. Am J
Central
Descriptive statistics: Cardiol.
Register of
- a total of 3650 patients 2008;101(11):1523-1530.
ControlledTrial
s - follow up: 2 years in 4 trials, 4 years in one trial, 6 Esposito K, et al. Ann
years in one trial Intern Med.
Search
- Mediterranean diet was defined 2009;151(5):306-314.
Strategie was
reported Heterogeneity:
Inclusion: - Sign. Heterogeneity
publication - Sens. Analysis: no qualitative differences
type;
Publication bias:
comparing
Mediterranean - small number of included trials precluded
with low-fat - a sensitive exploration of publication bias, although
diets in either the plots of standardized effect against precision
overweight/ob for all outcomes did not indicate evidence for such
ese patients a bias (p= n.s.)
with at least Results (for weight):
one additional Body weight, body mass index, and waist
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 213
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
cardiovascular circumference decreased more in subjects
risk factor randomized to Mediterranean diets than in subjects
or patients randomized to low-fat diets.
with After 2 years:
established the weighted mean difference (WMD) in body weight
coronary between subjects randomized to Mediterranean and
artery low-fat diets was 2.2 kg (95% confidence interval [CI],
disease; RCT, 3.9 to 0.6, P for heterogeneity <0.001, I2 =97%) the
minimum WMD in body mass index 0.6 kg/m2 (95% CI, 1 to
follow-up of 6 0.1, P for heterogeneity <0,.001, I2=94%) WMD in
months; waist circumference 0.9 cm (95% CI, 2-0.2, P for
heterogeneity <0.001, I2=92%)
report ITT,
data on
changes of
body weight,
blood
pressure, and
lipid values.
Quality
assestment
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 214
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
Meta- Ross Databases: Extended care (at Included studies: Baum JG, et al. J Behav 1+ Relatively small
analysis Middleton PubMED, least two sessions, 11 RCT were included in the meta-analysis and an Med 1991;14: 287–302. number of
KM, et al. PsychInfo and delivered either in- additional two were retained for qualitative analysis Carels RA, et al. Eat articles;
(2012) Cochrane person or via (flow chart) Behav 2008; 9: 228–237. Quality of
[73] Reviews telephone by a included studies:
Study quality: (Randomization/ Dropout rate/ Perri MG, et al. Arch
Date: from trained middle
intention-to-treat): Intern Med 2008; 168:
1980 until interventionist,
- 2 reviewer, the Physiotherapy Evidence Database 2347–2354.
June 2011 which focused on
providing (PEDro) scale was used, for included studies Perri MG, et al. J Consult
Search terms PEDro ranged from 5 to 8 (11-item in total), only Clin Psychol 1986; 54:
continuing support
were reported four had post-test data with less than 15% attrition; 670–675.
for behaviours
Included: RCT associated with only three studies with ITT Perri MG, et al. J Consult
that assessed weight Descriptive statistics: Clin Psychol 1984; 52:
the impact of management) vs. 480–481.
- majority of the studies used a problemsolving
extended care control component, three further included relapse Perri MG, et al. J Consult
on weight
prevention training; Clin Psychol 1988;56:
regain, after
- mean follow-up 16.1 months (range = 6–30 529–534.
initial weight
loss, in months); Perri MG, et al. J Consult
overweight - average of 28.6 treatment contacts; Clin Psychol 2001; 69:
and obese Heterogeneity: 722–726.
individuals; - Random-effects modelling Perri MG, et al. J Consult
adults; studies Clin Psychol 1984;
- Q-Statistik: no significant heterogeneity between
included a 52:404–413.
randomized studies, Q = 5.63, P = 0.845
Svetkey LP, et al. JAMA
extended care Publication bias:
2008; 299: 1139–1148.
component - funnel plot and a fill-and-trim analysis: minimal
that focused Wing RR, et al. N Engl J
evidence for publication bias (g = 0.321)
Med 2006; 355: 1563–
on Results (for weight):
maintenance 1571.
of weight loss; The effect of extended care on long-term weight loss Perri MG, et al. J Consult
Clin Psychol 1987; 55:
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 215
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
extended care maintenance varied by study, from g = 0.270 to 615–617.
interventions 0.933; average effect was g = 0.385 (95% confidence
delivered via interval: 0.281, 0.489; P <0.0001).
the Internet This effect would lead to the maintenance of an
were excluded additional 3.2 kg weight loss over 17.6 months post-
due to intervention
concerns
regarding the
heterogeneity
of methods
used in these
studies
Systematic Esfahani A, Literature low glycemic index GI, GL, and weight loss in adults: For GI, GL, and weight 1(-)-2(-) Quality of
Review et al. (2011) search across (GI) and glycemic Included studies: loss in adults: included studies
[74] MEDLINE load (GL) diets on Sichieri, et al (2007) Am. was not
20 trials (19 controlled trials)
(1950 to June weight loss J. Clin. Nutr. 86, 707–713. assessed;
2009 Week 4), (Included) Study quality: n.a. included and
Retterstol, et al. (2009)
EMBASE Descriptive statistics: excluded criteria
Clin. Nutr. 28, 213–215.
(1980 to June - The majority of trials compared a low GI/GL diet to are not clear,
2009 Week 4), Pereira, et al. (2004) assessment of
either low fat or high GI/GL controls;
All EBM JAMA 292, 2482–2490. publication bias
- several studies the GI/GL values were not
Reviews— Abete, I., et al. (2008) n. a.
reported: in one study the GI units were 55.5 and
Cochrane Clin. Nutr. 27, 545–551. Weight loss was
63.9 (difference of 8.4 units) while in another 78.6
DSR, ACP Aston, L. M., et al. (2008) not a primary
and 102.8 (difference of 24.2) for low- and high-GI
Journal Club, Int. J. Obes. (Lond) 32, outcome
diets
DARE, CCTR, 160–165. measure in a
CMR, HTA, - 1 study (Aston et al.) showed a nonsignificant
weight Bahadori, B., et al. (2005) number of the
and NHSEED; studies included
search terms - gain in both the groups (P =0.8). Diabetes Obes. Metab.
7,290–293. in this meta-
‘‘glycemic - 2 studies consisted of multiple interventions: in one analysis; several
index OR study, four different diets (high protein/high GI or Bouche, et al. (2002)
studies were not
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 216
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
glycemic load’’ low GI and high carbohydrate/high GI and low GI) Diabetes Care 25, 822– designed to
Included: led to similar reductions in weight (P 5 0.17 828. induce weight
clinical trials between treatments; In another study, three Das, S. K., et al .(2007) loss by
with dietary different diets (high calcium, high calcium/low GI Am. J.Clin. Nutr. 85, restricting the
interventions and moderate calcium/moderate fiber diet) caloric intake of
de Rougemont, A., et al
of different resulted in similar reductions in weight (P =0.88 the participants;
(2007) Br. J. Nutr. 98,
glycemic between treatments). none of these
1288–1298.
indices with Heterogeneity: n.a. studies were
Ebbeling, et al .(2005) Am. designed
weight loss as Publication bias: n.a. J. Clin. Nutr. 81, 976–982. specifically to
the primary
Results: Ebbeling, et al . (2007) compare weight
outcome; at
least 7 days in Weight loss: JAMA 297, 2092–2102. regain between
duration and - 4 trials reported statistically significant differences Maki, et al .(2007) Am. J. the groups;
did not include in weight loss between the treatments in favor low Clin. Nutr. 85, 724–34. several studies
studies with GI/GL diets over the control or other interventions; the GI/GL values
McMillan-Price, et al were not
exercise as a - In 10 of the other studies, low GI/GL diets (2006) Arch. Intern. Med.
cointervention. reported
enhanced weight loss by comparison to the 166,
control, though the differences were not Pittas, et al. (2006)
statistically significantly. Obesity (Silver Spring) 14,
- 1 study (Bellisle et al.) showed better, albeit 2200–2209.
nonsignificant, weight reduction with a standard
Raatz, S. K., et al (2005)
Weight Watchers diet by comparison to a Weight J. Nutr. 135, 2387–2391.
Watchers diet supplemented with low GI foods
(24.5 6 3.4 kg vs. 24.0 6 3.1 kg; P= 0.68). Slabber, M., et al. (1994)
Am. J. Clin. Nutr. 60, 48–
BMI or fat mass: (13 controlled trials), only two
53.
reported statistically significant improvements with a
low GI/GL diet by comparison to the control. Sloth, B., et al. (2004) Am.
J. Clin. Nutr. 80, 337–347.
Authors conclusion: In general, these studies showed
much inconsistency in their findings. While a few Thompson, et al. (2005)
studies found significantly greater weight loss on the Obes.Res. 13, 1344–
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 217
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
low GI/GL diets, most of the other studies showed a 1353.
non-significant trend that favored low GI/GL diets; Bellisle, et al .(2007) Br. J.
suggesting that factors other than GI/GL may play a Nutr. 97, 790–798.
role.
Systematic Tsai AG, et Literature (1) PCP Included studies: 10 RCT Ashley JM, et al Arch 1+ Clearly focused
Review al. (2009) search of counseling alone, Study quality: doublecheck, CONSORT criteria were Intern Med. question,
[75] MEDLINE, (2) PCP used to assess study quality: two as good quality and 2001;161:1599–1604. methodology
PubMed, counseling + eight as fair Ely AC, et al J Rural was reported,
Cochrane pharmacotherapy, Health. 2008;24:125–32. study quality is
Descriptive statistics:
Systematic and (3) assessed
- Most studies provided low-(<1 visit per month) or Logue E, et al Obes Res.
Reviews, “collaborative” Publication bias
moderate-intensity (at least one counseling visit 2005;13:917–27.
CINAHL, and obesity care n.a.
EMBASE (treatment per month) counseling, 29. Poston WS, Haddock
(1950- delivered by a - Only two met the Task Force’s recommendation of CK, Pinkston MM, et al. et
January, non-physician providing a highintensity intervention (at least two al J Intern Med.
2009). provider), visits per month for the first 3 months) 2006;260:388–98.
Inclusion Primary outcome: - Mean number of treatment contacts was 17 (over Martin PD, et al Obesity.
criteria for weight loss 7.5 months), 14.8 (over 13.5 months), and 7.2 2008;16:2462–7.
studies were: (over 16 months) Cohen MD, et al Fam
(1) - Six studies gave explicit descriptions of the training Med. 1991;23:25–8.
randomized and supervision of PCPs during the trial
trial, (2) Christian JG, et al Arch
Heterogeneity:high Intern Med.
obesity
intervention in Publication bias: n.a. 2008;168:141–6.
US adults, and Results (for weight): Hauptman J, et al. Arch
(3) conducted Fam Med.2000;9:160–7.
PCR counceling (4 studies):
in primary care Ockene IS, et al Arch
or explicitly Weight losses ranged from 0.1 to 2.3 kg
Intern Med.
intended to None of the four studies in which PCPs provided low- 1999;159:725–31.
model a to moderate-intensity behavioral counseling alone,
Wadden TA, et al N Engl J
primary care resulted in clinically significant weight loss
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 218
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
setting. PCR counceling + pharmacotherapie (3 studies): Med. 2005;353:2111–20.
Exclusion Weight losses ranged from 1.7 to 7.5 kg
criteria: (1) Collaborative obesity treatment (3 studies):
intervention
Weight losses from 0.4 to 7.7 (in high-intensity study)
trials that were
kg
not primary
care-based;
(2) non-US
studies; (3)
pediatric trials;
(4) studies
based in
primary care
and related to
obesity but
that were not
intervention
trials (e.g.,
surveys).
search terms
“obesity OR
obesity,
morbid” and
“primary
health care”
(for EMBASE;
“primary
medical care”).
Systematic Leblanc E, Search: behavioral-based Included studies: The Diabetes Prevention 1(+)-2(+) High
Review/ et al. (2011) MEDLINE, the treatment 58 trials of benefits of weight loss interventions, Program: Diabetes Care. heterogeneity
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 219
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
Meta- [76] Cochrane Orlistat, metformin reported in 98 publications : Trials that included 1999;22:623-34.
analysis Central behavioral-based treatment (38 trials) or the use of Hypertension Prevention
Registry of orlistat (18 trials) Trial Research Group.
Controlled Study quality: Arch Intern Med. 1990;
Trials, and
- one good-quality trial of orlistat Anderssen S, et al Blood
PsycINFO
- 2 reviewers reviewed all abstracts Press. 1995;4:343-9.
from January
1, 2005 - Quality assestment (USPSTF methods) is reported Burke V, et al J
through Descriptive statistics: Hypertens. 2005;23:1241-
September 9, 9.
- Trials that included behavioral-based treatment
2010; (n=13,495) or the use of orlistat (n=11,256) or Christian JG, et al Arch
Relevant trials metformin (n=2,652) Intern Med. 2008;168:141-
published prior 6.
to 2005 were - behavioral interventions : mean BMI values from
25 to 39 kg/m2 ; 3 of the trials were limited to Cohen MD, et al Fam
identified Med. 1991;23:25-8.
through good- obese persons, and the remaining included
quality overweight as well as obese persons, usually Cussler EC, et al Obesity
systematic requiring a BMI of at least 25 kg/m2. (Silver Spring). 2008;16:
reviews - medication trials : participants with BMI of at least Davis BR, et al
27 kg/m2. The mean BMI values in the medication Hypertension.
Included
trials were all in the obese range (32 to 38 kg/m2) ; 1992;19:393-9.
studies:
18 trials examined the effect of 120 mg tid of Frey-Hewitt B, et al Int J
randomized or
orlistat on some measure of weight over at least Obes. 1990;14:327-34.
controlled
12 to 18 months
clinical trials Haapala I, et al .Public
(additionally, Heterogeneity: Health Nutr.
cohort or - Signifikant : See results 2009;12:2382-91.
case-control Publication bias: Irwin ML, et al. JAMA.
studies for KQ 2003;289:323-30.
- Results n.a.
4) that
involved Results (outcome: weight loss): Jeffery RW, et al .J
behavioral- Behavioral treatment : meta-analysis ( 21 weight loss Consult Clin Psychol.
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 220
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
based trials) reporting kilograms or pounds lost at 12 to 18 1993;61:1038-45.
treatment or months estimated an average effect of 3.0 kg more Jones DW, et al. Am J
the use of lost in the intervention than control groups (95% CI, - Hypertens. 1999;12:1175-
orlistat or 4.0 to -2.0; I2=94.9%; k=21; n=7,343); greater weight 80.
metformin for loss in trials with more treatment sessions (generally
Kastarinen MJ, et al. J
weight loss or 4–7 kg lost in the intervention group in trials with 11–
Hypertens. 2002;20:2505-
weight 26 treatment sessions in the first year); Intervention
12.
maintenance groups had an almost 2.5 times greater probability of
in adults in losing 5 percent of their initial weight compared with Kulzer B, et al. Diabetes
settings that control groups (relative risk [RR], 2.39 [95% CI, 1.72 Care. 2009;32:1143-6.
are to 3.31]; n=1,387) Langford HG, et alJAMA.
generalizable Orlistat was additive to behavioral counseling, 1985;253:657-64.
to U.S. resulting in even greater weight loss (generally 6–9 Martin PD, et al. Obesity
primary care. kg total): In terms of overall weight loss, most trials (Silver Spring).
Additional reported a weight loss of 6 to 9 kg among those 2008;16:2462-7.
studies were taking orlistat compared with 3 to 6 kg in those taking
included for Mayer-Davis EJ, et al. Am
placebo; Overweight and obese participants who J Public Health.
the evaluation were randomized to orlistat lost an average of 3 kg
of weight loss 2004;94:1736-42.
more than those randomized to placebo after 12
treatment Mensink M, et al. Obes
months (WMD, -3.0 [95% CI, -3.9 to -2.0]; I2=84.9%;
harms; Only k=12); Overweight and obese participants who were Res. 2003;11:1588-96.
outcomes randomized to orlistat had a 1.6-fold greater chance Mitsui T, et al. Tohoku J
reported at 12 of losing 5 percent of their initial weight than those Exp Med. 2008;215:355-
months or who were randomized to placebo (RR, 1.57 [95% CI, 61.
longer were 1.40 to 1.75]; I2= 76.2%; k=13; n=8,579) Moore H, et al. BMJ.
included 2003;327:1085.
Authors conclusion: Behavioral-based treatments are
Excluded safe and effective for weight loss, although they have Narayan KM, et al. Diabet
trials: not been studied in persons with class III obesity. Med. 1998;15:66-72.
excluded trials Medication may increase weight loss beyond
with control Perri MG, et al. J Consult
behavioral approaches alone, although side effects Clin Psychol.
groups are common.
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 221
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
receiving 1988;56:529-34.
frequent Pritchard DA, et al.J
weigh-ins, Epidemiol Community
advice more Health. 1999.
frequently than
Silva MN, et al. J Behav
annually, or at-
Med. 2010;
home study
materials; Simkin-Silverman LR, et
these studies al.Ann Behav Med.
were 2003;26:212-20.
considered to Stevens VJ, et al. Arch
be Intern Med. 1993;153:849-
comparative 58.
effectiveness Stevens VJ, et al. Ann
studies. Intern Med. 2001;134:1-
Interventions 11.
were restricted
to those Svetkey LP, et al. JAMA.
focusing on 2008;299:1139-48.
weight loss ter Bogt NC, et al. Am J
and those not Prev Med. 2009;37:270-7.
reporting Tuomilehto J, et al. N Engl
weight J Med. 2001;344:1343-50.
outcomes Villareal DT, et alJ Clin
were Endocrinol Metab. 2008;
excluded.
Werkman A, et al. BMC
Public Health.
2010;10:110.
Whelton PK, et al. JAMA.
1998;279:839-46.
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 222
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
Wood PD, et al. N Engl J
Med. 1988;
Wood PD, et al N Engl J
Med. 1991;325:461-6.
Woollard J, et al. J
Cardiovasc Risk.
2003;10:31-40.
Apfelbaum M, et alAm J
Med. 1999;106:179-84.
Berne C; Diabet Med.
2005;22:612-8.
Broom I, et al. Int J Clin
Pract. 2002;56:494-9.
Davidson MH, et al.
JAMA. 1999;281:235-42.
Derosa G, et al Clin Ther.
2003;25:1107-22.
Finer N, et al. Int J Obes
Relat Metab Disord.
2000;24:306-13.
Fontbonne A, et al.
Diabetes Care.
1996;19:920-6.
Gambineri A, et al. J Clin
Endocrinol Metab. 2006;.
Hanefeld M, Diabetes
Obes Metab. 2002;4:415-
23.
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 223
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
Hauner H, Exp Clin
Endocrinol Diabetes.
2004;112:201-7.
Hauptman J, et al. Arch
Fam Med. 2000;9:160-7.
Hill JO, et al. Am J Clin
Nutr. 1999;69:1108-16.
Hollander PA, et al.
Diabetes Care.
1998;21:1288-94.
Kaukua JK, et al. Int J
Obes Relat Metab Disord.
2004
Krempf M, et al. Int J
Obes Relat Metab Disord.
2003
Lindgärde F. J Intern Med.
2000;248:245-54.
Mathus-Vliegen EM; Eur J
Clin Nutr. 2005;59(Suppl
1):S31-8.
McNulty SJ, et al.
Diabetes Care.
2003;26:125-31.
Miles JM, et al. Diabetes
Care. 2002;25:1123-8.
Richelsen B, et al.
Diabetes Care.
2007;30:27-32.
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 224
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
Rössner S et al. Obes
Res. 2000;8:49-61.
Sjöström L, et al. Lancet.
1998;352:167-72.
Swinburn BA, et al.
Diabetes Obes Metab.
2005;7:254-62.
Torgerson JS, et
al.Diabetes Care.
2004;27:155-61.
Wirth A, Krause J. JAMA.
2001;286:1331-9.
Systematic Loveman E, Search in 10 multicomponent Included studies: Dubbert PM, et al Behav 1+ 4 included trials
Review/ et al. (2011) electronic weight 12 RCTs in the clinical effectiveness review Res Ther 1984;22:227– provided
HTA- [77] bibliographic management 42. information on
Study quality:
Bericht databases programmes Wadden TA, et al. J their
MEDLINE; (including diet, - quality of included studies was assessed using randomisation
Consult Clin Psychol
EMBASE; physical activity standard criteria : quality of included studies was sequence, 3
1988;56:925–8.
MEDLINE In- and behaviour assessed using criteria based on those trials described
recommended by the Centre for Reviews and Stevens V, et al. Ann
Process & change strategies) their allocation
Dissemination (CRD) Intern Med 2001;134:1–
Other Non- that assessed concealment,
11.
Indexed weight measures - 7 trials were judged to have a low risk of selection None of the
Citations; The (outcome) bias Burke LE, et al. Int J Obes trials clearly
Cochrane - 2 reviewer 2008;32:166–76. reported blinding
Library Descriptive statistics: Logue E, et al. Obes Res of their
including the participants or
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 225
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
Cochrane - 5 RCTs compared multicomponent interventions 2005;13:917–27. care providers,
Database of with non-active comparator groups Simkin-Silverman LR, et so it is unknown
Systematic - 2 RCTs compared multicomponent interventions al. J Womens Health whether blinding
Reviews, that focused on the diet component 1998;4:255–71. occurred,
Cochrane - 4 RCTs compared multicomponent interventions Blinding of
Stevens VJ, et al. Arch
Central that focused on the physical activity component outcome
Intern Med 1993;153:849–
Register of assessors,
- 1 RCT the intervention focused on the goal-setting 58.
Controlled however, is
interval Jeffery RW, et al. J
Trials, more feasible
Database of - All RCTs that met the inclusion criteria were Consult Clin Psychol but was only
Abstracts of conducted in the USA. 1995;63:793–6. reported in two
Reviews of - Most (83%) of included RCT were published Jeffery RW et al. J Consult trials; Six RCTs
Effects, NHS between 1993 and 2008, with two older RCTs, Clin Psychol were judged to
Economic published in 1984 and 1988 1998;66:777–83. have low risk of
Evaluation - The total number of participants randomised Tate DF, et al. Am J Clinl bias from
Database and ranged from 59 to 1191 while the number of Nutr 2007;85:954–9. dropout (no
HTA participants, per intervention group ranged from 18 dropout
databases; Weinstock RS, et al. Arch imbalance);
to 596 ; Only four of the 12 RCTs had sample
Web of Intern Med publications bias
sizes > 100 participants per intervention group.
1998;158:2477–83.
Science; - In all but one of the 12 RCTs the target population analysis n.a.
PsycINFO; was stated as being overweight ; overweight (pre- Skender ML, et al. J Am
BIOSIS; and obese) in two RCTs, class I obese in five RCTs, Diet Assoc 1996;96:342–6
databases and class II obese in one RCT
listing ongoing - The upper age limit specified for inclusion of
clinical trials participants was 45 years to 69 years ; None of the
from inception trials specifically included elderly populations
to December
- The duration of follow-up (post randomisation)
2009
ranged from 18 to 54 months
Inclusion:
- Weight change from baseline was reported as a
Clinical
primary outcome in 11 RCTs
effectiveness
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 226
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
studies were - In one study the setting of the intervention was
included if reported to be in primary care
participants Heterogeneity:
were adults
- N.a.
with a BMI >
25 kg/m2; if Results (outcome: weight loss)
the - multicomponent interventions versus non-active
interventions comparator groups (5 RCT): weight loss appeared
were well- to be greater in the intervention groups ; One of
described these RCTs (perimenopausal women) provided
multicompone evidence that longer term (up to 42 months) weight
nt (diet, change in these intervention group was
exercise and significantly different from that of the control group,
behaviour although much of the weight lost had been
therapy) regained ; One trial with a 24 month duration found
weight no statistically significant differences ; two trials
management showed statistically significant difference in weight
approaches loss (using similar weight loss interventions) at 18
with a weight months or 36 months
loss outcome; - multicomponent interventions that focused on the
and if the diet component (2 RCT ; One of these studies
studies were also had a third arm to investigate the dietary
RCTs with at component VLCD alone): no statistically significant
least 18 differences in weight loss between interventions ;
months’ After completing the intervention participants from
follow-up both studies regained weight over time
- multicomponent interventions that focused on the
physical activity component (4 RCT): little
consistency in the pattern of results
- intervention focused on the goal-setting interval (1
RCT) : weight loss was greatest in those given
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 227
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
daily goals compared with weekly goals
Overall, where measured, it appeared that most
groups began to regain weight at further follow-up.
Authors conclusion: Long-term multicomponent
weight management interventions were generally
shown to promote weight loss in overweight or obese
adults. Weight changes were small however and
weight regain was common. There were few
similarities between the included studies;
consequently an overall interpretation of the results
was difficult to make.
Cochrane Colquitt JL, Search in The different surgical Included studies: Agren 1989; 1+-2+ Studies with
Review et al. (2009) Cochrane procedures 23 of the 26 included studies were RCTs. One study Nilsell 2001; different desing
[78] Library (Issue Primary outcomes (SOS 1997-2007)was a prospective multicentre were included;
Olbers 2005;
3/2008); cohort study with matched concurrent controls. Two different quality
- measures of SOS 1997-2007;
MEDLINE studies had prospective cohort designs (Buddeberg of included
weight change,
(until 2006; Stoeckli 2004).Two of the eligible studies were Sundbom 2004; studies
fat content (for
29/7/2008); reported as abstracts only (Agren 1989; VanWoert Westling 2001
example body
EMBASE (until 1992)
mass index) or Bessler 2007;
29/7/2008);
fat distribution Study quality: Howard 1995;
PsychINFO
(for example - see methodological quality summary
(until Nguyen 2006;
waist-hip ratio);
29/7/2008); - Allocation: Nine of 23 RCTs described adequate Sugerman 1987;
CINAHL (until - quality of life, allocation sequence generation
16/7/2008); ideally VanWoert 1992
- Blinding: Only oneRCTreported that outcome
Science and measured using assessorswere blinded to the intervention Angrisani 2007;
Social a validated
assignment Mingrone 2002;
Sciences instrument;
- Incomplete outcome data for weight loss were Morino 2003.
Citation Index - obesity related
adequately addressed by 14 RCTs Buddeberg 2006;
(until co-morbidities
- Selective reporting : The most of studies were
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 228
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
29/7/2008); (for example judged to be of uncertain risk of bias. Stoeckli 2004,
British Nursing diabetes, Descriptive statistics: deWit 1999;
Index (until hypertension).
- Participants: Most studies included participants van Dielen 2005
6/8/2008). Secondary with morbid obesity (BMI greater than 40 was Dixon 2008;
Databases of outcomes commonly used, often with the additional criteria of
grey literature: O’Brien 2006
- mortality BMI greater than 35 or 37 with comorbid disease),
Web of (perioperative Excluding the three studies with notably different Himpens 2006
Science and total); inclusion criteria, mean baseline BMI ranged from MacLean 1995
Proceedings to 52
- adverse effects DavilaCervantes 2002
(until (for example - The individual study sample size ranged from 20 to
29/7/2008); Lujan 2004
perioperative 4047
BIOSIS (until morbidity such Lee 2004
5/8/2008); - The majority of participants in the studies were
as staple line female and mean age ranged from 32 years to 49 Karamanakos 2008
AMED (until
breakdown and years
5/8/2008). wound infection, - Intervention : The included studies compared a
Ongoing trials gastrointestinal variety of interventions (Three RCTs and three
National disturbances, cohort studies (one cohort study had three arms)
Research reoperations); compared surgery with non-surgical interventions.
Register (until - revision rates The remaining 20 RCTs compared different
30/7/2008); (reversal or surgical procedures, including various types of
UKCRN (until conversions to gastric bypass, vertical banded gastroplasty,
30/7/2008); normal or other adjustable gastric banding and isolated sleeve
Clinical procedures). gastrectomy, performed with open or laparoscopic
Trials.gov
surgery
(until
30/7/2008); - The minimum duration of follow-up for inclusion in
Controlled this review was 12 months, and most studies
Clinical Trials followed participants for 12, 24 or 36 months.
(until - Country: Six studies were conducted in Sweden,
30/7/2008); and five studieswere conducted in the USA, Three
Australia NZ studies were conducted in Italy, Two studies were
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 229
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
Clinical Trial conducted in each of Switzerland, The
Register (until Netherlands, and Australia, One study was
30/7/2008). conducted in Belgium, Mexico, Spain, Taiwan,
Included: Greece
Randomised Heterogeneity:
controlled - N.a.
trials (RCTs)
Results
comparing
different - greater weight loss than conventional treatment in
surgical moderate (body mass index greater than 30) as
procedures, well as severe obesity.
and RCTs, - Reductions in comorbidities, such as diabetes and
controlled hypertension, also occur. Improvements in health-
clinical trials related quality of life occurred after two years, but
and effects at ten years are less clear.
prospective; - Surgery is associated with complications, such as
cohort studies pulmonary embolism, and some postoperative
comparing deaths occurred.
surgery with - Five different bariatric procedures were assessed,
non-surgical but some comparisons were assessed by just one
management trial.
for obesity;
- The limited evidence suggests that weight loss
exclusion
following gastric bypass is greater than vertical
criteria were
banded gastroplasty or adjustable gastric banding,
reported
but similar to isolated Surgery for obesity
Systematic Picot J, et al. 17 electronic Intervention: Open Included studies: For clinical effectiveness: 1+-2+ Publication bias
Review/ (2009) databases and laparoscopic 26 studies reported in 52 publications were included : Dixon et al., 2008, RCT; analysis n.a.; it
HTA- [79] were searched bariatric surgical 23 RCTs, 1 study (SOS) was a prospective was not
O’Brien et al., 2006, RCT;
Bericht [MED-LINE; procedures in multicentre cohort study with matched concurrent considered
EMBASE; widespread Stoeckli et al., 2004, appropriate to
control ; 2 studies had prospective cohort designs
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 230
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
PreMedline In- current use. and 2 studies were reported as abstracts only Cohort study combine the
Process & Comparators: Sur- Study quality: Mingrone et al., 2002, included RCTs
Other Non- gical procedures in RCT in a meta-
- clinical effectiveness: the quality of included cohort
Indexed current use in analysis
studies was assessed using criteria recommended SOS 1997 to 2007, Cohort
Citations; The comparison with because of the
by NHS Centre for Reviews and Dissemination study;
Cochrane one another; open heterogeneity in
(CRD) ; RCTs were assessed using the Cochrane Buddeberg-Fischer et al.,
Library surgery compared the patient
criteria for judging risk of bias 2006, Cohort study
including the with laparoscopic groups, com-
Cochrane Sys- - Quality criteria were applied independently by 2 Howard et al., 1995; parator
surgery for the
tematic reviewers treatments and
same procedure; VanWoert et al., 1992;
Reviews surgical Descriptive statistics: outcomes
Database, MacLean et al., 1995;
procedures in - 3 RCTs and 3 cohort studies compared surgery
Cochrane current use with non-surgical interventions; 20 RCTs Sugerman et al., 1987;
Con-trolled compared with compared different surgical procedures ; 2 studies Lee et al., 2004;
Trials non-surgical inter- focused on patients with a lower BMI (< 35 or < Olbers et al., 2005;
Register, ventions (medical 40)
DARE, NHS Agren and Naslund, 1989
manage-ment, - The risk of bias of most of the trials was uncertain,
EED and HTA usual care or no Bessler et al., 2007
only 9 of the RCTs reported adequate sequence
data-bases; treatment); generation and only 5 reported adequate allocation Angrisani et al., 2007
Web of concealment Karamanakos et al., 2008
Main outcomes At
Knowledge
least one of the Heterogeneity: Nilsell et al., 2001;
Sci-ence
following reported - N.a. Morino et al., 2003;
Citation Index
following a
(SCI); Web of Publication bias: van Dielen et al., 2005
minimum of 12
Knowledge ISI
months - N.a. Himpens et al., 2006
Proceedings;
PsycInfo; CRD follow-up: Results Puzziferri et al., 2006;
databases; measures of - Surgery versus non-surgical interventions : Lujan et al., 2004;
BIO-SIS; and weight change; bariatric surgery is a more effective intervention for Westling and Gustavsson,
data-bases quality of life weight loss than non-surgical options ; surgery led 2001;
listing ongoing (QoL); peri- to a greater reduction in weight in all 6 studies, the
operative and Sundbom and
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 231
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
clinical trials]; post-operative difference was statistically significant in 5 studies Gustavsson, 2004
Search date: mortality and mor- reporting a statistical comparison ; in 2 RCTs that Davila-Cervantes et al.,
from incep-tion bidity; change in reported outcomes at two years, mean initial 2002
to August obesityrelated weight loss in the surgical groups was 20% and
de Wit et al., 1999
2008 comorbidities; 21.6%, whereas the non-surgical groups had lost
Inclusion cost-effectiveness 1.4% and 5.5% of their initial weight ; In the 2
criteria were [reporting cohort studies reporting outcomes at 2 years, per
reported (see outcomes as cent weight change ranged from a weight loss of
intervention, either life-years or 16% to 28.6% in the surgical groups, but the non-
comparator, quality-adjusted surgical groups had gained weight with per cent
outcomes, life-years weight change ranging from 0.1 to 0.5% ; 1 RCT
Popu-lation: (QALYs)]. and 1 of 2 cohort studies assessing QoL found
Adult patients greater, and statistically significant, improvements
with (BMI) of after surgery on some measures, but not others ; 2
30 or over and RCTs found that significantly fewer people had
young people metabolic syndrome in the surgical group, and 1
who fulfil the found significantly higher remission of Type 2
definition of diabetes following surgery..
obesity for - Comparison of surgical procedures : gastric
their age, sex bypass (GBP) is more effective for weight loss
and height; than vertical banded gastroplasty (VBG) and
study types: adjustable gastric banding (AGB) ; 5 of the 7
Systematic included RCTs reported greater weight loss
review of following GBP than VBG excess weight loss at one
clinical year ranging between 62.9% and 78.3% for GBP,
effectiveness: and ranging between 43% and 62.9% for VBG ; in
Surgery 2 studies there was no statistically significant
versus surgery difference in ‘success rate’ or ‘per cent ideal body
– RCTs; weight’
surgery versus Adverse events: varied between studies; few were
non-surgical compared statistically and none were powered to do
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 232
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
procedure – so ; 14 RCTs reported no deaths ; the large SOS
RCTs, study reported mortality of 0.25% in the surgical
controlled cohort ; adverse events from conventional therapy
clinical trials included intolerance to medication, acute
and cholecystitis and gastrointestinal problems ; Major
prospective adverse events following surgery, some necessitating
cohort studies reoperation, included anastomosis leakage,
(with a control pneumonia, pulmonary embolism, band slippage and
cohort)) band erosion
Systematic Kodama S, Search in Web based Included studies: Wing RR, et al. N EngI J 1+ High
Review/ et al. (2012) Electronic controlling dietary Med 2006 heterogeneity;
23 RCTs were included
Meta- [80] Iiterature intake and Reviewer n.a
Study quality: Patrick K, et al. J Med
analysis searches increasing
Internet Res 2009
(MEDLINE physical activity - 17 studies used an intention-to-treat analysis
(Milestone van Wier MF, et al. BMC
(between 1980 Outcome: weight - 12 studies : Mean dropout rate was 17,8 %
paper) Public Health 2009
and 2011 April loss - Methods of randomization were described in only 7
2) and studies Wylie-Rosett et al. J Am
EMBASE Diet Assoc 2001
Descriptive statistics:
(between 1980 Harvey-Berino J, et al. Int
and 2011 April - Intervention periods ranged from 3-30 months; 11 J Obes Relat Metab
2)) studies had intervention periods of 12 months or Disord 2002
more.
Search terms Harvey-Berino J, et al.
were reported - 16 studies were conducted in the USA
Obes Res 2004
- In 11 studies participants were at least 80 %
Inclusion Womble LG, et al. Obes
women
criteria: (1) Res 2004
RCTs; (2) all - mean age was 46 ( ± 6) years
Rothert K, et al. Obesity
participants - - mean BMI was 32 ( ± 3) kg/m2
2006
adults and - Intervention : 1 study used as a substitute face-to-
overweight or Mobley AR. Department of
face counseling
obese (3) they Nutrition & Food Science,
Heterogeneity: University of Maryland:
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 233
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
consisted of a - large and highly significant between-study Maryland, 2006
Web-user heterogeneity was observed in the effect size (I2 Actachi Y, et al. Behav
experimental 84.4%; P<0.001) Res Ther 2007
group and - Sensiticity analysis available. Polzien KM, et al. Obesity
non-Web user
Publication bias: 2007
control group;
(4) - Publication bias was not statistically detected McConnon A, et al. BMC
intervention (P=0.62 for Begg's test and P=0.79 for Egger's Health Serv Res 2007
included test) Svetkey LP', et al. JAMA
Controlling Results 2008
dietary intake Using the Internet had a modest but significant Cussler EC, et al. Obesity
and increasing additional weight-loss effect when compared with 2008
physical results in non-Web-user control groups (-0.68 kg, P =
activity; (5) the Hunter CM et al. Am J
0.03) Prev Med 2008
aim of using
the Internet Digenio AG, et al. Ann
was initial Intern Med 2009
weight loss or Morgan PJ, et al. 2009
weight Ueki K, et al. Clin Exp
maintenance; Hypertens 2009
and (6) effect
on absolute Yoo HJ, et al. Diabet Med
body-weight 2009
change. Bennett GG, et al. Obesity
2010
Harvey-Berino J, et al.
Prev Med 2010
Tanaka M, et al. Intl
Behav Med 2010
Christian JG et al J Am
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 234
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
Diet Assoc 2011
Systematic Neve M, et Search in web-based Included studies: Carr L.J, et al. 2008 1+ Mittle-low quality
Review/ al. (2010) MEDLINE and interventions; 18 RCTs were included Cussler EC, et al. 2008; of included
Meta- [81] ClNAHL for outcome body studies
Study quality: Gold IK, et al. 2007;
analysis keywords; weight
second search - 2 reviewer MrConnoti A, et al. 2007
(Milestone
paper) in Cochrane - Study quality was assessed using a standardized Mirco N, et al. 2007;
Library, critical apparisal instrument from the JBI Meta- Rotherr K, et al. 2006;
MEDLINE, Analysis of Statictics Assessment and Review
EMBASE, Instument Tate DF et al. 2003
CINAHL, Web - No high quality studies ; 3 studies meet 8 of 10 Tare DF 2001
of Sciense, criteria Wehber KH et al. 2007,
Scopus, - 14 studies did not speciity method of Womble LG et al. 2004:
Australian randomization
Digital Theses Harvey-Berino J. et al.
- 14 studies – ITT analysis 2002
Program and
Dissertations/ Descriptive statistics: Harvey-Berino J. et al.
Abstracts - Total number of particioants was 5700 2004
English - 77 % were female Harvey-Berino J. et al.
Language - 13 studies had a primary aim of achieving weight 2002 (Behav Modif)
from 1995 loss an 5 focused an maintenance of weight loss Prolzien KM, et al. 2007;
onwards - Duration : 6 week to 2 years (8 interventions were Svetkey LP, et al. 2008;
Inclusion 12 months in duration) Tate DF, et al. 2006;
criteria: RCTs, - Intervention : 3 studies : web-based programme
with at least Mobley AR et al. 2006
compared with a control or minimal intervention
one web- group ; 5 studies : generic web-based programme
based compared with enhanced web-based programme ;
intervention 5 studies : web-based programme compared with
study arm defferent types of face-to-face interventions ; 2
whose primary studies motivational interviewing within a web-
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 235
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
aim was based programme
achieving Heterogeneity:
weight loss or
- See results
weight loss
maintenance Results
or achieving Interventions aiming to achieve weight loss:
positive - 12 studies reported total weight loss change, 6
dietary and studies reported percentage weight change (3
physical were successful in achieving 5% or greater weight
activity; adults change)
and
- 3 studies were combined in meta-analysis : n.s.
overweight or
heterogeneity (I2=20,9 %, p=0,28) ; greater
obese
decrease in weight in the web-based programmes
with enhanted features (WMD 2.24, CI [1.27, 3.21]
, p<0,0001)
- Author conclusion : Meta-analysis suggest that
web-based imervenrions achieve similar weight
loss to control or minimal intervention groups, and
web-based inrerventions with enhanced features
achieve greater weight loss than those with
educarion alone
Interventions aiming to achieve weight loss:
- On 1 study reponted percentage weight loss-
greater than 5 % weight change
- Web-based interventions compared with no
intervention or minimal intervention (2 studies) :
n.s. heterogeneity (I2=0%), significant difference in
the change in weight (WMD -0,30 CI[-0,34 ; -0,26],
p<0,00001)
- Compared with face-to-face interventions (2
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 236
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
studies) : significant heterogeneity (I2=77,5%,
p=0,007), difference in the change of weight non-
significant (WMD 1,8, CI [-1,18 ; 4,79] ; p=0,24)
- Author conclusion: similar levels of weight loss
maintenance to face-to-face interventions and less
weight is regained in comparison to no intervention
Systematic Shimizu H, Pubmed was any form of Included studies: W. J. Lee, et al., “Obesity 2+ Publication bias
Review et al. (2012) searched from bariatric/metabolic 2 retrospektive and 16 prospektive studies 2011. analysis n.a.,
(Milestone [82] January 1, surgery
Descriptive statistics: C. Boza, et al., “ Obesity observational
paper) 1980, to Outcomes: Surgery, 2011. studies were
- 17 (94%) were performed outside of the United included
November 1, Diabetes-related V. C. de Sa, et al. Obesity
States, in Brazil (7, 39%), Italy (4, 22%), Taiwan
2011, for clinical outcomes: Surgery, 2011.
(4, 22%), Chile (1, 6%), and India (1, 6%)
citations using fasting plasma
- 13 studies (72%) have been published in the last 3 C. K. Huang, et al. Obesity
the following glucose (FPG),
years from 2009 to 2011 Surgery, 2011.
keywords: glycated
“metabolic hemoglobin - Surgical procedures included Roux-en-Y gastric N. Scopinaro, et al.,
surgery”, (HbA1c), and bypass (RYGB) in 6 (33%) studies, duodenal- “Annals of Surgery, 2011.
“bariatric postoperative jejunal bypass (DJB) in 4 (22%), biliopancreatic S. S. Shah, et al. Surgery
surgery”, clinical status diversion (BPD) in 3 (17%), minigastric bypass for Obesity and Related
“diabetes (MGB) in 2 (11%), ileal interposition with sleeve or Diseases, 2010.
surgery”, diverted sleeve gastrectomy (II-SG or II-DSG) in 2 W. J. Lee, et al., Surgery,
“T2DM”, “type (11%), sleeve gastrectomy (SG) in 1 (6%), and
2010.
2 diabetes”, stomach and pylorus-preserving BPD (BPD-SPP)
in 1 (6%) A. L. Depaula, et al.
“obesity”,
Surgical Endoscopy and
“BMI < 35 - Patients : in total total 477 patients ; 16 studies
Other Interventional
kg/m2”, “mild reported the patient gender, and 53% of the total
Techniques,
to moderate study population was female ; mean age ranged
obesity”, and from 34 to 56 (mean 47) ; 2009.
“low-BMI”. - Follow-up period ranged from 6 months to 18 A. L. DePaula, et al.
additionally years, (weighted mean was 22 months) ; 2 studies Surgical Endoscopy and
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 237
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
manual reported the results of a longer than 5-year Other Interventional
reference followup ; Techniques, 2009.
checks were - duration of diabetes prior to surgery ranged from 6 A. C. Ramos, et al.,
performed in months to 28 years (weighted mean 8.2 years) ; Obesity Surgery, 2009.
the identified 30.1%patients using insulin G. S. Ferzli, et al. World
studies. Heterogeneity: Journal of Surgery, 2009.
Inclusion: - n.a. B. Geloneze, et al.
studies
Publication bias: Obesity Surgery, 2009.
published
containing - N.a. C. Chiellini, et al.
data on weight Results Diabetologia, 2009.
loss and W. J. Lee, et al. Journal of
- BMI decreased from 30.4 (95% CI 28.4–32.3) to
T2DM-related Gastrointestinal Surgery,
24.8 (95% CI 24.1–25.5) kg/m2 ; only two studies
outcomes of 2008.
reporting that one of the total 15 patients was in
patients N. Scopinaro, et al.
the mildly undernourished range (BMI 17–18.5
treated with Obesity Surgery, 2007.
kg/m2) after RYGB without any evidence of
any form of
malnutrition and 12 patients (17.4%) after II-DSG R. V. Cohen, et al.
bariatric/metab
were underweight (BMI < 20 kg/m2) without Surgery for Obesity and
olic surgery
lowering serumalbumin value ; overall, the risk of Related Diseases, 2007.
where the
excessive weight loss after metabolic surgery was R. Cohen, et al. Surgery
mean study
2.7% (13 patients) for Obesity and Related
BMI <35
kg/m2.; - T2DM Outcomes : FPG - (12 studies) decreased Diseases, 2006.
language from 203.5 (95% CI 187.4–219.6) to 112.5 (95%
G. Noya, et al., Obesity
English CI 103.9–121.1) mg/dL ; HbA1c (10 studies)
Surgery, 1998
decreased from 9.0 (95% CI 8.6–9.5) to 6.3 (95%
Excluded: BMI CI 6.1–6.6) %. ; diabetes : 86.8% of the patients
≥35 kg/m2, stopped taking antidiabetic medication after
not T2DM surgery ; remission of T2DM : When it is defined
patients, as FPG < 126 mg/dL and/or HbA1c < 6.5% without
diabetic the use of antidiabetic medication at the time of
participants
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 238
Studien- Autoren, Einschluss- Welche Charakteristik eingeschlossener Studien / Literaturbelege Evidenz- Meth.
typ Jahr kriterien/ Behandlungen Befunde in Bezug auf Therapiewirkungen niveau Bemerkungen
Angaben zu wurden geprüft (SIGN)
systemati-
scher
Recherche
had gastric evaluation, 64.7% of the patients met the criteria ;
surgery with Remission of T2DM was achieved in 66.0% of the
anatomical patients with a short history (≤8 years) of T2DM
similarities to and 52.9% of those with a long history (>8 years)
RYGB of T2DM (P = 0.03)
because of - Complications and Mortality : complication rate
gastric cancer was 10.3% (range 4.5–33.3%) in 16 studies ; types
and ulcer, or of complication varied and were dependent on
they did not follow-up period and surgical procedures ;
report mortality rate was 0%in 17 studies
diabetes-
related
outcomes
such as
fasting plasma
glucose
(FPG),
glycated
hemoglobin
(HbA1c), and
postoperative
clinical status
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 239
c) Einzelstudien
Artikel Anzahl der Intervention/ Vergleichs- Outcomes Ergebnisse Evidenz- Bemerkungen
(Autor, Patienten/ ggf. intervention niveau
Jahr)/ Patienten- Nachverfolgung (z.B. SIGN)
Studien- merkmale
typ
Davis LM, 90 obese adults MD=Medifast FB=isocaloric Weight loss Greater initial weight loss (16 week): 1- Duration < 1 year
et al. (BMI 30-50 replacement diet food-based plan Others : Biomarker of MD 12,3% vs. FB 6,7% Small group
(2010) kg/m2), aged 18- (providing 800- (providing ~1000 inflammation and BMI decrease of 12,3% for MD and Overall drop-out rate
[83] 65, no allergies 1000 kcal/day) kcal/day) oxidative stress (CRP, 6,7% for FB (week 16) of 43,2% for MD
against soy, 16 week=weight ULP, Cholesterol, BMI remained reduced by 7,8% in MD Impossible to blind
RCT wheat, gluten and loss + 24 week Triglycerides) vs. 5,9% in FB (week 40) subjects to
nuts, before <= 14 weight
alcoholic Statistically similar weight loss after 40 intervention
maintenance
beverages per week
week and no Mean net loss of 8,9 +/- 8,9 kg in MD
alcohol intake and 5,7 +/- 8,6 kg in FB (week 40)
during the study, Significant improvements in body
not currently using composition in MD vs. FB (week 16 &
appetite-affecting week 40)
meds, not
pregnant, not Improvements in biochemical outcomes
and other clinical indicators (week 40)
lactating, normal
EKG and lab work CRP: significant interaction between
baseline CRP levels, intervention group
and time; MD group with high baseline
CRP levels significant decreases over
40 weeks
ULP: significant difference between
groups (MD 17,5% vs. FB 5,4%) (week
40); significant interaction between
intervention group & time; significant
mean decrease over time in MD over 40
weeks.
Cholesterol: VLDL significantly
decreased in both groups (MD -8,8%
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 240
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 241
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 242
Frisch S, 200 overweight Low fat diet (DGE), Low carbohydrate Weight loss and loss of Intention to treat analysis 1- Energy intake
et al. subjects, aged 18- weekly nutrition diet (LOGI), fat mass decreased by only 400
(2009) 70 y, BMI > 27 education program, weekly nutrition Others (waist kcal/day within the first
Energy intake decreased by only 400
[88] kg/m² counselling by education circumference, blood 6 month and
kcal/day within the first 6 month and
Exclusion: telephone program, pressure, lipids, increased within the
increased within the second 6 month,
RCT cardiovascular >55% from counselling by parameters of glucose second 6 month
but below baseline value
symptomatology, carbohydrates, telephone, metabolism)
Mean macronutrient composition
ischemia, <30% from fat, <40% energy
differed significantly between both
cholelithiasis, 15% from protein from
groups between month 1 and month 12
urolithiasis, insulin 52 weeks carbohydrates,
dependent >35% from fat, Both diet resulted in similar weight loss
Results: 6 and 12 (p=0.065)
diabetes mellitus, 25% from protein
months after begin
pacemaker In both groups ~76% of weight
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 243
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 244
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 245
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 246
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 247
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 248
Kreider 90 sedentary, Meal-replacement- Meal-plan-based Weight loss (weight, fat Significantly higher moderate and 1- Small study group
RB, et al. apparently healthy based diet (MRP) diet + supervised mass, centimetres from vigorous physical activity levels in SDE <3 months horizon, for
(2011) obese women, exercise program hips and waist) group with no differences between subgroup (n=77) >3
[93] aged 18-55y, BMI (SED) Body composition, groups in daily energy intake months
Duration: 10 weeks
27-40 kg/m² REE, and fitness SDE group lost more weight (P = 0,03),
(+24 weeks weight
RCT Fasting blood lipid, fat mass (P = 0,02),centimetres from
maintenance
Exclusion: recent glucose, and insulin hips (P = 0,002) and waist (P = 0,005)
phase, n= 77)
story of weight and had greater increase in peak
Nutrition intake and
change (+/- 3,2kg) aerobic capacity (P = 0,001) vs. MRP
physical activity
within 3 months, group
metabolic or REE levels significantly decreased in
cardiovascular both groups (P = 0,001)
disorder, including Energy and fat intake decreased
known electrolyte significantly over time with no significant
abnormalities, differences observed between groups;
heart disease, protein intake was significantly higher in
arrhythmias, SDE group
diabetes, thyroid
HDL-C levels were significantly higher
disease,
in SDE group
hypogonadism, or
history of Significant time effects were seen in
hypertension, physical function (P = 0,02), vitality (P =
hepatorenal, 0,01) and mental health (P = 0,001)
musculoskeletal, with no differences between groups
autoimmune or
neurologic Maintenance phase: (n=77)
disease,
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 249
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 250
Te 83 overweight or Moderately high High fiber, Weight loss Participants on HP lost more body 1- Drop out rate 11 %
Morenga obese women, protein diet (HP) relatively high Total body fat mass, weight (p = 0,039) and total body fat (p Analysis of 74
LA, et al. aged 18-65y, BMI Energy: 30% carbohydrate diet lean mass, body fat = 0,029) individuals = small
(2011) >= 27 kg/m² protein, 40% (HiFib) percentage, truncal fat Diastolic blood pressure decreased study group
[94] carbohydrate, 30% Energy: 50% mass, waist more on HP (p = 0,005) Short duration
Exclusion: heart fat carbohydrate, circumference, resting Change in weight was statistically CI
RCT disease, cancer or >35g total dietary blood pressure, fasting significant predictor for the reduction in
fibre, 20% protein, insulin, glucose, Flow chart
kidney disease Duration: 8weeks SBP (p= 0,026)
diagnosed; taking 10% fat triglycerides, AE n.a.
Significantly greater energy reduction
medication cholesterol, metabolic Partially-blinded
on HFiB than on HP
influencing syndrome
Sample size (n=35)
appetite and determined by power
weight control; analysis (power =
participated in a 90%)
weight loss
Computer-generated
programm or had
lost more than 1kg randomization
bodyweight in (schemea n.a.)
previous 2mo; Per-protocol analysis
pregnancy, Comparability of diets
planning a concerning energy
pregnancy or intake not clear
breastfeeding (p=0,047)
Kerksick 141 sedentary, Diet + exercise No diet + no Weight loss diet+exercise groups reported 1- Wide question
CM, et al. obese women groups: exercise group Body composition significant greater anthropometric (waist Small groups (in total
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 251
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 252
Duration: 14 weeks
(Phase I 1week,
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 253
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 254
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 255
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 256
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 257
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 258
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 259
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 260
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 261
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 262
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 263
Vazquez 62 Caucasian Intervention group Control group Maintenance of weight Weight maintenance or further weight 1+ Not blinded
C, et al. adults, 18-75y, Phase 1+2: diet loss or further weight loss occurred in 83,9% of patients in the Small study
(2009) male and female, 400-500kcal/d loss intervention group, only 58,1% in population; but power
Phase 1:diet
[106] >=5% weight loss Energy: 55% Changes in body control group (P=0,025). analysis: 31 patients
Phase 2:
during induction carbohydrates, composition, blood Intervention group lost significantly per group for β=0,2
low-calorie diet
RCT phase 30% fat , 15% pressure and more of initial weight compared to and α=0,05.
formular instead of
dinner proteins biochemical variables control group (P=0,030). Flow chart
Exclusion: related to glucose and Waist circumference diminished Patients’
pharmacological lipid metabolism (P<0,001) and HDL concentration
Phase 1+2: 400- characteristics not
therapy for weight increased (P=0,001) with time very detailed
500kcal/d
loss, renal, (significant within-subject effects) in the
Energy: 55% ITT
hepatic, pulmonary studied patients.
carbohydrates, CI n.a.
or cardiovascular
30% fat , 15%
disease, major AE reported
proteins
depression, Sufficient duration
pregnancy or
lactation Duration: phase 1
6mo; phase 2
(weight
maintenance) 6mo
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 264
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 265
RCT
Befort 34 rural women, Group phone Individual phone Weight loss Completers analysis showed that 1- Randomisation
CA, et al. age 22–65 y, counselling counselling Dietary, physical weight loss was greater in the group described
(2010) residence in a rural Diet: 1200- Diet: 1200- activity, and condition compared to the individual Small study
[110]
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 266
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 267
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 268
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 269
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 270
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 271
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 272
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 273
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 274
Morgan 65 overweight / SHED-IT (Self- Control group: Change in body weight ITT-analysis using linear mixed models 1+ Assessor blinded
PJ, et al. obese male Help, Exercise and one information (kg & %change) revealed significant and sustained ITT
(2011) participants, BMI Diet using session BMI, waist weight loss of −5.3 kg (95%CI: −7.5,
CI
[119] 25-37kg/m², aged Information circumference, blood −3.0) at 12 months for the Internet
18-60y Technology) group and −3.1 kg (95% CI: −5.4, −0.7) Power analysis: 80%
pressure
Internet group: one for the control group with no group power for sample size
RCT
face-to-face difference. of 18 participants for
Exclusion:
information session A significant time effect was found for each group was
history of major
(75 min) plus 3 all outcomes (P < 0.001). needed to detect a 3
medical problems
months of online kg difference
such as heart Per-protocol analysis revealed a
support significant group-by-time interaction for among groups
disease in the past
5 years, diabetes, weight, waist circumference, BMI, and AEs n.a.
orthopaedic, or Duration: 12 mo systolic blood pressure. Flow chart
joint problems that Internet group compliers (who self-
would be a barrier monitored as instructed) maintained
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 275
Rock CL, 442 overweight or The program, Usual care control Weight loss and weight For Weight loss and weight loss 1+ Randomized, not
et al. obese women which involves in- group Participants loss maintenance maintenance: blinded
(2010) BMI 25-40 kg/m2 person center- assigned to usual Others At 24 months: analysis for 407 women Allocation
[120] age 18-69 years based or telephone care received 2 (Cardiopulmonary (92.1% of the study sample) concealment was
(mean age, 44 based on weekly individualized Fitness and reported
In the intent-to-treat analysis using
RCT years), from USA; one-to-one weight weight loss Psychosocial and baseline value substitution: ITT
loss counselling counseling Laboratory Measures)
No differences At 24 months: mean weight loss: CI
with follow up e- sessions (at
in baseline mail contacts and baseline and For center-based group: 7.4 kg (95% Flow chart
characteristics web site or again at a 6 CI, 6.1-8.7 kg) or 7.9% (95% CI, 6.5%- Power analysis (83%
across the study message board months) with a 9.3%) of initial weight power
groups were availability. Freeof- dietetics For telephone-based group: 6.2 kg to detect an
observed. professional and
charge counseling (95% CI, 4.9-7.6 kg) or 6.8% (95% CI, intervention effect)
Eligibility criteria sessions were monthly contacts 5.2%-8.4%)
included age 18 offered via e-mail or
telephone. For usual care control: 2.0 kg (95% CI,
years or older; BMI
to participants for 0.6-3.3 kg) or 2.1% (95% CI, 0.7%-
of 25 to 40 and a Energy intake
the entire 2-year 3.5%) (P<0,001 for intervention effect)
minimum of 15 kg level
over ideal weight; period.
to achieve a
not pregnant or Duration: over a 2- At 12 months: mean weight loss:
weight loss of
breastfeeding or year period. For center-based group: 10.1 kg (95%
10% over a
planning to Behavioral goals CI, 9.0-11.2 kg) or 10.9% (95% CI,
become pregnant were an energy- 6-month period
was prescribed, 9.7%-12.1%) of initial weight
in the next 2 years; reduced,
willing to nutritionally aiming For telephone-based group: 8.5 kg
(95% CI, 7.2-9.7 kg) or 9.2% (95% CI,
participate in any adequate diet, for a deficit of 500
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 276
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 277
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 278
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 279
Duration: 24
months
Ryan DH, Setting: 8 cities in intensive medical usual care Primary outcome: year- After 2 years: 1+ Randomization and
et al. Louisiana (family intervention (IMI) condition (UCC) 2 percentage change 5% or more weight loss : data acquisition using
(2010) or internal (recommendations: (instruction in an from baseline weight an Internet-based data
31% in the IMI group vs. 9% in the UCC
[124] medicine; 4 appr. 900-kcal Internet capture system
group.
dietitians) liquid diet for 12 ITT
weight 20% or more weight loss:
RCT Participants: 465 weeks or less management Blinding n.a.
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 280
Duration: 24
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 281
Jolly K, et Setting: Primary 6 Weight loss 12 vouchers The primary outcome Weight loss at programme end: 1+ Age differences
al. (2011) care trust in programmes of 12 enabling free was weight loss at all programmes achieved significant between interventions
[125] Birmingham, weeks’ duration: entrance to a programme end (12 weight loss from baseline to programme and control groups
England Three weight loss local leisure weeks). Secondary end (range 1.4 kg (general practice) to Blinding n.a.
RCT Participants: 740 programmes were (fitness) centre outcomes were weight 4.4 kg (Weight Watchers)) ITT
(Lighten obese or provided by (=exersice only). loss at one year, self
In the between group analyses, only the
Up, 8 overweight men commercial reported physical
commercial providers (Weight Watchers
arm) and women with a operators:Weight activity, and percentage
(adjusted MD −2.34 (−3.56 to −1.13)
comorbid disorder Watchers; weight loss at
and Rosemary Conley (adjusted MD
identified from Slimming World; programme end and
−2.39 (−3.61 to −1.16) had a
general practice Rosemary Conley; one year.
statistically significantly (p<0.001)
records Three were greater weight loss and percentage
provided by the weight loss than the exercise only
NHS: a group comparator
weight loss
the proportion of participants in each
programme (Size
arm who achieved at least 5% weight
Down) and two
loss at programme end ranged from
primary care
16% to 46% (between general practice
programmes—
and Weight Watchers)
nurse led one to
one support in Weight loss at one year:
general practice all programmes except general practice
and one to one and pharmacy provision resulted in
support by a significant weight loss at one year
pharmacist only the Weight Watchers group had
7. study arm significantly greater weight loss than did
allowed for the comparator group (adjusted MD 2.5
participants to (95% CI 0.83 to 4.15) kg greater loss,
choose one of the p=0.024).
six interventions the commercial programmes achieved
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 282
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 283
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 284
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 285
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 286
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 287
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
12 Anhänge | 288
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
13 Literatur | 289
13. Literatur
1. Scottish Intercollegiate Guidelines Network (SIGN). SIGN Guidelines. An introduction
to SIGN methodology for the development of evidence-based clinical guidelines.
Edinburgh: SIGN; 1999 (SIGN Publications; 39).
5. Institute for Clinical Systems Improvement (ICSI). Health Care Guideline: Prevention
and Management of Obesity for Adults. Bloomington: ICSI; 2011.
7. National Institute for Health and Clinical Excellence (NICE). Obesity: the prevention,
identification, assessment and management of overweight and obesity in adults and
children. 2006 [cited: 2013 Mai 30]. Available from:
http://www.nice.org.uk/nicemedia/live/11000/30365/30365.pdf
8. Obesity Canada Clinical Practice Guidelines Expert Panel. 2006 Canadian clinical
practice guidelines on the management and prevention of obesity in adults and
children. CMAJ 2007;176(8 Suppl):1-117.
9. New Zealand Guidelines Group (NZGG). Handbook for the preparation of explicit
evidence-based clinical practice guidelines. Wellington: NZGG; 2001.
11. Gariepy G, Nitka D, Schmitz N. The association between obesity and anxiety
disorders in the population: a systematic review and meta-analysis. Int J Obes (Lond)
2010;34(3):407-19 http://www.ncbi.nlm.nih.gov/pubmed/19997072.
12. Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BW, Zitman FG.
Overweight, obesity, and depression: a systematic review and meta-analysis of
longitudinal studies. Arch Gen Psychiatry 2010;67(3):220-9
http://www.ncbi.nlm.nih.gov/pubmed/20194822.
13 Literatur | 290
14. van Duijvenbode DC, Hoozemans MJ, van Poppel MN, Proper KI. The relationship
between overweight and obesity, and sick leave: a systematic review. Int J Obes
(Lond) 2009;33(8):807-16 http://www.ncbi.nlm.nih.gov/pubmed/19528969.
15. Muthuri SG, Hui M, Doherty M, Zhang W. What if we prevent obesity? Risk reduction
in knee osteoarthritis estimated through a meta-analysis of observational studies.
Arthritis Care Res (Hoboken ) 2011;63(7):982-90
http://www.ncbi.nlm.nih.gov/pubmed/21425246, DOI: 10.1002/acr.20464.
17. Harrington M, Gibson S, Cottrell RC. A review and meta-analysis of the effect of
weight loss on all-cause mortality risk. Nutr Res Rev 2009;22(1):93-108
http://www.ncbi.nlm.nih.gov/pubmed/19555520.
18. Fabricatore AN, Wadden TA, Higginbotham AJ, Faulconbridge LF, Nguyen AM,
Heymsfield SB, Faith MS. Intentional weight loss and changes in symptoms of
depression: a systematic review and meta-analysis. Int J Obes (Lond)
2011;35(11):1363-76 http://www.ncbi.nlm.nih.gov/pubmed/21343903, DOI:
10.1038/ijo.2011.2.
19. Papaioannou A, Kennedy CC, Cranney A, Hawker G, Brown JP, Kaiser SM, Leslie
WD, O'Brien CJ, Sawka AM, Khan A, Siminoski K, Tarulli G, Webster D, McGowan J,
Adachi JD. Risk factors for low BMD in healthy men age 50 years or older: a
systematic review. Osteoporos Int 2009;20(4):507-18
http://www.ncbi.nlm.nih.gov/pubmed/18758880.
22. Torloni MR, Betran AP, Horta BL, Nakamura MU, Atallah AN, Moron AF, Valente O.
Prepregnancy BMI and the risk of gestational diabetes: a systematic review of the
literature with meta-analysis. Obes Rev 2009;10(2):194-203
http://www.ncbi.nlm.nih.gov/pubmed/19055539, DOI: 10.1111/j.1467-
789X.2008.00541.x.
23. Nordmann AJ, Suter-Zimmermann K, Bucher HC, Shai I, Tuttle KR, Estruch R, Briel
M. Meta-analysis comparing Mediterranean to low-fat diets for modification of
cardiovascular risk factors. Am J Med 2011;124(9):841-51
http://www.ncbi.nlm.nih.gov/pubmed/21854893.
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
13 Literatur | 291
24. Poobalan AS, Aucott LS, Gurung T, Smith WC, Bhattacharya S. Obesity as an
independent risk factor for elective and emergency caesarean delivery in nulliparous
women--systematic review and meta-analysis of cohort studies. Obes Rev
2009;10(1):28-35 http://www.ncbi.nlm.nih.gov/pubmed/19021871.
25. Strazzullo P, D'Elia L, Cairella G, Garbagnati F, Cappuccio FP, Scalfi L. Excess body
weight and incidence of stroke: meta-analysis of prospective studies with 2 million
participants. Stroke 2010;41(5):e418-e426
http://www.ncbi.nlm.nih.gov/pubmed/20299666.
26. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and
incidence of cancer: a systematic review and meta-analysis of prospective
observational studies. Lancet 2008;371(9612):569-78
http://www.ncbi.nlm.nih.gov/pubmed/18280327.
27. Oreopoulos A, Padwal R, Kalantar-Zadeh K, Fonarow GC, Norris CM, McAlister FA.
Body mass index and mortality in heart failure: a meta-analysis. Am Heart J
2008;156(1):13-22 http://www.ncbi.nlm.nih.gov/pubmed/18585492.
29. Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JP,
Sledge I. Weight and type 2 diabetes after bariatric surgery: systematic review and
meta-analysis. Am J Med 2009;122(3):248-56
http://www.ncbi.nlm.nih.gov/pubmed/19272486.
30. Gill RS, Al-Adra DP, Shi X, Sharma AM, Birch DW, Karmali S. The benefits of
bariatric surgery in obese patients with hip and knee osteoarthritis: a systematic
review. Obes Rev 2011;12(12):1083-9
http://www.ncbi.nlm.nih.gov/pubmed/21883871.
31. De Groot NL, Burgerhart JS, Van De Meeberg PC, de Vries DR, Smout AJ, Siersema
PD. Systematic review: the effects of conservative and surgical treatment for obesity
on gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2009;30(11-12):1091-
102 http://www.ncbi.nlm.nih.gov/pubmed/19758397.
33. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with
overweight and obesity using standard body mass index categories: a systematic
review and meta-analysis. JAMA 2013;309(1):71-82
http://www.ncbi.nlm.nih.gov/pubmed/23280227, DOI: 10.1001/jama.2012.113905.
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
13 Literatur | 292
35. Neville LM, Milat AJ, O'Hara B. Computer-tailored weight reduction interventions
targeting adults: a narrative systematic review. Health Promot J Austr 2009;20(1):48-
57 http://www.ncbi.nlm.nih.gov/pubmed/19402816.
36. Lombard CB, Deeks AA, Teede HJ. A systematic review of interventions aimed at the
prevention of weight gain in adults. Public Health Nutr 2009;12(11):2236-46
http://www.ncbi.nlm.nih.gov/pubmed/19650959.
38. Enwald HP, Huotari ML. Preventing the obesity epidemic by second generation
tailored health communication: an interdisciplinary review. J Med Internet Res
2010;12(2):e24 http://www.ncbi.nlm.nih.gov/pubmed/20584698.
39. Anderson LM, Quinn TA, Glanz K, Ramirez G, Kahwati LC, Johnson DB, Buchanan
LR, Archer WR, Chattopadhyay S, Kalra GP, Katz DL. The effectiveness of worksite
nutrition and physical activity interventions for controlling employee overweight and
obesity: a systematic review. Am J Prev Med 2009;37(4):340-57
http://www.ncbi.nlm.nih.gov/pubmed/19765507.
40. Lin JS, O'Connor E, Whitlock EP, Beil TL. Behavioral counseling to promote physical
activity and a healthful diet to prevent cardiovascular disease in adults: a systematic
review for the U.S. Preventive Services Task Force. Ann Intern Med
2010;153(11):736-50 http://www.ncbi.nlm.nih.gov/pubmed/21135297.
42. Farley AC, Hajek P, Lycett D, Aveyard P. Interventions for preventing weight gain
after smoking cessation. Cochrane Database Syst Rev 2012;1:CD006219
http://www.ncbi.nlm.nih.gov/pubmed/22258966.
44. Oken E, Levitan EB, Gillman MW. Maternal smoking during pregnancy and child
overweight: systematic review and meta-analysis. Int J Obes (Lond) 2008;32(2):201-
10 http://www.ncbi.nlm.nih.gov/pubmed/18278059.
45. Mattes RD, Shikany JM, Kaiser KA, Allison DB. Nutritively sweetened beverage
consumption and body weight: a systematic review and meta-analysis of randomized
experiments. Obes Rev 2011;12(5):346-65
http://www.ncbi.nlm.nih.gov/pubmed/20524996.
46. Malik VS, Schulze MB, Hu FB. Intake of sugar-sweetened beverages and weight
gain: a systematic review. Am J Clin Nutr 2006;84(2):274-88
http://www.ncbi.nlm.nih.gov/pubmed/16895873.
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
13 Literatur | 293
47. Streuling I, Beyerlein A, von KR. Can gestational weight gain be modified by
increasing physical activity and diet counseling? A meta-analysis of interventional
trials. Am J Clin Nutr 2010;92(4):678-87
http://www.ncbi.nlm.nih.gov/pubmed/20668049.
48. Streuling I, Beyerlein A, Rosenfeld E, Hofmann H, Schulz T, von KR. Physical activity
and gestational weight gain: a meta-analysis of intervention trials. BJOG
2011;118(3):278-84 http://www.ncbi.nlm.nih.gov/pubmed/21134106.
49. Streuling I, Beyerlein A, Rosenfeld E, Schukat B, von KR. Weight gain and dietary
intake during pregnancy in industrialized countries--a systematic review of
observational studies. J Perinat Med 2011;39(2):123-9
http://www.ncbi.nlm.nih.gov/pubmed/21070130.
50. Gardner B, Wardle J, Poston L, Croker H. Changing diet and physical activity to
reduce gestational weight gain: a meta-analysis. Obes Rev 2011;12(7):e602-e620
http://www.ncbi.nlm.nih.gov/pubmed/21521451, DOI: 10.1111/j.1467-
789X.2011.00884.x.
52. Gallo MF, Lopez LM, Grimes DA, Schulz KF, Helmerhorst FM. Combination
contraceptives: effects on weight. Cochrane Database Syst Rev 2011;9:CD003987
http://www.ncbi.nlm.nih.gov/pubmed/21901687.
53. Verweij LM, Coffeng J, van MW, Proper KI. Meta-analyses of workplace physical
activity and dietary behaviour interventions on weight outcomes. Obes Rev
2011;12(6):406-29 http://www.ncbi.nlm.nih.gov/pubmed/20546142.
54. Vuillemin A, Rostami C, Maes L, Van CE, Van Lenthe FJ, Brug J, De B, I, Oppert JM.
Worksite physical activity interventions and obesity: a review of European studies (the
HOPE project). Obes Facts 2011;4(6):479-88
http://www.ncbi.nlm.nih.gov/pubmed/22249000.
55. ter Bogt NC, Bemelmans WJ, Beltman FW, Broer J, Smit AJ, van der MK. Preventing
weight gain: one-year results of a randomized lifestyle intervention. Am J Prev Med
2009;37(4):270-7 http://www.ncbi.nlm.nih.gov/pubmed/19765497.
56. ter Bogt NC, Bemelmans WJ, Beltman FW, Broer J, Smit AJ, van der MK. Preventing
weight gain by lifestyle intervention in a general practice setting: three-year results of
a randomized controlled trial. Arch Intern Med 2011;171(4):306-13
http://www.ncbi.nlm.nih.gov/pubmed/21357805.
57. Mediano MF, Barbosa JS, Moura AS, Willett WC, Sichieri R. A randomized clinical
trial of home-based exercise combined with a slight caloric restriction on obesity
prevention among women. Prev Med 2010;51(3-4):247-52
http://www.ncbi.nlm.nih.gov/pubmed/20654643.
58. Haakstad LA, Bo K. Effect of regular exercise on prevention of excessive weight gain
in pregnancy: a randomised controlled trial. Eur J Contracept Reprod Health Care
2011;16(2):116-25 http://www.ncbi.nlm.nih.gov/pubmed/21417561.
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
13 Literatur | 294
59. Phelan S, Phipps MG, Abrams B, Darroch F, Schaffner A, Wing RR. Randomized trial
of a behavioral intervention to prevent excessive gestational weight gain: the Fit for
Delivery Study. Am J Clin Nutr 2011;93(4):772-9
http://www.ncbi.nlm.nih.gov/pubmed/21310836.
62. Witham MD, Avenell A. Interventions to achieve long-term weight loss in obese older
people: a systematic review and meta-analysis. Age Ageing 2010;39(2):176-84
http://www.ncbi.nlm.nih.gov/pubmed/20083615.
63. Kastorini CM, Milionis HJ, Goudevenos JA, Panagiotakos DB. Mediterranean diet and
coronary heart disease: is obesity a link? - A systematic review. Nutr Metab
Cardiovasc Dis 2010;20(7):536-51 http://www.ncbi.nlm.nih.gov/pubmed/20708148.
65. Tuah NA, Amiel C, Qureshi S, Car J, Kaur B, Majeed A. Transtheoretical model for
dietary and physical exercise modification in weight loss management for overweight
and obese adults. Cochrane Database Syst Rev 2011;(10):CD008066
http://www.ncbi.nlm.nih.gov/pubmed/21975777.
66. Thorogood A, Mottillo S, Shimony A, Filion KB, Joseph L, Genest J, Pilote L, Poirier
P, Schiffrin EL, Eisenberg MJ. Isolated aerobic exercise and weight loss: a systematic
review and meta-analysis of randomized controlled trials. Am J Med 2011;124(8):747-
55 http://www.ncbi.nlm.nih.gov/pubmed/21787904.
67. Ismail I, Keating SE, Baker MK, Johnson NA. A systematic review and meta-analysis
of the effect of aerobic vs. resistance exercise training on visceral fat. Obes Rev
2012;13(1):68-91 http://www.ncbi.nlm.nih.gov/pubmed/21951360.
69. Esposito K, Kastorini CM, Panagiotakos DB, Giugliano D. Mediterranean diet and
weight loss: meta-analysis of randomized controlled trials. Metab Syndr Relat Disord
2011;9(1):1-12 http://www.ncbi.nlm.nih.gov/pubmed/20973675.
70. Burke LE, Wang J, Sevick MA. Self-monitoring in weight loss: a systematic review of
the literature. J Am Diet Assoc 2011;111(1):92-102
http://www.ncbi.nlm.nih.gov/pubmed/21185970.
71. Pearson ES. Goal setting as a health behavior change strategy in overweight and
obese adults: a systematic literature review examining intervention components.
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
13 Literatur | 295
73. Ross Middleton KM, Patidar SM, Perri MG. The impact of extended care on the long-
term maintenance of weight loss: a systematic review and meta-analysis. Obes Rev
2012;13(6):509-17 http://www.ncbi.nlm.nih.gov/pubmed/22212682.
74. Esfahani A, Wong JM, Mirrahimi A, Villa CR, Kendall CW. The application of the
glycemic index and glycemic load in weight loss: A review of the clinical evidence.
IUBMB Life 2011;63(1):7-13 http://www.ncbi.nlm.nih.gov/pubmed/21280171, DOI:
10.1002/iub.418.
75. Tsai AG, Wadden TA. Treatment of obesity in primary care practice in the United
States: a systematic review. J Gen Intern Med 2009;24(9):1073-9
http://www.ncbi.nlm.nih.gov/pubmed/19562419.
76. Leblanc E, O'Connor E, Whitlock EP, Patnode C, Kapka T. Screening for and
Management of Obesity and Overweight in Adults. Internet 2011;
http://www.ncbi.nlm.nih.gov/pubmed/22049569.
77. Loveman E, Frampton GK, Shepherd J, Picot J, Cooper K, Bryant J, Welch K, Clegg
A. The clinical effectiveness and cost-effectiveness of long-term weight management
schemes for adults: a systematic review. Health Technol Assess 2011;15(2):1-182
http://www.ncbi.nlm.nih.gov/pubmed/21247515.
78. Colquitt JL, Picot J, Loveman E, Clegg AJ. Surgery for obesity. Cochrane Database
Syst Rev 2009;(2):CD003641 http://www.ncbi.nlm.nih.gov/pubmed/19370590.
79. Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, Clegg AJ.
The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for
obesity: a systematic review and economic evaluation. Health Technol Assess
2009;13(41):1-357, iii http://www.ncbi.nlm.nih.gov/pubmed/19726018.
81. Neve M, Morgan PJ, Jones PR, Collins CE. Effectiveness of web-based interventions
in achieving weight loss and weight loss maintenance in overweight and obese
adults: a systematic review with meta-analysis. Obes Rev 2010;11(4):306-21
http://www.ncbi.nlm.nih.gov/pubmed/19754633, DOI: 10.1111/j.1467-
789X.2009.00646.x.
82. Shimizu H, Timratana P, Schauer PR, Rogula T. Review of Metabolic Surgery for
Type 2 Diabetes in Patients with a BMI < 35 kg/m(2). J Obes 2012;2012:147256
http://www.ncbi.nlm.nih.gov/pubmed/22720136, DOI: 10.1155/2012/147256.
83. Davis LM, Coleman C, Kiel J, Rampolla J, Hutchisen T, Ford L, Andersen WS,
Hanlon-Mitola A. Efficacy of a meal replacement diet plan compared to a food-based
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
13 Literatur | 296
diet plan after a period of weight loss and weight maintenance: a randomized
controlled trial. Nutr J 2010;9:11 http://www.ncbi.nlm.nih.gov/pubmed/20222968.
84. Klemsdal TO, Holme I, Nerland H, Pedersen TR, Tonstad S. Effects of a low glycemic
load diet versus a low-fat diet in subjects with and without the metabolic syndrome.
Nutr Metab Cardiovasc Dis 2010;20(3):195-201
http://www.ncbi.nlm.nih.gov/pubmed/19502017.
85. Tapsell L, Batterham M, Huang XF, Tan SY, Teuss G, Charlton K, Oshea J,
Warensjo E. Short term effects of energy restriction and dietary fat sub-type on
weight loss and disease risk factors. Nutr Metab Cardiovasc Dis 2010;20(5):317-25
http://www.ncbi.nlm.nih.gov/pubmed/19570664.
86. Bradley U, Spence M, Courtney CH, McKinley MC, Ennis CN, McCance DR,
McEneny J, Bell PM, Young IS, Hunter SJ. Low-fat versus low-carbohydrate weight
reduction diets: effects on weight loss, insulin resistance, and cardiovascular risk: a
randomized control trial. Diabetes 2009;58(12):2741-8
http://www.ncbi.nlm.nih.gov/pubmed/19720791.
87. Christiansen T, Paulsen SK, Bruun JM, Overgaard K, Ringgaard S, Pedersen SB,
Positano V, Richelsen B. Comparable reduction of the visceral adipose tissue depot
after a diet-induced weight loss with or without aerobic exercise in obese subjects: a
12-week randomized intervention study. Eur J Endocrinol 2009;160(5):759-67
http://www.ncbi.nlm.nih.gov/pubmed/19211707.
88. Frisch S, Zittermann A, Berthold HK, Gotting C, Kuhn J, Kleesiek K, Stehle P, Kortke
H. A randomized controlled trial on the efficacy of carbohydrate-reduced or fat-
reduced diets in patients attending a telemedically guided weight loss program.
Cardiovasc Diabetol 2009;8:36 http://www.ncbi.nlm.nih.gov/pubmed/1961509.
89. Layman DK, Evans EM, Erickson D, Seyler J, Weber J, Bagshaw D, Griel A, Psota T,
Kris-Etherton P. A moderate-protein diet produces sustained weight loss and long-
term changes in body composition and blood lipids in obese adults. J Nutr
2009;139(3):514-21 http://www.ncbi.nlm.nih.gov/pubmed/19158228.
91. Brinkworth GD, Noakes M, Buckley JD, Keogh JB, Clifton PM. Long-term effects of a
very-low-carbohydrate weight loss diet compared with an isocaloric low-fat diet after
12 mo. Am J Clin Nutr 2009;90(1):23-32
http://www.ncbi.nlm.nih.gov/pubmed/19439458.
92. Aldrich ND, Reicks MM, Sibley SD, Redmon JB, Thomas W, Raatz SK. Varying
protein source and quantity do not significantly improve weight loss, fat loss, or
satiety in reduced energy diets among midlife adults. Nutr Res 2011;31(2):104-12
http://www.ncbi.nlm.nih.gov/pubmed/21419314.
93. Kreider RB, Serra M, Beavers KM, Moreillon J, Kresta JY, Byrd M, Oliver JM,
Gutierrez J, Hudson G, Deike E, Shelmadine B, Leeke P, Rasmussen C, Greenwood
M, Cooke MB, Kerksick C, Campbell JK, Beiseigel J, Jonnalagadda SS. A structured
diet and exercise program promotes favorable changes in weight loss, body
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
13 Literatur | 297
94. Te Morenga LA, Levers MT, Williams SM, Brown RC, Mann J. Comparison of high
protein and high fiber weight-loss diets in women with risk factors for the metabolic
syndrome: a randomized trial. Nutr J 2011;10:40
http://www.ncbi.nlm.nih.gov/pubmed/21524314.
95. Kerksick CM, Wismann-Bunn J, Fogt D, Thomas AR, Taylor L, Campbell BI, Wilborn
CD, Harvey T, Roberts MD, La BP, Galbreath M, Marcello B, Rasmussen CJ, Kreider
RB. Changes in weight loss, body composition and cardiovascular disease risk after
altering macronutrient distributions during a regular exercise program in obese
women. Nutr J 2010;9:59 http://www.ncbi.nlm.nih.gov/pubmed/21092228.
96. Claessens M, van Baak MA, Monsheimer S, Saris WH. The effect of a low-fat, high-
protein or high-carbohydrate ad libitum diet on weight loss maintenance and
metabolic risk factors. Int J Obes (Lond) 2009;33(3):296-304
http://www.ncbi.nlm.nih.gov/pubmed/19153580.
97. Delbridge EA, Prendergast LA, Pritchard JE, Proietto J. One-year weight
maintenance after significant weight loss in healthy overweight and obese subjects:
does diet composition matter? Am J Clin Nutr 2009;90(5):1203-14
http://www.ncbi.nlm.nih.gov/pubmed/19793858.
98. Dale KS, McAuley KA, Taylor RW, Williams SM, Farmer VL, Hansen P, Vorgers SM,
Chisholm AW, Mann JI. Determining optimal approaches for weight maintenance: a
randomized controlled trial. CMAJ 2009;180(10):E39-E46
http://www.ncbi.nlm.nih.gov/pubmed/19433812.
99. Jeffery RW, Levy RL, Langer SL, Welsh EM, Flood AP, Jaeb MA, Laqua PS, Hotop
AM, Finch EA. A comparison of maintenance-tailored therapy (MTT) and standard
behavior therapy (SBT) for the treatment of obesity. Prev Med 2009;49(5):384-9
http://www.ncbi.nlm.nih.gov/pubmed/19695283.
101. Cooper Z, Doll HA, Hawker DM, Byrne S, Bonner G, Eeley E, O'Connor ME, Fairburn
CG. Testing a new cognitive behavioural treatment for obesity: A randomized
controlled trial with three-year follow-up. Behav Res Ther 2010;48(8):706-13
http://www.ncbi.nlm.nih.gov/pubmed/20691328.
104. Wing RR, Crane MM, Thomas JG, Kumar R, Weinberg B. Improving weight loss
outcomes of community interventions by incorporating behavioral strategies. Am J
Public Health 2010;100(12):2513-9 http://www.ncbi.nlm.nih.gov/pubmed/20966375.
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
13 Literatur | 298
105. Nackers LM, Ross KM, Perri MG. The association between rate of initial weight loss
and long-term success in obesity treatment: does slow and steady win the race? Int J
Behav Med 2010;17(3):161-7 http://www.ncbi.nlm.nih.gov/pubmed/20443094.
107. Anderson JW, Reynolds LR, Bush HM, Rinsky JL, Washnock C. Effect of a
behavioral/nutritional intervention program on weight loss in obese adults: a
randomized controlled trial. Postgrad Med 2011;123(5):205-13
http://www.ncbi.nlm.nih.gov/pubmed/21904103.
108. van Wier MF, Dekkers JC, Hendriksen IJ, Heymans MW, Ariens GA, Pronk NP, Smid
T, van MW. Effectiveness of phone and e-mail lifestyle counseling for long term
weight control among overweight employees. J Occup Environ Med 2011;53(6):680-6
http://www.ncbi.nlm.nih.gov/pubmed/21654441.
109. van Wier MF, Ariens GA, Dekkers JC, Hendriksen IJ, Smid T, van MW. Phone and e-
mail counselling are effective for weight management in an overweight working
population: a randomized controlled trial. BMC Public Health 2009;9:6
http://www.ncbi.nlm.nih.gov/pubmed/19134171.
110. Befort CA, Donnelly JE, Sullivan DK, Ellerbeck EF, Perri MG. Group versus individual
phone-based obesity treatment for rural women. Eat Behav 2010;11(1):11-7
http://www.ncbi.nlm.nih.gov/pubmed/19962115.
111. Patrick K, Calfas KJ, Norman GJ, Rosenberg D, Zabinski MF, Sallis JF, Rock CL,
Dillon LW. Outcomes of a 12-month web-based intervention for overweight and
obese men. Ann Behav Med 2011;42(3):391-401
http://www.ncbi.nlm.nih.gov/pubmed/21822750.
112. McDoniel SO, Wolskee P, Shen J. Treating obesity with a novel hand-held device,
computer software program, and Internet technology in primary care: the SMART
motivational trial. Patient Educ Couns 2010;79(2):185-91
http://www.ncbi.nlm.nih.gov/pubmed/19699049.
114. Burke LE, Conroy MB, Sereika SM, Elci OU, Styn MA, Acharya SD, Sevick MA,
Ewing LJ, Glanz K. The effect of electronic self-monitoring on weight loss and dietary
intake: a randomized behavioral weight loss trial. Obesity (Silver Spring)
2011;19(2):338-44 http://www.ncbi.nlm.nih.gov/pubmed/20847736.
115. Acharya SD, Elci OU, Sereika SM, Styn MA, Burke LE. Using a personal digital
assistant for self-monitoring influences diet quality in comparison to a standard paper
record among overweight/obese adults. J Am Diet Assoc 2011;111(4):583-8
http://www.ncbi.nlm.nih.gov/pubmed/21443993.
116. Shuger SL, Barry VW, Sui X, McClain A, Hand GA, Wilcox S, Meriwether RA, Hardin
JW, Blair SN. Electronic feedback in a diet- and physical activity-based lifestyle
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
13 Literatur | 299
intervention for weight loss: a randomized controlled trial. Int J Behav Nutr Phys Act
2011;8:41 http://www.ncbi.nlm.nih.gov/pubmed/21592351.
118. Morgan PJ, Lubans DR, Collins CE, Warren JM, Callister R. The SHED-IT
randomized controlled trial: evaluation of an Internet-based weight-loss program for
men. Obesity (Silver Spring) 2009;17(11):2025-32
http://www.ncbi.nlm.nih.gov/pubmed/19343018.
119. Morgan PJ, Lubans DR, Collins CE, Warren JM, Callister R. 12-month outcomes and
process evaluation of the SHED-IT RCT: an internet-based weight loss program
targeting men. Obesity (Silver Spring) 2011;19(1):142-51
http://www.ncbi.nlm.nih.gov/pubmed/20523304.
120. Rock CL, Flatt SW, Sherwood NE, Karanja N, Pakiz B, Thomson CA. Effect of a free
prepared meal and incentivized weight loss program on weight loss and weight loss
maintenance in obese and overweight women: a randomized controlled trial. JAMA
2010;304(16):1803-10 http://www.ncbi.nlm.nih.gov/pubmed/20935338.
121. Silva MN, Markland D, Carraca EV, Vieira PN, Coutinho SR, Minderico CS, Matos
MG, Sardinha LB, Teixeira PJ. Exercise autonomous motivation predicts 3-yr weight
loss in women. Med Sci Sports Exerc 2011;43(4):728-37
http://www.ncbi.nlm.nih.gov/pubmed/20689448.
122. Jebb SA, Ahern AL, Olson AD, Aston LM, Holzapfel C, Stoll J, mann-Gassner U,
Simpson AE, Fuller NR, Pearson S, Lau NS, Mander AP, Hauner H, Caterson ID.
Primary care referral to a commercial provider for weight loss treatment versus
standard care: a randomised controlled trial. Lancet 2011;378(9801):1485-92
http://www.ncbi.nlm.nih.gov/pubmed/21906798.
123. Appel LJ, Clark JM, Yeh HC, Wang NY, Coughlin JW, Daumit G, Miller ER, III, Dalcin
A, Jerome GJ, Geller S, Noronha G, Pozefsky T, Charleston J, Reynolds JB, Durkin
N, Rubin RR, Louis TA, Brancati FL. Comparative effectiveness of weight-loss
interventions in clinical practice. N Engl J Med 2011;365(21):1959-68
http://www.ncbi.nlm.nih.gov/pubmed/22085317, DOI: 10.1056/NEJMoa1108660.
124. Ryan DH, Johnson WD, Myers VH, Prather TL, McGlone MM, Rood J, Brantley PJ,
Bray GA, Gupta AK, Broussard AP, Barootes BG, Elkins BL, Gaudin DE, Savory RL,
Brock RD, Datz G, Pothakamuri SR, McKnight GT, Stenlof K, Sjostrom LV.
Nonsurgical weight loss for extreme obesity in primary care settings: results of the
Louisiana Obese Subjects Study. Arch Intern Med 2010;170(2):146-54
http://www.ncbi.nlm.nih.gov/pubmed/20101009.
125. Jolly K, Lewis A, Beach J, Denley J, Adab P, Deeks JJ, Daley A, Aveyard P.
Comparison of range of commercial or primary care led weight reduction programmes
with minimal intervention control for weight loss in obesity: lighten Up randomised
controlled trial. BMJ 2011;343:d6500 http://www.ncbi.nlm.nih.gov/pubmed/22053315.
126. Foster GD, Wyatt HR, Hill JO, Makris AP, Rosenbaum DL, Brill C, Stein RI,
Mohammed BS, Miller B, Rader DJ, Zemel B, Wadden TA, Tenhave T, Newcomb
CW, Klein S. Weight and metabolic outcomes after 2 years on a low-carbohydrate
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
13 Literatur | 300
127. Molenaar EA, van Ameijden EJ, Vergouwe Y, Grobbee DE, Numans ME. Effect of
nutritional counselling and nutritional plus exercise counselling in overweight adults: a
randomized trial in multidisciplinary primary care practice. Fam Pract 2010;27(2):143-
50 http://www.ncbi.nlm.nih.gov/pubmed/20026554.
128. Wadden TA, Volger S, Sarwer DB, Vetter ML, Tsai AG, Berkowitz RI, Kumanyika S,
Schmitz KH, Diewald LK, Barg R, Chittams J, Moore RH. A two-year randomized trial
of obesity treatment in primary care practice. N Engl J Med 2011;365(21):1969-79
http://www.ncbi.nlm.nih.gov/pubmed/22082239.
129. Werrij MQ, Jansen A, Mulkens S, Elgersma HJ, Ament AJ, Hospers HJ. Adding
cognitive therapy to dietetic treatment is associated with less relapse in obesity. J
Psychosom Res 2009;67(4):315-24 http://www.ncbi.nlm.nih.gov/pubmed/19773024,
DOI: 10.1016/j.jpsychores.2008.12.011.
130. Harvie MN, Pegington M, Mattson MP, Frystyk J, Dillon B, Evans G, Cuzick J, Jebb
SA, Martin B, Cutler RG, Son TG, Maudsley S, Carlson OD, Egan JM, Flyvbjerg A,
Howell A. The effects of intermittent or continuous energy restriction on weight loss
and metabolic disease risk markers: a randomized trial in young overweight women.
Int J Obes (Lond) 2011;35(5):714-27 http://www.ncbi.nlm.nih.gov/pubmed/20921964,
DOI: 10.1038/ijo.2010.171.
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014
13 Literatur | 301
Erstellungsdatum: 11/1998
Die AWMF erfasst und publiziert die Leitlinien der Fachgesellschaften mit
größtmöglicher Sorgfalt - dennoch kann die AWMF für die Richtigkeit des Inhalts
keine Verantwortung übernehmen. Insbesondere bei Dosierungsangaben sind
stets die Angaben der Hersteller zu beachten!
© Deutsche Adipositas-Gesellschaft
Autorisiert für elektronische Publikation: AWMF online
© DAG | Leitlinienreport zur S3-Leitlinie "Prävention und Therapie der Adipositas" | für Version 2.0, 1. Aktualisierung 2011-2014